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Abstract of the thesis 
Approaches to the prediction of the interactions of co-crystals and their 
components with hypromellose acetate succinate and the characterization of 
that interaction using crystallographic, microscopic, thermal, and vibrational 
analysis 
Abdullah Isreb 
Keywords: co-crystals, polymer, caffeine, malonic acid, ibuprofen, 
nicotinamide, HPMCAS, solvent effect, solubility parameters. 
Dispersing co-crystals in a polymeric carrier may improve their physicochemical 
properties such as dissolution rate and solubility. Additionally co-crystal stability 
may be enhanced. However, such dispersions have been little investigated to 
date. This study focuses on the feasibility of dispersing co-crystals in a 
polymeric carrier and theoretical calculations to predict their stability. 
Acetone/chloroform, ethanol/water, and acetonitrile were used to load and grow 
co-crystals in a HPMCAS film. Caffeine-malonic acid and ibuprofen-
nicotinamide co-crystals were prepared using solvent evaporation method. The 
interactions between each of the co-crystals components and their mixtures 
with the polymer were studied. A solvent evaporation approach was used to 
incorporate each compound, a mixture, and co-crystals into HPMCAS films.  
Differential scanning calorimetry data revealed a higher affinity of the polymer to 
acidic compounds than their basic counterparts as noticed by the depression of 
the glass transition temperature (Tg). Moreover, the same drug loading 
produced films with different Tgs when different solvents were used. Solubility 
parameter values (SP) of the solvents were employed to predict that effect on 
the depression of polymer Tg with relative success. SP values were more 
successful in predicting the preferential affinity of two acidic compounds to 
interact with the polymer. This was confirmed using binary mixtures of 
naproxen, flurbiprofen, malonic acid, and ibuprofen. On the other hand, 
dispersing basic compounds such as caffeine or nicotinamide with malonic acid 
in HPMCAS film revealed the growth of co-crystals. A dissolution study showed 
that the average release of caffeine from films containing caffeine-malonic acid 
was not significantly different to that of films containing similar caffeine 
ii 
 
concentration. The stability of the caffeine-malonic acid co-crystals in HPMC-AS 
was prolonged to 8 weeks at 95% relative humidity and 45°C.  
The theory developed in this project, that an acidic drug with a SP value closer 
to the polymer will dominate the interaction process and prevent the majority of 
the other material from interacting with the polymer, may have utility in 
designing co-crystal systems in polymeric vehicles.  
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Chapter 1 
Introduction
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1.1 Introduction 
The improvement in drug solubility and dissolution rate is considered one of the 
main targets in drug formulation. This improvement can give rise to a better 
bioavailability of the drug. There are many approaches that can be used to 
serve this purpose. These approaches can be divided into physical 
modifications and chemical modifications. 
Changing the physical properties of the active pharmaceutical ingredients (API) 
can be performed by using one of the various methods that are well 
documented in the literature such as reducing the particle size, modifying the 
crystal habit, using polymorphs, and dispersing the drug in carriers. On the 
other hand, chemical modification includes a variety of methods such as using 
the salt form of the drug or using the co-crystalline form in addition to others. 
Using a combination of these aforementioned methods might further improve 
the solubility and the dissolution rate for drugs and is the underpinning strategy 
of this thesis.  
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1.2 Physical modification: solid dispersions 
The solid dispersion approach is one of the techniques used to enhance the 
dissolution rate and the solubility of the poorly soluble drugs (Bashiri-Shahroodi 
et al., 2008 , Patel et al., Pan et al., 2000). A solid dispersion can be simply 
defined as the molecular mixture of a poorly soluble drug and a hydrophilic 
polymer. Both materials are in their solid-state. A solid dispersion was first 
defined by (Mayersohn and Gibaldi, 1966). A solid dispersion is similar to a 
eutectic system regarding the improvement on the dissolution and the solubility 
of the poorly soluble drugs. However, solid dispersions are usually formed as a 
result of the interaction between the drug and the polymer. This interaction 
helps to slow or stop the rate of growth of drug crystals and in certain cases it 
helps to convert the drug into an amorphous material. Reducing the size of the 
drug has a great effect on dissolution rate as it increases the contact surface 
between the drug and the dissolution media.  
Solid dispersions can be divided into three generations (Vasconcelos et al., 
2007) that are summarized in figure 1.1. 
Figure 1.1 types of solid dispersions obtained from (Vasconcelos et al., 2007). 
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The first generation was noted by Sekiguchi and Obi in 1961. They prepared a 
eutectic mixture of several drugs and urea (used as a carrier). This mixture 
resulted in improving the dissolution rate of the drugs. However, the preparation 
of solid dispersions was improved later by using a molecular dispersion instead 
of eutectic mixture in preparing the solid dispersion(Levy, 1963 , Kanig, 1964). 
The second generation is characterized by the use of an amorphous carrier as 
an opposite to the first generation that is using a crystalline carrier for the drug. 
In this case, the drug is molecularly dispersed within the amorphous carrier. 
Amorphous solid dispersions can be classified according to the molecular 
interaction of the drug and the carrier into: solid solutions, solid suspension, or a 
mixture of both. 
Amorphous solid solutions are characterized by the complete miscibility of the 
drug and the amorphous polymeric carrier resulting in a homogenous molecular 
interaction between them. This type is considered to be homogenous on the 
molecular level (Van Drooge et al., 2006). 
Amorphous solid suspensions occur when the drug has a limited solubility in the 
amorphous carrier or it has an extremely high melting point (Chiou and 
Riegelman, 1971). Unlike the solid solution, this type of solid dispersion is 
composed of two phases. When the drug is dissolved and suspended in the 
amorphous carrier, a heterogeneous structure is obtained with mixed properties 
of amorphous solid solution and suspension and amorphous solid suspension 
(Van Drooge et al., 2006). 
The third generation of the solid dispersion is obtained with the use of a surface 
active agent in addition to the amorphous carrier. The third generation solid 
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dispersion is intended to provide the highest degree of bioavailability and 
stability for poorly soluble drugs in their amorphous form. 
The solubility improvement from the physical modification of the drug resulted 
from reducing drug’s particle size, solubilising it in a water soluble carrier, 
providing a better wettability, and to a certain limit producing an amorphous 
drug (Damian et al., 2000). 
 
1.2.1 Advantages and disadvantages of solid dispersion technique 
Physical modification of the drug is better than chemical modification as the 
product is not considered as a new chemical entity that needs to go through a 
clinical trial test before it goes to the market (Charman and Charman, 2003) in 
(Vasconcelos et al., 2007). However, recent discoveries unveiled the toxicity of 
some physically modified drugs. Therefore, they have to go through some of the 
clinical trial tests before being released into the market (Fischer and Chan, 
2007). 
The main advantage for the solid dispersion technique is the improvement in 
drugs bioavailability without the need to spend a lot of efforts in their 
preparation. 
The advantages of dispersing the drug in a solid carrier can be summarized in 
the following points: 
 
1- Reducing drug particle size 
A high surface area is formed as a result of reducing the drug particle size. This 
reduction can be up to the molecular level and is accompanied by dispersing 
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the drug in a highly water soluble carrier that will further enhance the release of 
the drug particles. Consequently, this will improve its bioavailability (Leuner and 
Dressman, 2000 , Bikiaris et al., 2005). 
 
2- Improving the wettability of the drug 
The improvement of drug wettability by solid dispersion of the drug was noticed 
to be independent of the surface activity of the carrier (Vasconcelos et al., 
2007). However, a carrier with a surface activity will provide a significant 
increase in the wettability of the drug by direct dissolution or co-solvent effect 
(Kang et al., 2004 , Leuner and Dressman, 2000 , Colin W, 2006). 
 
3- Increasing particles porosity 
Drug particles in solid dispersion were found to have a higher degree of porosity 
(Vasconcelos and Costa, 2007). Therefore, these solid dispersed drugs have a 
better release profile (Ghaderi et al., 1999). 
 
4- Production of amorphous drugs 
When the drug is dissolved in the polymeric carrier, it may convert into its 
amorphous state. This conversion will provide the drug with a higher solubility 
and dissolution rate that characterize the amorphous materials (Lloyd et al., 
1999). 
On the other hand, there are few disadvantages for the solid dispersion 
technique. The low physical and chemical stability of the amorphous form of the 
drug is considered one of the major drawbacks that prevent the wide use of this 
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technique. In addition to that, most of the polymers that are used in this 
technique can absorb moisture. Consequently, this may give rise to a phase 
separation, crystal growth, or conversion of a meta-stable crystalline form into a 
more stable one resulting in decreasing the solubility and dissolution rate (Van 
den Mooter et al., 2006 , Wang et al., 2007 , Wang et al., 2005).  
Another disadvantage of solid dispersions is their poor ease of scale-up for 
industrial manufacturing (Vasconcelos et al., 2007). 
 
1.2.2 Methods of preparing solid dispersions 
Solid dispersions can be prepared using one of the two methods: melting and 
solvent evaporation. 
 
1.2.2.1 Melting method 
The melting method is the first method to be discovered for the preparation of 
solid dispersions. The first generation of solid dispersion was prepared using 
the melting of the urea with other drugs to form an eutectic mixture (Sekiguchi 
Keiji and Obi Noboru, 1961). Both drug and carrier are melted and mixed to 
form the new phase. A common adaptation of this technique was conducted by 
suspending the drug into a previously melted carrier, instead of melting both 
drug and carrier (Vippagunta et al., 2007). This in turn results in the ability to 
reduce the processing temperature. 
After melting the drug and the carrier, a cooling step is performed by either 
using an ice bath agitation (Sekiguchi et al., 1964), stainless steel thin layer 
spreading followed by a cold draught (Chiou and Riegelman, 1969), or using dry 
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ice or liquid nitrogen (Ceballos et al., 2005 , Timko and Lordi, 1979) in addition 
to a few other less commonly employed methods.  
The high temperature needed to melt both drug and its carrier may cause the 
degradation of some drugs. This can be considered as one of the 
disadvantages for this method. Therefore, some improvements to this method 
were implied by using mechanical forces as in hot melt extrusion or melt 
agglomeration (Verreck et al., 2005 , Seo et al., 2003). 
 
1.2.2.2 Solvent evaporation method 
This method consists of dissolving the drug and the carrier in a proper solvent. 
After that, the solvent evaporates and leave behind the dispersed drug in the 
carrier (Rodier et al., 2005). Evaporating the solvent can be carried out through 
vacuum drying (Yoshihashi et al., 2006), using some heat (Desai et al., 2006), 
slow evaporation at low temperature (Yoshihashi et al., 2006), spray drying 
(Pokharkar et al., 2006), freeze drying (Van Drooge et al., 2006). 
Using a low temperature over the whole preparation process is considered the 
main advantages of this method over the melt approach.  
As previously mentioned, the solid dispersion is considered one of the physical 
modifications to improve the dissolution rate and therefore the bioavailability of 
the drug. On the other hand, chemical modifications, such as co-crystal 
formation, can be used to alter the solubility and the dissolution rate of drugs. 
However, these modifications are harder to achieve and may need to go 
through a clinical trial tests to insure their potency and safety. 
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1.3 Chemical modifications: co-crystallization 
Co-crystal formation is a new technique introduced recently to improve the 
physicochemical properties of APIs. This technique is based on the combination 
of two materials together in order to obtain a hybrid compound that has mixed 
properties of both. There is no unified definition of co-crystals in literature. Some 
workers have defined them as a combination of multiple components that are 
solid at room temperature (Aakeröy and Salmon, 2005 , Shan and Zaworotko, 
2008 , Almarsson and Zaworotko, 2004). This definition excluded combinations 
that contain solvent (solvates) or gas molecules as a constituent of the co-
crystal. Others have included those divisions in the definition of the co-crystals. 
Therefore, it is better to define co-crystals as crystalline forms that contain more 
than one compound in the crystal (Schultheiss and Newman, 2009). 
Co-crystals differ from salts in that they are made of polar compounds rather 
than ionisable compounds as in salts. This suggests that the bonds that link the 
constituent particles are hydrogen bond, Vander Waals or π-π bonds (Aakeröy 
and Salmon, 2005 , Etter, 1991 , Friščić and Jones, 2010 , Bertolasi et al., 2001 
, Aakeroy, 1999 , Aakeroy et al., 2001). 
There is no clear boundary that separates co-crystals and salts. It is difficult to 
differentiate between both as the difference depends mainly on the extent of 
proton transfer from one molecule to the other or in other words, the bond 
length (Schultheiss and Newman, 2009). However, there has been suggestions 
to use the rule of three to differentiate between salts and co-crystals (Ward et 
al., 2003). This rule states that a PKa difference of three or more between the 
individual components of the system will cause it to be considered a salt and 
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less than three will make it a co-crystal (Variankaval et al., 2006 , Ward et al., 
2003 , Alshahateet et al., 2004 , Ainouz et al., 2009). 
In order to predict the co-crystal formation between two materials a phase 
diagram is drawn. A ternary phase diagram is classically employed and it is a 
triangle that has each angle representing one of the components in the co-
crystals with the third angle representing the solvent used in preparing the co-
crystal. The solubility of each of the two components in the solvent is defined on 
the triangle and the stoichiometric ratio for co-crystal formation is represented 
on the third side. This helps to give some idea about the amount required from 
each of the components and the amount required from the solvent in order for 
the co-crystals to be formed (figure 1.2). 
 
Figure 1.2. General ternary phase diagram(Ainouz et al., 2009). Phase 1: co-crystals formation 
zone, 2: API+solvent, 3: co-former+solvent, 4: API+co-crystals, 5:co-former+co-crystals, and 6: 
solution of the mixture. 
 
A ternary phase diagram simplifies the relation between the API, co-crystal 
former and the solvent. It shows the optimal ratios of co-crystal formers and 
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solvent. The optimal mixing ratio in figure 1.1 is 1:1 molar ratio of API/co-crystal 
former. 
Generally speaking, co-crystal’s properties are usually the average of their 
component’s properties. This means that mixing poorly soluble drugs with a 
highly soluble entity will result in improving the solubility of the API. Co-
crystallization allows changing the physical properties of drugs without any 
covalent chemical modification.  
 
1.3.1 Methods of preparing co-crystals 
Co-crystals can be prepared by solvent or solid based methods. The solvent 
methods include slurry conversion, anti-solvent addition, solvent evaporation, 
cooling crystallization and precipitation. The solid-based methods include 
grinding (dry and wet), melt crystallization, and sonication (wet and dry). In 
addition to that, there are other methods to prepare co-crystals such as the 
Kofler method, and the use of moisture amongst others (Maheshwari et al., 
2009b , Lu et al., 2008 , Jayasankar et al., 2007). 
Co-crystal properties might differ depending on the production technique. 
Furthermore, co-crystals might only be possible to form using one or two 
techniques but not others. In addition, one method might produce a polymorphic 
form of one of the components and this will result in a different final co-crystal. 
 
 11 
 
1.3.1.1 Solvent based co-crystallization methods 
1.3.1.1.1 Solution co-crystallization 
The co-crystal components must have similar solubility patterns in the solvent 
used in the process. If not, the component with the lowest solubility will 
precipitate first without interacting with other components. Similar solubility of 
the compounds is not the only condition for this method. Polymorphism plays a 
role in co-crystal formation in this method. The ability of the compound to form 
intermolecular bonds plays a role as well (Trask et al., 2005 , Trask et al., 2006 
, Chiarella et al., 2007 , Gagniere et al., 2009). 
 
1.3.1.1.2 Slurry conversion 
In this technique solvents are added to the co-crystals components and the 
resulting suspension is stirred for few days. Afterward, the solvent is decanted 
and the solid materials dried under the flow of nitrogen gas (Rodríguez-Hornedo 
et al., 2006 , Porter Iii et al., 2008 , Hickey et al., 2007 , Li et al., 2009). 
 
1.3.1.1.3 Anti solvent addition 
Anti solvent addition is based on the precipitation or re-crystallization of co-
crystal formers with the API. An example of this method is the preparation of co-
crystals of aceclofenac using chitosan (Padrela et al., 2009 , Trask and Jones, 
2005a , Padrela et al., 2010 , Sander et al., 2010). 
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 1.3.1.2 Non-solvent methods 
1.3.1.2.1 Grinding 
Co-crystal formation can be achieved by mechanical activation of materials by a 
mechanical process (grinding). Grinding can be carried out without the addition 
of a solvent (dry grinding) or with the addition of small amount of solvent (wet-
grinding). The amount of added solvent is only enough to wet and partially 
dissolve parts of the components but not enough to dissolve them completely. 
The grinding technique depends on the input of mechanical forces to the 
system that will result in breaking down the crystals and forcing them together in 
order to create a link or a bond (Trask et al., 2005 , Shan et al., 2002 , Braga et 
al., 2007). The use of a small amount of a solvent is meant to aid such bond 
breaking and bond formation by partially dissolving the particles. Co-crystals 
have been widely formed by dry or wet grinding (Trask et al., 2006 , Etter, 1990 
, Etter, 1991 , Etter and Reutzel, 1991 , Caira et al., 1995 , Pedireddi et al., 
1996 , Oguchi et al., 2000 , Trask and Jones, 2005b , Jayasankar et al., 2006a , 
Childs et al., 2008). 
The formation of co-crystals passes through the formation of amorphous 
materials or a disordered phase formed by the reactants. As the process 
continues, the amorphous reactants convert into co-crystals. This conversion 
was monitored in the formation of anhydrous carbamazepine and saccharin 
(Jayasankar et al., 2006b). Although co-crystals usually require some energy to 
form, some co-crystals formed spontaneously after being stored together with 
no input of any kind of force. This was the case in the formation of 
carbamazepine-nicotinamide and carbamazepine-saccharin co-crystals 
(Maheshwari et al., 2009a). 
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Co-crystals obtained from grinding are usually similar to those obtained from 
solution co-crystallization. This indicates that the hydrogen bonds formed 
between the crystals by these two methods are not idiosyncratic. However, 
there are few exceptions to this rule. Some co-crystals can be prepared by 
either solvent-based processes or solid-state grinding. An example is the co-
crystallization of 2,4,6-trinitrobenzoic acid and indole-3-acetic acid. On the other 
hand, some co-crystals cannot be prepared by grinding. This might be due to 
the inability of the grinding technique to generate suitable co-crystal 
arrangements rather than the stability of the initial phases. The addition of small 
amount of solvent during the grinding process has been shown to enhance the 
kinetics and facilitate co-crystal formation (Maheshwari et al., 2009a).  
 
1.3.2 Factors that affect the formation of co-crystals 
There are some factors that might influence the quality and the outcome yield of 
co-crystallization processes. These factors can be divided according to the 
method of manufacturing and the mechanism behind the formation. Solvent-
related methods are characterized by the obvious effect of the nature of the 
solvent used in the experiment. The type of solvent might play a significant role 
in enhancing or blocking the formation of co-crystals. The formation of co-
crystals in solvent-dependent methods (wet-methods) depends on dissolving 
the co-crystal formers in a solvent to break down the bond between similar 
molecules and allow the different type of molecule to meet up and form a bond. 
If the solvent used in this experiment does not have the adequate strength to 
dissolve those particles. This might cause interference to the whole formation 
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process. If the solvent was too strong and formed a bond with one of the 
materials, it might block the formation of the co-crystal bond.  
On the other hand, dry co-crystallization methods are affected by other factors. 
Grinding for example uses mechanical forces to break similar crystals apart. 
This technique reduces the size of the crystals and consequently increases the 
surface free energy and the surface charges. This might trigger the formation of 
co-crystals. On the other hand any electrostatic charge that results from the 
grinding may cause the particles to aggregate and prevent the formation of co-
crystals. 
Melting the materials is another technique used to form co-crystals. However, 
some drugs can be adversely affected by the increase in temperature. The 
heating of such drugs can result in the degradation of these drugs and 
consequent loss of pharmacological activity.  
 
1.3.3 Advantages and disadvantages of co-crystals 
The main disadvantage of the co-crystals is their short-term physical stability. 
This has resulted in keeping the co-crystals out of the market so far. 
Co-crystallization means an improvement of physical properties without 
changing drugs chemically. In contrast to salt formation co-crystallization is 
applicable for a larger number of APIs. This is because most of the APIs are 
polar in nature, while the formation of a salt requires the ionization of the 
compounds. In addition to that, co-crystal formation does not require full 
ionization of the molecules involved. The polar nature of most APIs makes co-
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crystallization potentially a much more widely preferable technique over salt 
formation. 
Moreover, there is a wider range of molecules that can be used as co-crystal 
formers compared to salt formers (Mirza et al., 2008). 
Many physicochemical properties can be manipulated through co-crystal 
formation these includes hygroscopicity, melting point, stability, bioavailability, 
and dissolution rate. These changes makes co-crystals better than their parent 
drugs for the pharmaceutical field. 
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1.3.3.1 Melting point 
The melting point of a compound is related to aqueous solubility and vapour 
pressure (Abramowitz and Yalkowsky, 1990). The melting point of a co-crystal 
can be either lower than one of their constituents or in some cases lower than 
the melting point of all the constituents (Rodríguez-Hornedo et al., 2006 , 
Jayasankar, 2008 , Childs, 2008 , Reddy et al., 2008 , Maheshwari et al., 
2009b). Characterization of co-crystals using differential scanning calorimeter 
(DSC) to determine their melting point can be a useful tool to check the 
formation of co-crystals and to provide an overall idea about the percentage of 
co-crystal formation (Schultheiss and Newman, 2009). 
 
1.3.3.2 Stability  
Drug stability is considered to be one of the main issues during the formulation 
of the drug and for choosing the crystal form to be used in formulation. The 
stability of the co-crystals is determined by the ability of the co-crystals to stay 
intact without breaking the bond in between the constituent compounds. The 
resistance of drug to moisture stress is an important consideration in stability 
study. 
The effect of moisture on the stability of the co-crystals has not been thoroughly 
investigated. Some crystals were found to interact and form co-crystals under 
high relative humidity atmospheres (Jayasankar et al., 2007). However, not all 
co-crystals can be formed by moisture interaction. Whilst moisture can 
theoretically act as a solvent it can also act to break co-crystal bonds. There is 
little if any information in the open literature to prove or disprove this point.  
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Some studies, however, have shown that co-crystals are less hygroscopic than 
their parent drugs (Basavoju et al., 2008 , Schultheiss and Newman, 2009).  
 
1.3.3.3 Solution stability 
This property is an important characteristic for the dissolution of the co-crystals 
in the GI tract (Schultheiss and Newman, 2009 , Stanton et al., 2009 , 
Jayasankar, 2008). 
 
1.3.3.4 Solubility 
Solubility is considered as one of the main issues in the bioavailability of drugs. 
There is a large number of drugs that have either poor or low solubility in 
simulated aqueous GI tract solutions. Co-crystals formation may improve the 
solubility of drugs. However, co-crystals can be formed with neutral drugs while 
salts formation requires the ionization of the drugs. 
Many studies were carried out on co-crystal systems to compare their solubility 
and their dissolution to the parent API. The result was a large difference 
between the co-crystals formation and the raw drug. However, they showed that 
co-crystals are not as good as salts in improving the solubility or the dissolution 
rate (Bethune, 2009).  
A study of three co-crystal systems for itraconazole showed that two of the 
three gave an enhanced solubility similar to the amorphous form of itraconazole 
(Remenar et al., 2003). 
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1.3.3.5 Dissolution 
The dissolution step can be the rate limiting step towards the bioavailability of 
the drugs. The dissolution of the drug depends on many factors. Co-crystals 
improve the dissolution rate of drugs (Anderson et al., 2008). The dissolution 
rate is enhanced due to the combining of the drug with a highly soluble entity 
(co-crystal former). This interaction may help to reduce relative lattice energy 
compared to that of the API. 
 
1.3.3.6 Bioavailability 
The bioavailability of a drug is the measurement of the amount of unchanged 
drug that reaches the systemic circulation and then the site of action. Different 
forms of the same drug can result in different bioavailability patterns. Thus, 
choosing the right form of the drug is crucial in the pharmaceutical formulation 
field. 
McNamara studied the co-crystals of 2-[4-(4-chloro-2-fluorophenoxy)phenyl] 
pyrimidine-4-carboxamide with glutaric acid and identified that co-crystals have 
a dissolution rate 18 times higher than that of the pure API (McNamara et al., 
2006). 
The study of the solid dispersion and the co-crystals showed that they both 
either started as or they are a part of eutectic systems. Thus, the study of 
eutectic mixture and the prediction of compounds miscibility may provide a 
better understanding for both systems. 
A eutectic mixture is defined as “a mixture of elements or chemical compounds 
in definite proportions which is crystallized from melt or solution simultaneously 
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at a lower temperature than any other composition” (Patra and Samantray, 
2011). The behaviour and miscibility of compounds forming eutectic mixtures 
were studied and documented in the literature. A relation was found between 
the ability of the compounds to be miscible and form an eutectic mixture and 
their chemical structure (Stott et al., 1998). A new theoretical rule was 
investigated to allow the prediction of eutectic mixtures formation. This rule 
depends on the solubility and cohesion parameters of these compounds to 
predict the feasibility of eutectic mixture formation.  
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1.4 Solubility and cohesion parameters 
The chemical structure of any material and the arrangement of the atoms in that 
material play a crucial rule in the interaction with other materials. The type of 
functional groups, their orientation in the space, and the existence of any 
adjacent electron withdrawing or donating groups will have a huge impact on 
the polarity of the molecule. This effect can influence the intensity of the bond to 
be formed between the two compounds. The polarity participates in the 
formation of the intermolecular bonds such as the bonding between water 
molecules. Such interactions have a huge effect on the physical and the 
chemical properties of the compounds. Hildebrand studied the effect of the 
different groups and the volume occupied by these groups on the capability of 
solvents to form bonds and to be miscible with each others. 
The effect of the volume that is occupied by these groups can be explained by 
the effect of steric hindrance. If the groups are too bulky then the large volume 
of them will interfere with the formation of any bond with the functional groups. 
Hildebrand has worked on the interaction between solvents and devised an 
equation to predict the miscibility of liquids. According to Hildebrand the 
solubility parameter of a solvent is calculated by the square root of its cohesive 
energy density. The equation takes into consideration the effect of each group 
separately. 
      
(equation 1.1(Hildebrand and Scott, 1950)) 
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Where  is the heat of vaporization, R is the gas constant, T temperature, 
and Vm molar volume. 
Hildebrand suggested that liquids with solubility parameter difference of 7 or 
less are miscible and can form a homogeneous monophase mixture. The use of 
solubility parameters was expanded to predict the miscibility of solids in order to 
form an eutectic mixture (Greenhalgh et al., 1999).  
The limitation of this equation comes from the fact that it can be applied only on 
the associated solutions. There are some other factors that can be taken into 
consideration such as the ability of the compound to form internal bonding. On 
the other hand, Hansen suggested another equation to calculate the solubility 
parameter for the solvents based on the principle of “like dissolves like”. Each 
molecule has three parameters named  which calculates the dispersion 
energy,  calculates the polarity energy, and  which calculates the energy 
from the hydrogen bond formed by two molecules. 
The dispersion forces arise from the effect of positive nucleus and a negative 
electron. The effect of the dispersion can be explained with London theory 
(Kristyán and Pulay, 1994 , London, 1937 , Mahanty and Ninham, 1976). The 
effect of non-polar dispersive interaction between unlike molecules provides a 
contribution to the cohesion pressures. On the other hand, the polarity force 
arises from the effect of two factors: the orientation and the induction of the 
contributing groups. The orientation factor results from the dipole-dipole or 
Keesom interaction, which occurs between molecules possessing a permanent 
dipole moment. The induction effect arises from the “dipole induced dipole 
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occurring between molecules with permanent dipole moments and other 
neighbouring molecules, whether polar or not and resulting in an induced non-
uniform charge distribution” (Barton, 1991). The last factor in the equation is the 
effect of the hydrogen bonding. The effect of the hydrogen bonding depends to 
a large extent to the degree of acidity or the basicity of the compounds to form 
the bond between each others. It is mainly related to the ability of each system 
to donate or accept an electron.  
 The summation of the three energies gives the relative energy difference of the 
compound. This parameter will determine the solubility of the molecules if they 
dissolve into each other or if they do not. Although the Hansen equation can be 
applied to a wider range of molecules, there are a few variables that it does not 
include to compute the solubility parameter of the compound.  
The solubility parameter of a compound can be calculated according to a more 
comprehensive equation that calculates the effect of the group molar cohesive 
energy divided over the molar volume. Dunkle was the first to introduce an 
equation to estimate the group molar vaporization enthalpy. He showed that 
liquid molar vaporization enthalpies at a given temperature can be estimated by 
the summation of the group contributions (Dunkel, 1928). Bondi has managed 
to estimate the contributions to the enthalpy of vaporization extrapolated to zero 
Kelvin (Bondi, 1947 , Bondi, 1968). 
The solubility parameter of the compounds used in this thesis were calculated 
based on the simple version of the group contribution method of Hildebrand 
equation that is explained with the required tables in the “Handbook of solubility 
parameters and other cohesion parameters, chapter 6” (Barton, 1991). The 
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effect of internal cycle formation has not been taken under consideration as it 
does not have significant impact on the calculated results on the molecules 
used in this study. 
As previously mentioned, an attempt was carried out to link the solubility 
parameter values of compounds to their miscibility and their ability to form 
eutectic mixture (Stott et al., 1998) which is considered as a solid dispersion 
system. These attempts found that in most of the cases two compounds should 
form eutectic mixture when the difference in their solubility parameter values is 
less than 7 MPa1/2. However, the same study reveals the existence of some 
compounds that are considered to be exception for this rule. 
On the other hand, there were some attempts as well to predict the co-crystal 
formation of two or more compounds through their solubility parameter values 
difference (Mohammad et al., 2011). These attempts were based on the fact 
that the co-crystals are eutectic mixtures in origin. It was expected that two 
compounds are able to form co-crystals when their SP value difference is no 
more than 7 MPa1/2. However, this rule is not applicable in all the cases. 
Ibuprofen RS/S and nicotinamide are known to form a co-crystalline system 
(Berry et al., 2008). The solubility parameter of ibuprofen is 19.5 MPa1/2 and 
nicotinamide is 27.52 MPa1/2. The difference is 8.02 MPa1/2 yet they form co-
crystals. 
There is a dearth of information about the behaviour of co-crystals in polymeric 
films. The one recently made available study followed the growth of 
carbamazepine-nicotinamide co-crystals from a mixture that contains polyvinyl 
pyrrolidone. The moisture absorbed by the polymer dissolved the two drugs and 
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bring them together to form co-crystals. A stability study of that system showed 
that the co-crystals were partially unstable (Good et al., 2011). 
The above experiment represents the available literature for the study of loading 
co-crystals in a polymeric film. It also draws attention to the fact that dispersing 
the co-crystals in a polymeric carrier might improve their stability. 
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1.5 Summary and scope of the thesis 
The improvement of the dissolution rate and the solubility of APIs are expected 
to greatly reflect on improving the bioavailability of drugs. These improvements 
can be achieved by physical (such as solid dispersions) or chemical (such as 
co-crystallization) modifications for the API. Combining both types of 
modifications is expected to improve the physicochemical properties of the API 
even more. There was only one attempt in the literature to load co-crystals 
inside a polymeric film. Therefore, there is almost no information about the 
possible behaviour of co-crystals in a polymeric carrier, their ease of formation 
and their stability and properties. This combination can be used in future for 
either transdermal or oral use. 
 
1.6 Aims and objectives 
The aim of this project is to investigate the possibility of combining both physical 
and chemical modification of an API and to discover the effect of such 
combination on resultant properties. In addition, the preparation media effect 
was studied through the use of different solvent systems. An important sub-aim 
of this project was to probe whether a theoretical basis could be developed for 
the ease of formation and stability of co-crystals in polymeric films by utilising 
compounds that have a theoretical affinity to interact with the polymer rather 
than interacting with each other to form co-crystals. This affinity was estimated 
through the use of the solubility and cohesion parameters of the starting 
materials. 
In order to fulfil the aim of this thesis, a number of objectives need to be met. 
These objectives are as follows: 
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 To identify suitable co-crystal forming starting materials and to analyse 
the materials and their physicochemical properties when recrystallized 
using various solvent systems. 
 To produce the selected co-crystals using a variety of solvent systems to 
monitor any morphology or behaviour change and to study the interaction 
between the materials in advance of their incorporation within a 
polymeric film matrix. 
 To study the effect of various solvent systems on the physicochemical 
properties of the pure polymeric film. 
 To investigate the effect of adding each single co-crystal component on 
the physicochemical properties of the film using various solvent systems. 
 To study the effect of adding two materials simultaneously to the polymer 
using different solvent systems. 
 To identify whether any novel co-crystal systems form in the polymeric 
vehicle for the use in transdermal or oral drug delivery. 
 To identify a rational approach as to whether a co-crystal can be 
successfully incorporated into a polymer.  Specifically to investigate the 
use of solubility parameters to predict the behaviour of a co-crystalline 
drug dispersed in a polymeric vehicle 
 To explore whether additives can be used to enhance the stability and 
ease of formation of co-crystals within a polymeric film. 
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1.7 Selection of materials 
Caffeine-malonic acid and ibuprofen-nicotinamide were used as model co-
crystal systems as they are cheap, and relatively non-toxic. In addition to that, 
both co-crystals are easy to prepare and their properties have been extensively 
studied (Bothe and Cammenga, 1980). Caffeine, malonic acid, and 
nicotinamide are water soluble (1 g/46 ml, 1 g/0.65 ml, and 1 g/1 ml water 
respectively) while ibuprofen is sparingly soluble in water (<1mg/ml) (Budavari, 
2006). Thus, the two systems are expected to interact with the polymer in 
different ways.  
Hypromellose Acetate Succinate (HPMCAS) was used because it is cheap, 
relatively non-toxic, dissolves in many common solvents and for its enteric 
coating property. This latter is particularly useful as ibuprofen is known to cause 
stomach ulcer. 
 On the other hand, the solvent systems used in the preparation step are either 
mentioned in the literature for their capability of providing the required 
properties or adapted from the literature and modified to serve the purpose of its 
use. The three systems mentioned in the literature are: 
 Chloroform/methanol 30:1 v/v was used in the production of 
caffeine/malonic acid co-crystals (Trask et al., 2005). Chloroform is a 
good solvent for both caffeine and malonic acid and spiking it with 
methanol gives the required polarity to the mixture. This improves the 
solubility of the raw material and the formation of co-crystals. 
 Ethanol/water 4:1 w/w was used for its capability of dissolving the 
polymer (HPMCAS) (Shin-Etsu, 2005).  
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 Acetonitrile is the solvent of choice for producing ibuprofen-nicotinamide 
co-crystals (Berry et al., 2008). However, there was no data regarding 
the solubility of HPMCAS in acetonitrile. 
Other solvent systems will be developed as required.
  
 
 
 
 
 
 
Chapter 2 
Materials and methods 
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2.1 Materials 
Materials used in the thesis are summarised in the following table. 
Material supplier 
Batch 
number 
Purity 
Caffeine Fluka 
1381891 
10808p01 
99% 
malonic acid 
Sigma-
Aldrich 
S43239-487 98% 
Ibuprofen 
Sigma-
Aldrich 
026H1368 98% 
Nicotinamide 
Sigma-
Aldrich 
079K1404 98% 
Naproxen 
Sigma-
Aldrich 
078K1629 99% 
Flurbiprofen 
Sigma-
Aldrich 
070M1445V 97% 
HPMCAS Shin-Etsu 9073188 NA 
Triethyl 
citrate 
Aldrich 18621AB 99% 
Table 2.1. Materials used in the thesis. 
 
The solvents used were:  
Acetone, acetonitrile, ethanol, chloroform, methanol, and distilled water. All the 
solvents were laboratory grade and purchased from Fischer scientific 
(Loughborough, UK). 
 30 
 
2.2 Data analysis 
2.2.1 Thermal analysis 
2.2.1.1 TGA 
A Thermal Analysis TGA Q5000 (TA instruments, Elstree, Hertfordshire, UK) 
was used to measure the thermal profile for the samples and in order to 
measure the residual solvent and moisture content. 
The TGA was calibrated in two steps. The first step includes the calibration for 
temperature. For this purpose, a sample of nickel was heated in the TGA. The 
cure point of nickel (627 K or 354°C) is used as a reference value for calibrating 
the temperature scale. 
On the second step of calibration, 25 mg and 125 mg standard weights are 
used to perform the mass calibration of the TGA. 
The thermal profiles for samples (powder, crystals, or films) were obtained by 
taring the TGA using the supplied software. After that, a sample of 
approximately 5 mg was placed inside the aluminum pan. The sample was 
heated from room temperature (around 25°C) to 300°C for unprocessed 
materials, recrystallized crystals, and co-crystals. Films were heated to 600°C. 
All the measurements were performed with a heating rate of 10°C/min. 
 
2.2.1.2 DSC 
A Thermal Analysis DSC Q2000 (TA instruments, Elstree, Hertfordshire, UK) 
was used to scan the samples and measure their melting enthalpy.  
Aluminum lid and pan were used for scanning unprocessed materials except for 
caffeine were TzeroTM hermetic pan and lid used for the analysis process. The 
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DSC was calibrated once a month using around 1 mg of indium. The onset 
temperature of the melting peak (156.6°C) was used to calibrate the DSC. 
Triplicates of 3-7 mg each were weighed and filled in a pan closed with a pin-
holed lid. Raw materials and the recrystallized ones were scanned from room 
temperature to above their melting point with a heating rate of 10°C (caffeine 
240°C, malonic acid 150°C, ibuprofen 120°C, nicotinamide 135°C, naproxen 
165°C, and flurbiprofen 135°C).  One sample of caffeine and recrystallized 
caffeine were scanned from room temperature to 240°C, then cooled to 0°C, 
after that the samples were reheated again to 240°C. The heating rate for that 
sequence was 10°C/min. 
HPMCAS and all the films were scanned in a different pattern. The sample were 
first heated to 100°C with a rate of 10°C/min. then the sample were kept on an 
isothermal  step at 100°C for 5 minutes in order to dry the sample off. After that, 
the sample was cooled to 0°C (films with 25% crystal concentration or above 
were cooled to -20°C at the same rate. The temperature was kept at 0°C or -
20°C for 5 minutes. Then the sample was heated again to 120°C with the same 
rate. Tg and melting points values were collected using the second run to avoid 
discrepancies due to the moisture content and the thermal history of the 
sample. For films containing ibuprofen the first run was used to measure the 
melting point as ibuprofen crystals were dissolving during the drying off step 
producing an amorphous system. 
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2.2.2 X-ray crystallography 
A Bruker D8 diffractometer (Bruker Corporation, Bruker AXS, Cambridge, UK) 
was used to scan the samples. The wavelength of the X-ray was 0.154 nm 
using Cu source. The voltage used was 40KV. Filament emission was 30 mA. 
The samples were either packed into a deep sample holder and pressed to 
have a flat surface and equal distribution, or sprayed over a flat surface sample 
holder. Samples were scanned from 5-50° (2q) using 0.01° step width and a 1 
second time count. The receiving slit was 1° and the scatter slit 0.2°. 
 
2.2.3 Vibrational spectroscopy (FT-IR) 
The samples were scanned using Digilab UMA 400 (DIGILAB, London, UK) 
was set to a scan speed of 20 KHz. Scan resolution was 4cm-1 and the 
sensitivity 1 transmission %. The accumulation of 128 scans was used and the 
samples were scanned from 4000 cm-1 to 600cm-1. 
 
2.2.4 Microscope analysis 
2.2.4.1 SEM 
Using the FEI QUANTA 400 SEM, (Oxford instruments, UK), INCAx-sight, with 
aluminum stubs and carbon tabs (12 mm Dia, FK100) samples were scanned 
for their topography and appearance. Samples often showed high electrostatic 
charge. In order to get rid of the charge, samples were coated with carbon dust 
using a coating machine (EMITECH K450, Quorumtech, the carbon thickness 
produced was 15 nm). The SEM chamber was subjected to a high pressure 
vacuum and high voltage was used for scan.  
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2.2.4.2 Hot stage microscope 
Crystals and films were scanned using a hot stage microscope (Zeiss, 
Thornwood, USA) equipped with Axiocam MRC 5 Zeiss, Tv2/3”c, 0.63x, 1069-
414 camera. The stage was connected to a heating unit (Linkam, Guildford, 
Surrey, UK). Cross polarized light was used to identify the crystals and co-
crystals. However, in some samples normal bi-focal used to observe the 
crystals as the films were thick and the light was barely passing by. Samples 
were heated using a heating rate of 5°C/min. Images were obtained when any 
change was observed. 
 
2.2.5 Dissolution station 
A USP basket method was followed to scan samples taken from the dissolution 
bath. Films containing drug (caffeine, ibuprofen), co-crystals (caffeine-malonic 
acid, ibuprofen-nicotinamide), films containing drug and a blocking agent 
(ibuprofen and malonic acid), and films containing co-crystals and a blocking 
agent were scanned in the dissolution bath by either using a small part of the 
film that can fit inside the stirring basket (caffeine and malonic acid) or by 
breaking the film and loading the pieces inside the basket (films containing 
ibuprofen, ibuprofen and malonic acid, ibuprofen co-crystals, and ibuprofen co-
crystals with a blocker). The basket was set to revolve at rate of 100 RPM. The 
dissolution vessel was connected with two rubber tubes to a peristaltic pump 
operating at a rate of 25 RPM. The tubes were connected to a closed UV cell in 
order to perform a continuous scanning for the dissolution media. The 
dissolution vessel was filled with pH 7.4 phosphate buffer solution maintained at 
a temperature of 37°C. 
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The flow through the tube was measure for 2 hrs in order to measure the drug 
release from the film. The samples were measured with a Jenway 6800 UV/VIS 
Spectrophotometer (Bibby Scientific Limited, Staffordshire, UK). The data were 
analysed using a program (Flight Deck version 1.0) and concentration v/s time 
curve were plotted. The release percentage was used instead of the released 
concentration in order to ease the comparison and eliminate the difference in 
samples concentrations. 
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2.3 Methods of preparation of materials 
2.3.1 Recrystallization experiments 
Solvent evaporation was used as a technique to prepare the recrystallised form. 
The raw materials were dissolved separately in acetone/chloroform, 
ethanol/water, and acetonitrile. Caffeine was recrystallised with 
chloroform/methanol as well as the previous solvents. After dissolving the raw 
materials in the solvents, the solution was stirred and an extra amount of the 
solute was added to ensure saturation. The solution was poured into a petri-
dish and it was left in a fume cupboard to allow the solvent to evaporate. The 
crystals were collected and stored in re-sealable plastic bags under room 
temperature (18°-25°).  
 
2.3.2 Co-crystallization experiments 
Caffeine and malonic acid co-crystals were prepared by dissolving them in their 
stoichiometric molar ratio of 2:1 mol/mol caffeine/malonic acid in one of the 
previously mentioned solvents and solvent allowed to evaporate under ambient 
conditions. 
143 mg caffeine and 380 mg malonic acid were added to 40 ml acetonitrile, 31 
ml chloroform/methanol, 50 ml acetone/chloroform, 50 ml ethanol/water. The 
mixture was stirred until all the particles dissolved. The solution was poured in a 
petri-dish and it was left in a fume cupboard to allow the solvent to evaporate. 
The co-crystals were collected and stored in re-sealable plastic bags under 
room temperature (18°-25°). 
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2.3.3 Preparation of films containing drugs or mixture 
Films containing one or more types of crystals were prepared by dissolving 
various amounts of the crystals in one of the solvents. The solution was stirred 
until all the particles dissolved. 4 g of HPMCAS were added to the solution 
gradually with continuous stirring. The solution was cast into a petri-dish with an 
acetate sheet covering its base. The films were placed in a fume cupboard to 
allow the solvent to evaporate. 
Films were separated from the acetate sheet and stored in re-sealable plastic 
bags and stored under room temperature (18°-25°) in a desiccator. 
 
2.3.4 Films containing co-crystals 
Films containing co-crystals were prepared by dissolving 4 g of HPMCAS in 
either 40 ml of acetonitrile or 50ml of acetone/chloroform 3:2 v/v. The solution 
was stirred for 1-1.5 hours using a magnetic stirrer to allow the viscosity to 
increase. 500 mg of caffeine-malonic acid co-crystals or 500 mg of ibuprofen-
nicotinamide were crushed using a mortar and pestle in order to reduce the 
particle size of the co-crystals then it was added gradually to the solution of the 
polymer. The solution was stirred for 2 minutes and then it was cast into a petri-
dish with an acetate sheet covering its base. The petri-dish was left for 2 weeks 
in a fume cupboard to allow the solvent to evaporate completely. Films were 
stored under room temperature (18°-25°) in a desiccator.
  
 
 
 
 
 
 
 
 
Chapter 3 
Raw material analysis and the study of the solvent effect on 
their properties 
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3.1 Raw material analysis 
The main aim of the thesis is to study the interaction between a co-crystal and a 
polymeric vehicle and the impact of such interaction on the physicochemical 
properties of the dosage form. Therefore it is imperative to start by first 
characterizing the unprocessed materials to be able to identify any changes that 
might arise when those materials interact with each other. Moreover, in order to 
produce the co-crystals alone or when interacting with the polymer, the starting 
components have to be dissolved or dispersed into a solvent system before 
they are recrystallized from the solvent. Hence, it is important to understand the 
effect of these solvent systems on the physical and chemical properties of the 
starting materials to differentiate between the effect of the solvent system and 
the effect of the interactions of the components when they are mixed together. 
For the above reasons, this chapter will investigate some of the 
physicochemical properties of the unprocessed materials: caffeine, malonic 
acid, ibuprofen, nicotinamide, and HPMCAS. It will also study the effect of re-
crystallizing these materials using ethanol/water and acetonitrile.  
A third solvent system was added after few studies that are related to the 
solubility of the previous drugs. This system is acetone/chloroform 3:2 v/v. 
The study of the solvent effect on the raw materials requires the knowledge of 
raw materials properties and hence the unmodified drugs were analyzed at first. 
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3.2 Unprocessed drug analysis 
3.2.1 Caffeine 
Caffeine (1, 3, 7 trimethyl-3, 7 dihydro-1H-purine-2, 
6-dione) is a natural alkaloid found in tea leaves, 
coffee beans, and cocoa beans. It was synthesized first by E. Fischer at 1882 
(figure 3.1). It sublimes at 178°C and melt at 238°C. Fast sublimation can be 
obtained at 160-165°C at 1mm Hg pressure. It has a hexagonal prism shape. It 
dissolves freely in alcohol and water/ alcohol mixtures. It can interact  with water 
to give a monohydrate derivative (Chemfinder, 2004). Caffeine has 2 
polymorphs I and II with a transition point of 141±2°C. Caffeine is considered as 
a CNS and respiratory tract stimulant. 
 
3.2.1.1 Thermal analysis 
TGA and DSC 
Unprocessed caffeine was scanned in order to measure the thermal 
degradation profile of the drug and its melting point.  TGA and DSC tests were 
carried out according to the method described in section 2.2.1.1 and 2.2.1.2 
TzeroTM hermetic pans and lids were used for DSC test in order to contain 
caffeine sublimation. The results are shown in figure 3.2. 
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Figure 3.2. Representative TGA (blue) and DSC (green) thermal profiles of unprocessed 
caffeine powder.  
 
Figure 3.2 shows that the TGA profile reveals an onset of weight loss due to 
sublimation/degradation at around 160°C. Meanwhile, the DSC curve shows an 
endothermic broad peak at 158°C which was correlated to the sublimation of 
caffeine (Hubert et al., 2011). The peak at 237°C corresponds to the theoretical 
value of the melting point of caffeine. However, it has to be noted that at the 
melting point of caffeine only 28% of the weight was left according to the TGA 
curve. This is due to caffeine sublimation  
 
3.2.1.2 Powder X-ray diffraction 
Caffeine was analyzed using powder x-ray diffraction in order to verify the 
crystal lattice structure of the compound. The measured diffraction was 
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compared to that obtained from the Cambridge Structure Database (CSD) 
library for the anhydrous and monohydrate forms of caffeine (figure 3.3). 
Figure 3.3. Representative X-ray diffraction patterns of caffeine monohydrate CSD (bottom), 
anhydrous caffeine CSD (middle), and caffeine as received (top). 
 
X-ray diffraction of anhydrous caffeine is characterized by a weak intensity 
single peak at 8° and another strong intensity peak at 11°. On the other hand, 
monohydrated caffeine is characterized by the existence of three peaks at 10°, 
12°, and 13°. In addition to a strong intensity peak that exists at 8°. The scan of 
caffeine as received in figure 3.3 shows a weak intensity peak at 8° and a 
strong single peak at 11°. This means that the diffraction pattern of caffeine 
received from Sigma-Aldrich corresponds well to that of anhydrous caffeine. 
Moreover, a further investigation reveals that the caffeine polymorph I has a 
single diffraction peak at 26.8° in comparison to polymorph II that reveals two 
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peaks at 26.3° and 27° (Kishi and Matsuoka, 2010). The unprocessed caffeine 
diffraction pattern contain two peaks at 26.3° and 26.9° indicating that it is type 
II polymorph. 
 
3.2.1.3 FT-IR transmission 
Caffeine was scanned with FT-IR spectroscopy as detailed in section 2.2.3. The 
results are represented in figure 3.4. The spectrum reveals three characteristic 
peaks at 3133 (N-H), 1700 (C=N), and 958 (N-H) cm-1. These peaks are 
significant since the nitrogen atom in that bond is expected to form a hydrogen 
bond when co-crystals of caffeine are formed. If such a hydrogen bond is 
formed then it will be manifested by a shift in one of those three peaks.  
Figure 3.4, Representative FT-IR spectrum of caffeine as received. 
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3.2.2 Malonic acid  
Malonic acid or propanedioic acid is a dicarboxylic 
acid. It has the structure of CH2(COOH)2 (figure 3.5). 
It has a molecular weight of 104.06146 [g/mol]. It forms crystals that melt at 
135°C (Sigma-Aldrich). It is freely soluble in water and alcohol. It is used in the 
manufacturing of barbiturates. 
Malonic acid is used as a co-crystal former with caffeine to protect caffeine from 
hydration. 
 
3.2.2.1 Thermal behaviour 
TGA and DSC 
Thermal behaviour of malonic acid was characterized using TGA and DSC 
(method section 2.2.1.1 and 2.2.1.2). The thermal profile scan revealed the 
degradation profile of malonic acid and its melting temperature (figure 3.6). A 
triplicate scan was carried out to ensure accuracy (figure Appendix II.1). 
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Figure 3.6. A representative TGA and DSC thermal profile of malonic acid as received 
 
The thermal degradation of malonic acid was observed to commence at 140°C 
on the TGA profile. The DSC profile shows two endothermic peaks. The first 
peak, at 136.6°C, can be correlated with the melting and / or decomposition 
point of malonic acid as it is similar to the theoretical value provided in Sigma-
Aldrich database (132-135°C). The difference between the two values may be 
related to the thermal lag due to the packing of the crystals in the DSC pan. The 
peak at 84°C was not mentioned in Sigma-Aldrich Database. (Caires et al., 
2009) analysed the thermal behaviour of malonic acid using TGA, X-ray, and 
FT-IR and they found that malonic acid has a solid phase transition peak at 
110°C (heating rate 20°/min) with melting point of 145°C and decomposition of 
215°C. (Bougeard et al., 1988) also analysed malonic acid thermally. They 
identified the solid phase transition peak from β to α at ca 360 K (87°C) with 
heating rate of 10°C/min. The latter result is only 2°C different to the result 
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obtained in the current and this difference might be related to the hygroscpicity 
or traces of impurity in malonic acid sample or an instrumental differences. 
 
3.2.2.3 Powder X-ray diffraction 
A malonic acid diffraction pattern using the powder x-ray diffractometer was 
performed in order to identify the polymorph type of malonic acid. Unlike 
caffeine, malonic acid has a one diffraction pattern provided by the CSD 
software. (Caires et al., 2009) provide the X-ray data for the two polymorphs  A 
comparison of the diffraction pattern provided by him shows that the diffraction 
pattern of α polymorph has two peaks at 17° and 18° in comparison to one peak 
at 17° for β polymorph. In addition β polymorph showed a diffraction peak at 27° 
with no similar peak in α polymorph. Figure 3.7 reveals that the diffraction 
pattern obtained by scanning malonic acid shows peaks at 17°, 18° and 27°. 
Thus the starting malonic acid sample used in this study is believed to contain 
both polymorphs. 
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Figure 3.7. Representative powder X-ray diffraction pattern of malonic acid as received (top) 
and a reference pattern for malonic acid from CSD (bottom). 
 
 
3.2.2.4 FT-IR transmission 
 Malonic acid is a complicated compound to analyze with FT-IR. It has two 
mirror-image carboxylate groups attached to CH2 center as shown in figure 3.5. 
Malonic acid was analyzed using FT-IR according to the method described in 
section 2.2.3. The results, shown in figure 3.8 reveals a characteristic peak at 
1700 cm-1. this peak can be correlated to the C=O and O-H bands (Bougeard et 
al., 1988). Both functional groups are expected to be involved in hydrogen bond 
formation. If such a hydrogen bond is formed then we would expect a shift in 
that peak in the FT-IR spectrum.  
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Figure 3.8.  A representitive of FT-IR spectrum of malonic acid as received. 
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3.2.3 Ibuprofen  
 
Ibuprofen or α-methyl-4-(2-methylpropyl) 
benzeneacetic acid is a non steroidal anti inflammatory drug (see figure 3.9). It 
has an analgesic antipyretic activity as well. Ibuprofen has a molecular weight of 
206.28 g/mol and a melting point of 75-77°C. It is a colorless crystalline stable 
solid. Ibuprofen exists as S, R, or R/S racemate isomer. The S isomer is more 
active than the R isomer. 
Ibuprofen (S, RS) is known to form a co-crystal with nicotinamide (Berry et al., 
2008). 
 
3.2.3.1 Thermal analysis 
TGA and DSC 
A thermal degradation profile and change of the enthalpy of ibuprofen was 
recorded using TGA and DSC following the methods described in sections 
2.2.1.1 and 2.2.1.2. TGA thermal profile in figure 3.10 shows that the thermal 
degradation of ibuprofen begins at around 150°C. The DSC scan shows a sharp 
endothermic peak at 76°C. This peak matches the melting point of ibuprofen 
(section 3.1.3). A triplicate scan is shown in Appendix  AII.2. 
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Figure 3.10. A representative of TGA and DSC thermal profile of unprocessed ibuprofen. 
 
3.2.3.2 Powder X-ray diffraction 
Ibuprofen has three isomers (R, S, and RS racemate). S and R/S isomers can 
form co-crystals with nicotinamide(Berry et al., 2008). In this study, ibuprofen 
was analyzed with PXRD using the method described in section 2.2.2. The 
results were compared with those obtained from CSD software (Mercury 3.0) 
(figure 3.11). Standard diffraction pattern of RS-ibuprofen shows a peak at 6°. 
On the other hand, S isomer has two peaks at 7° and 7.7° that do not appear in 
the racemate pattern. Figure 3.11 shows that the diffraction obtained for 
unprocessed ibuprofen using the method in section 2.2.2 has a high intensity 
peak at 6° with no sign for peaks at 7° or 7.7°. Therefore, it can be concluded 
that the unprocessed ibuprofen is a racemate form. 
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Figure 3.11. A representative powder X-ray diffraction pattern of unprocessed ibuprofen (top), 
standard diffraction pattern obtained from CSD for ibuprofen S (middle), and standard ibuprofen 
racemate (CSD) pattern (bottom). 
 
3.2.3.3 FT-IR transmission 
In order to detect any changes is the energy of the functional groups of 
Ibuprofen that may arise during co-crystal formation, a reference of the 
unprocessed ibuprofen FT-IR spectrum has to be obtained. Using the method 
described in section 2.2.3, ibuprofen was analyzed with FT-IR spectroscopy. 
The spectrum of ibuprofen was plotted in figure 3.12. COOH entity is the major 
functional group of the molecule. (Jubert et al., 2006) has identified the peak at 
around 1700 cm-1 and assigned it for C=O and OH vibrations. 
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Figure 3.12. A representative FT-IR spectrum of unprocessed ibuprofen. 
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3.2.4 Nicotinamide  
Nicotinamide (niacinamide) is an amide of nicotinic acid 
(figure 3.13). It can be described as a white or whitish 
crystalline powder that forms needle-shape crystals from benzene. It has a 
melting point of 128-131°C and a pKa of 3.3. It is freely soluble in water and 
alcohol. 1 gram of nicotinamide dissolves in 1 ml of water or 1.5 ml of alcohol. 
 
3.2.4.1 Thermal analysis 
TGA and DSC 
Nicotinamide has four known polymorphs (Hino et al., 2001). Those polymorphs 
can be differentiated by their thermal behaviour. Thus the thermal behaviour of 
unprocessed nicotinamide was obtained using TGA and DSC in order to identify 
its polymorphic type. Nicotinamide was examined using the methods described 
in section 2.2.1.1 and 2.2.1.2. The weight loss and the DSC profile of 
nicotinamide were plotted in figure 3.14. 
The thermal behaviour of nicotinamide polymorphs reveals different melting 
points for the polymorphs. The melting point for polymorph I, II, III, and IV as 
126°C -128°C, 112°C -117°C, 107°C -111°C, and 101°C -103°C respectively 
(Akalin and Akyuz, 2006). The TGA profile a weight loss associated with the 
thermal degradation of unprocessed nicotinamide to begin at around 
160°C(figure 3.14). Moreover, the DSC scan shows an endothermic peak at 
129.6°C. This peak can be correlated to the melting point of polymorph I. 
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Figure 3.14. Representative TGA and DSC thermal profiles for unprocessed nicotinamide. 
 
3.2.4.2 Powder X-ray diffraction 
The diffraction pattern of unprocessed nicotinamide was obtained using the 
method described in section 2.2.2. The results shown in figure 3.15 were 
comparable to the standard diffraction pattern obtained from CSD library. The 
measured spectrum will serve as a reference to detect any changes might arise 
as a result of a polymorphic or co-crystal formation. 
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Figure 3.15. A representative powder X-ray diffraction pattern for unprocessed (top) and a 
standard diffraction pattern of nicotinamide obtained from CSD software (bottom). 
 
3.2.4.3 FT-IR transmission 
The FT-IR spectrum of unprocessed nicotinamide was obtained using the 
method described in 2.2.3. To the best of the author’s knowledge, there is no 
available literature comparison between nicotinamide polymorphs FT-IR 
transmission spectrum. The measured spectrum will serve as a reference to 
detect any vibrational energy change that might arise due to polymorphic 
change or co-crystals formation. Figure 3.16 shows a transmission peak at 
3350 cm-1. This peak can be correlated to the NH2 vibration (Akalin and Akyuz, 
2006). This band is going to be of a particular interest to confirm the formation 
of nicotinamide-ibuprofen co-crystals. 
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Figure 3.16. A representative FT-IR spectrum for unprocessed nicotinamide. 
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3.2.5 Naproxen  
Naproxen or 2S-2-(6-methoxynaphthalen-2-yl) 
propanoic acid is a non steroidal anti-inflammatory 
drug (figure 3.17). It has analgesic and anti-pyretic activity as well. It is a white 
or whitish crystalline powder. It forms crystals when recrystallized using 
acetone-hexane. It melts at 154-158°C. Naproxen is considered to be practically 
insoluble in water. However, it dissolves in methanol, ethanol, and chloroform. 
 
3.2.5.1 Thermal analysis 
TGA and DSC 
Naproxen has four polymorphs. These polymorphs differ in their thermal profile. 
The melting point of polymorph I, II, III, IV is 156°C, 76°C, 140°C, and 148°C 
respectively (Song and Sohn, 2011). The thermal profile of unprocessed 
naproxen was measured using the methods described in section 2.2.1.1 for 
TGA and section 2.2.1.2 for DSC. The TGA scan reveals a weight loss 
associated with the degradation of naproxen begins at around 170°C (figure 
3.18). An endothermic peak at 156°C is observed in the DSC scan. This peak 
can be correlated to the melting of naproxen polymorph I as mentioned above 
(Song and Sohn, 2011). 
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Figure 3.18. Representative TGA and DSC thermal profiles for unprocessed naproxen. 
 
3.2.5.2 X-Ray 
The x-ray diffraction pattern of naproxen was obtained using the method 
described in section 2.2.2. The CSD database offers one diffraction pattern for 
naproxen. The diffraction patterns of naproxen polymorphs are available (Song 
and Sohn, 2011). The polymorphs I, III, and IV have a peak at 6°. However, 
polymorph I has two additional peaks at 11° and 12°. The measured diffraction 
of the unprocessed naproxen shows peaks at 6°, 12°, and 13° (figure 3.19). The 
difference in the peak positioning can be related to the use of a powder XRD 
instead of a single crystal XRD. This result indicates that the unprocessed 
naproxen as well as the diffraction pattern provided by the CSD software is form 
I naproxen.  
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Figure 3.19. A representative powder X-ray diffraction pattern for unprocessed (top) and 
standard diffraction pattern from CSD library for naproxen (bottom). 
 
3.2.5.3 FT-IR transmission 
Unprocessed naproxen was analysed with the FT-IR using the method 
described in section 2.2.3(figure 3.20). The scan of unprocessed naproxen will 
be used as a reference for comparison to detect any change in the vibrational 
behaviour of the bonds in the compound after processing. The full assignment 
of naproxen bond can be obtained from (Jubert et al., 2006). 
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Figure 3.20. A representative FT-IR spectrum for unprocessed naproxen. 
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3.2.6 Flurbiprofen 
Flurbiprofen is a white or whitish crystalline powder. It 
is a non- steroidal anti-inflammatory drug (figure 
3.21). It is considered as practically insoluble in water. However, it is freely 
soluble in ethanol and methylene chloride. It has a melting point of 114-117°C 
with a molecular weight of 244.26 g/mol.  
 
3.2.6.1 Thermal analysis 
TGA and DSC 
Flurbiprofen has two polymorphs, each of which has a different thermal 
behaviour. The melting point of polymorph I and II using a heating rate of 
10°C/min is 112.8°±0.2°C and 94°±0.2°C respectively (Lacoulonche et al., 
1997). In this study, the unprocessed flurbiprofen thermal profile was obtained 
using the methods described in section 2.2.1.1 and 2.2.1.2. The thermal profile 
obtained (figure 3.22) shows a weight loss resulted from the thermal 
degradation of unprocessed flurbiprofen begins at 155°C. DSC scan of 
ibuprofen reveals an endothermic peak at 114.8°C. This indicates that the 
unprocessed flurbiprofen is form I polymorph. A duplicate scan of pure 
flurbiprofen is provided in Appendix AII.4. 
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Figure 3.22. Representative TGA and DSC thermal profiles for unprocessed flurbiprofen. 
 
3.2.6.2 X-ray 
The diffraction pattern of polymorph I flurbiprofen characterized by two peaks at 
3.6° and 5.5° while polymorph II has one peak at 4.6°(Lacoulonche et al., 
1997). CSD library was found to contain one diffraction pattern for flurbiprofen 
without specifying the type of polymorph used. A sample of unprocessed 
flurbiprofen was analyzed with powder XRD using the method described in 
section 3.2.2. The diffraction pattern was found to contain a high noise/signal 
ratio preventing the identification of the polymorph (figure 3.23). This was 
caused by some cracks on the sample holder.Thus the diffraction pattern 
obtained from the unprocessed flurbiprofen was used as a template for 
comparison to detect any changes may occur to flurbiprofen. 
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Figure3.23. A representative powder X-ray diffraction pattern for unprocessed flurbiprofen (top) 
versus diffraction pattern obtained from CSD library (bottom). 
 62 
 
3.2.7 HPMCAS 
Hydroxypropyl methyl cellulose or hypromellose acetate succinate is a cellulosic 
enteric coating agent. It is manufactured by Shin-Etsu. 
It is used in aqueous coatings. Tri ethyl citrate is a recommended plasticiser 
(Shin-Etsu, 2005). 
 
3.2.7.1 Thermal analysis 
TGA and DSC 
HPMCAS is known to be a hygroscopic polymer. In order to estimate the 
amount of absorbed moisture, the thermal profile for HPMCAS was obtained 
using the method described in section 2.2.1.1 and 2.2.1.2. The TGA profile 
(figure 3.24) indicates that the polymer has lost 2% of its weight at 100°C. This 
loss is believed to be due to the evaporation of residual moisture. The DSC 
profile shows a glass transition step with a value of 123.13°C calculated with TA 
software compared to a Tg literature value of around 122 ± 0.8°C (Kablitz et al., 
2006).  A duplicate scan of pure HPMCAS is shown in the Appendix AII.5. 
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Figure 3.24. Representative TGA and DSC thermal profiles for unprocessed HPMCAS powder.  
 
3.2.7.2  Powder X-ray diffraction 
The diffraction pattern of HPMCAS was obtained using the method described in 
section 2.2.2. The diffraction pattern in figure 3.25 reveals a very high 
noise/signal ratio, in addition to the appearance of two wide peaks. This 
diffraction pattern is a typical diffraction pattern for amorphous materials. This 
suggests that the polymer is predominantly amorphous which conforms with the 
reported literature (Shin-Etsu, 2005). 
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Figure 3.25. A representative powder x-ray diffraction pattern for unprocessed HPMCAS 
powder. 
 
3.2.7.3 FT-IR transmission 
The FT-IR transmission spectrum of HPMCAS was obtained using the method 
described in section 2.2.3. The FT-IR spectrum for unprocessed HPMCAS can 
be used as a reference to detect any vibrational energy changes might arise 
during processing (figure 3.26). 
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Figure 3.26. A representative FT-IR spectrum for unprocessed HPMCAS powder. 
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3.3 Recrystallization experiments 
The unprocessed materials were studied in section 3.1 in order to identify their 
thermal, crystallographic, and their spectroscopic characteristics. This section 
studied the effect of solvent on the raw materials (after a recrystallization with 
various solvent systems). The comparison of the data obtained from the 
analysis of the recrystallized materials should provide a clear evidence about 
the effect of solvent systems on the physicochemical properties of the 
unprocessed drugs.  
 
3.3.1 Caffeine recrystallization 
The analysis of the unprocessed caffeine section 3.1.1 revealed that caffeine is 
in the form of polymorph I. The crystal structure and the vibrational features 
were identified. The study of the solvent effect on unprocessed caffeine was 
performed by re-crystallizing caffeine using the method described in section 
2.3.1 and analyzing the resultant compound.  
 
3.3.1.1 Recrystallization using acetone/chloroform 3:2 v/v 
In order to form a drug-containing film, a suitable solvent was needed to 
dissolve the polymer (HPMCAS). Acetone is considered as a good solvent for 
the polymer. However, it is considered as a polar solvent. Therefore, it might 
disrupt the co-crystals loaded into the polymeric film and prevent their 
components from re-forming co-crystals again. Chloroform on the other hand, is 
a good solvent for caffeine, malonic acid, ibuprofen and nicotinamide but not for 
HPMCAS. Therefore a few attempts were carried out to investigate the best 
mixing ratio of both solvents. Consequently, the result revealed that the best 
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ratio is 3:2 v/v acetone/chloroform. Care was taken over the exothermic solvent 
mixing reaction. 
The recrystallization process of caffeine from acetone acetone/chloroform was 
performed using the method described in section 2.3.1. The physicochemical 
properties of the final drug after drying was identified and compared to that of 
unprocessed caffeine.  
Recrystallized caffeine was scanned using TGA, DSC, X-ray, and FT-IR. 
 
3.3.1.1.1 Thermal analysis 
TGA and DSC 
Recrystallized caffeine was scanned using TGA and DSC in order to detect any 
change in the thermal behaviour of caffeine, and to identify the existence of any 
residual solvent. TzeroTM hermetic pans were used for DSC analysis in order to 
minimize the sublimation and consequently any instrument damage. 
Recrystallized caffeine was analyzed using the method described in section 
2.2.1.1 and 2.2.1.2. The TGA profile reveals that caffeine lost about 3% of its 
weight at 35°C of the weight loss continues to around 80°C (figure 3.27). This 
3% is expected to be due to the evaporation of the residual solvent. Another 
sharp onset of weight loss for caffeine appears to begin at about 160°C. The 
DSC profile reveals 4 endothermic peaks at 79°C, 139°C, 179°C, and 235°C. 
The peak at 79°C is a strong intensity narrow peak, untypical of a solvent 
evaporation peak. the literature revealed that this peak is related to the 
peritectic decomposition process of the hydrate(Griesser and Burger, 1995 , 
Bothe and Cammenga, 1980). Hence the weight loss in the TGA profile below 
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80°C may be explained by the evaporation of water molecules. The second 
endothermic peak at 140°C in the DSC profile is found to be linked to the phase 
transformation of caffeine from polymorph I into polymorph II (Manduva et al., 
2008). It is noticeable from figure 3.27 that the peak at 179°C has a wide base. 
This peak is linked in the literature to the sublimation temperature of caffeine 
(Bothe and Cammenga, 1980). The last peak is at the melting range of caffeine 
thus it can be correlated to the melting of recrystallized caffeine. 
Figure 3.27. Representative TGA and DSC thermal profiles for recrystallized caffeine from 
acetone/chloroform. 
 
In order to identify the solvent effect on the caffeine physicochemical properties, 
DSC thermal profile of recrystallized and unprocessed caffeine were plotted in 
figure 3.28. It is noticeable that caffeine sublimation is shifted from 158°C in the 
thermal profile in unprocessed caffeine to 179°C in the thermal profile of the 
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recrystallized one. The melting point of unprocessed caffeine is shifted from 
237°C to 235°C. This shift is thought to be related to the water effect in the 
hydrated form. 
Figure 3.28. A representative DSC thermal profile of recrystallized (green) and unprocessed 
(blue) caffeine. 
 
As a conclusion, the recrystallization of caffeine from acetone/chloroform 
solvent system resulted in the conversion of anhydrous caffeine form II into 
monohydrated caffeine. 
  
3.3.1.2 Powder X-ray diffraction 
The diffraction pattern of recrystallized caffeine was obtained using the method 
described in section 2.2.2. The diffraction pattern of the recrystallized caffeine 
was compared to the diffraction pattern of the unprocessed caffeine and 
anhydrous and hydrated caffeine obtained from the CSD library (figure 3.29). 
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The diffraction pattern of recrystallized caffeine reveals a diffraction peak at 6°. 
This peak is not observed in the diffraction of hydrated or anhydrous caffeine 
(CSD). To the best of knowledge this peak could not be correlated neither to the 
polymorphism nor to the hydration of caffeine. However, it might be related to 
the sampling process. The diffraction pattern of recrystallized caffeine reveals 
peaks at 8°, 11°, 12°, and 13°. These peaks are correlated to the diffraction 
pattern of monohydrated caffeine.  
Figure 3.29. A representative powder X-ray diffraction pattern of recrystallized caffeine (top-
blue), caffeine as received (second from top-red), caffeine monohydrate CSD (third from top-
green), and anhydrous caffeine CSD (bottom-yellow). 
 
Consequently, both thermal profile and the x-ray diffraction pattern confirm the 
conversion of anhydrous caffeine form II polymorph to monohydrated caffeine.  
 71 
 
3.3.2 Recrystallization with ethanol/water 4:1 w/w  
Caffeine was recrystallized from ethanol/water using the method described in 
section 2.3.1. The product was characterized and compared to the 
physicochemical properties of unprocessed caffeine. 
 
3.3.2.1 Thermal analysis 
TGA and DSC 
Thermal behaviour of recrystallized caffeine was obtained using the method 
described in section 2.2.1.1 and 2.2.1.2. The thermal behaviour of recrystallized 
caffeine was plotted in figure 3.30. The TGA profile shows a weight loss of 3% 
beginning at 35°C and ending at 75°C. This behaviour is similar to the TGA 
thermal behaviour of recrystallized caffeine section 3.2.1.1.1. The loss is 
expected to be correlated to the slow evaporation of residual solvent or water 
evaporation. DSC profile reveals four endothermic peaks at 78°C, 138°C, 
192°C and 236°C. Similarly to the DSC analysis of the recrystallized caffeine in 
section 3.2.1.1.1, those peaks can be correlated to: the peritectic decomposition 
process of the hydrate (78°C), the phase transformation temperature of caffeine 
from polymorph I into polymorph II (138°C), the sublimation temperature of 
caffeine (192°C), and the melting point of caffeine (236°C). 
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Figure 3.30. Representative TGA and DSC thermal profiles for recrystallized caffeine from 
ethanol/water. 
 
The same comparison used in section 3.2.1.1.1 is applicable in this section, i.e.  
This concluded that recrystallization of caffeine from ethanol/water has resulted 
in the conversion of anhydrous caffeine form II into monohydrated caffeine. 
 
3.3.2.2 Powder X-ray diffraction 
The diffraction pattern of recrystallized caffeine was obtained using the method 
described in section 2.2.2. The diffraction pattern of recrystallized caffeine was 
plotted and compared to the diffraction pattern of unprocessed caffeine and 
standard diffraction patterns for anhydrous (form II) and monohydrated caffeine 
(figure 3.31). Similarly to section 3.2.2, the diffraction pattern of recrystallised 
caffeine revealed four characteristic peaks at 8°, 11°, 12°, and 13°. These 
peaks can be correlated to monohydrated caffeine diffraction pattern. Thus 
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caffeine was converted by re-crystallization from anhydrous form II into a 
monohydrated from. This conclusion conforms with the conclusion obtained in 
section 3.2.2.1. 
Figure 3.31. A representative powder x-ray diffraction pattern for anhydrous caffeine CSD 
standard (bottom-purple), monohydrate caffeine CSD standard (second from bottom-red), 
caffeine as received (third from bottom-yellow), and recrystallized caffeine with ethanol/water 
(top-green).  
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3.3.3 Recrystallization of caffeine using acetonitrile 
Caffeine was recrystallized from acetonitrile using the method described in 
section 2.3.1. The physicochemical properties of the resultant product were 
obtained from analysis with TGA, DSC, and X-ray.  
 
3.3.3.1 Thermal analysis 
TGA & DSC 
The thermal profile of recrystallized caffeine was obtained using the method 
described in section 2.2.1.1 and 2.2.1.2. TGA and DSC thermal profiles were 
plotted in figure 3.32. TGA profile in figure 3.32 reveals that the weight loss 
associated with the degradation of caffeine begins at 140°C with no weight loss 
step at around 35°C such as those observed in section 3.2.1.1.1 and 3.2.2.1. 
On the other hand, DSC scan reveals the same 4 peaks observed in section 
3.2.1.1.1 and 3.2.2.1, i.e. the recrystallization of caffeine with acetonitrile 
resulted in the formation of caffeine monohydrate. 
Figure 3.32. A representative TGA and DSC thermal profile for recrystallized caffeine form 
acetonitrile. 
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3.3.3.2 Powder X-ray scan diffraction 
The diffraction pattern of recrystallized caffeine was obtained using the method 
described in section 2.2.2. The diffraction pattern was compared to the patterns 
of unprocessed anhydrous and monohydrated caffeine in figure 3.33. The 
diffraction pattern of the recrystallized caffeine reveals peaks at 8°, 10°, 11°, 
and 12°. This is similar to the diffraction pattern observed in section 3.1.2.2 and 
3.2.2.2. Those peaks can be observed in the diffraction pattern of 
monohydrated caffeine. Thus the caffeine recrystallized from acetonitrile can be 
considered as monohydrated caffeine as well. This result conforms with the 
result obtained from the thermal analysis in section 3.2.3.1.   
Figure 3.33. Representative powder x-ray diffraction pattern for a standard anhydrous caffeine 
CSD (bottom purple), a standard monohydrate caffeine CSD (second from bottom-red), caffeine 
as received  (third from bottom- yellow), and caffeine recrystallized from acetonitrile (top-bluish 
green). 
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Caffeine recrystallized with acetone/chloroform, ethanol/water, and acetonitrile 
is found to convert into the monohydrated form. This may be explained in the 
recrystallization process using ethanol/water as the caffeine comes into a 
contact with water molecules. However, it is unusual in the case of acetonitrile 
or acetone/chloroform. Caffeine most likely must have interacted with 
atmospheric moisture during the evaporation of the solvents to form the 
monohydrated caffeine form. 
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3.3.2 Recrystallization of malonic acid 
Malonic acid was recrystallized from acetone/chloroform, ethanol/water, and 
acetonitrile using the method described in section 2.3.1. Physicochemical 
properties of recrystallized malonic acid were obtained from analysis with TGA, 
DSC, and XRD.  
 
3.3.2.1. Thermal analysis 
TGA and DSC 
The thermal profiles of recrystallized malonic acid from acetone/chloroform 
were obtained using the methods described in section 2.2.1.1 and 2.2.1.2. The 
results of the thermal analyses were plotted in figure 3.34. The TGA profile 
reveals that a weight loss resulted from the thermal degradation of malonic acid 
begins at 140°C in a similar manner to the unprocessed malonic acid 
degradation profile. The DSC thermal profile reveals two endothermic peaks at 
90°C and 134°C. The first be can be correlated to the phase transition 
temperature of malonic acid (Bougeard et al., 1988). However, a shift was 
observed for the solid phase transition temperature from 85°C in the 
unprocessed malonic acid to 90°C in the recrystallized form.  
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Figure 3.34. A representative TGA and DSC thermal profile for recrystallized malonic acid from 
acetone/chloroform. 
 
The thermal profiles for malonic acid recrystallized with acetonitrile and 
ethanol/water were obtained using the methods described in section 2.2.1.1 and 
2.2.1.2 the data are given in figure AII.7. The thermal profiles for both solvent 
systems reveal similarity to the thermal profile of recrystallized malonic acid with 
acetone/chloroform. Hence, the recrystallization of malonic acid from 
acetone/chloroform, ethanol/water, and acetonitrile shifted the solid phase 
transition peak. However, it did not change the melting point of malonic acid.  
 
3.3.2.2 Powder X-ray diffraction 
The diffraction pattern of recrystallized malonic acid was obtained using the 
method described in section 2.2.2. The collected pattern is shown with the 
diffraction pattern of malonic acid recrystallized from ethanol/water, 
recrystallized from acetonitrile, and the unprocessed batch in figure 3.35. Two 
characteristic diffraction peaks at 17° and 18° are observed in the diffraction 
patterns of malonic acid recrystallized from ethanol/water, recrystallized from 
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acetonitrile, or unprocessed. However, the diffraction pattern of recrystallized 
malonic acid from acetone/chloroform reveals one peak at 17° and a very low 
intensity peak at 18°. The difference between the diffraction patterns in figure 
3.35 can be correlated to the use of a smaller quantity of sample for 
recrystallized malonic acid with acetone/chloroform, ethanol/water, and 
acetonitrile.  
Fig
ure 3.35. Representative powder x-ray diffraction pattern for  unprocessed malonic acid 
(bottom-red), malonic acid recrystallized from acetone/chloroform (second from bottom-dark 
red), recrystallized from ethanol/water (third from bottom-blue), and recrystallized from 
acetonitrile (top-pink). 
 
Therefore, it can be concluded that all the solvent systems resulted in the same 
polymorphic form. 
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3.4 Summary and conclusion 
The raw materials were characterized in order to identify their physicochemical 
properties. In addition to that, the solvent systems effect was studied as well by 
re-crystallizing these drugs. 
The characterization of the unprocessed materials revealed that caffeine is a 
form II anhydrous caffeine, malonic acid is a form α, ibuprofen is a racemic 
mixture, and nicotinamide and naproxen are form I. On the other hand, the 
morphology of flurbiprofen was hard to identify. 
Thermal DSC profile of malonic acid showed a small solid phase transition 
endotherm from polymorph β to polymorph α. 
The solvent systems were observed to have no effect on the raw materials 
except in the case of caffeine. Recrystallizing caffeine using the aforementioned 
solvent systems resulted in the conversion of anhydrous caffeine into a 
monohydrated one. It was observed as well that the thermal DSC scan of 
caffeine the appearance of a solid phase transition peak that confirms the 
presence of polymorph I. This indicates the conversion of some caffeine from 
polymorph II to polymorph I. The TGA thermal profile for caffeine showed a 3% 
weight loss except in the case of acetonitrile. This weight loss was correlated to 
the evaporation of the residual moisture. 
  
 
 
 
 
 
 
 
 
Chapter 4 
Preparation of co-crystals and their characterization 
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4.1 Introduction 
Drug-excipients interaction can impact the bioavailability and stability of the API. 
The study of such interactions requires a knowledge of the properties and the 
behaviour of the compounds involved. The interaction of a system composed of 
a co-crystalline drug and a polymorphic vehicle can be understood by individual 
components and their behaviour in the preparation media. Chapter 3 has 
brought to the light the properties of the APIs and other co-crystal formers. It 
also provided the information needed to understand about the behaviour of 
those materials in the preparation media of the final dosage form (co-crystals 
containing films).  
This chapter focuses on the process of co-crystal formation and their 
physicochemical properties. It also studies the possibility of producing the co-
crystals using different media in order to provide wider options to select from for 
the film loading process.  
Two co-crystal systems will be studied: caffeine-malonic acid and (±) ibuprofen 
(RS)-nicotinamide. A novel third system was discovered during the progress of 
the project. Thus, malonic acid-nicotinamide co-crystal formation is studied in 
this chapter and its physicochemical properties presented. 
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4.2 Co-crystallization of caffeine and malonic acid 
Caffeine-malonic acid co-crystals were prepared using the method described in 
section 2.3.2. In addition to the use of chloroform/methanol 30:1 v/v as a co-
crystallization solvent (Trask et al., 2005), the possibility of growing caffeine-
malonic acid co-crystals from other solvent systems was investigated. The use 
of acetone/chloroform 3:2 v/v, ethanol/water 4:1 w/w, and acetonitrile as a co-
crystallization solvent is investigated in this chapter. The properties of any 
successfully formed co-crystalline system will be characterized in order to have 
a better understanding of the formation process. 
 
4.2.1 Co-crystal analysis 
Caffeine-malonic acid co-crystals were prepared using the method described in 
section 2.3.2 using chloroform/methanol, acetone/chloroform, ethanol/water, 
and acetonitrile as preparation media. The physicochemical properties of the 
co-crystals were characterized using techniques presented in the previous 
chapter. 
  
4.2.1.1 Thermal analysis 
4.2.1.1.1 TGA analysis 
Thermal profiles of caffeine-malonic acid co-crystals from the aforementioned 
solvent systems were obtained using the method described in section 2.2.1.1. 
The obtained profiles were compared to the thermal profiles of unprocessed 
caffeine and malonic acid (figure 4.1). The TGA profile reveals a two event for 
the co-crystals. The first stage commences at around 140°C and the second 
one commences at around 170°C.  Comparing the degradation steps to the 
 83 
 
thermal degradation profile obtained for caffeine and malonic acid reveals that 
the degradation step at 140°C can be correlated to the degradation of malonic 
in the co-crystals. The second degradation step can be correlated to caffeine 
degradation.  However, there is a noticeable difference between the thermal 
degradation profiles of co-crystals prepared from different solvents in a similar 
manner to the profiles of recrystallized caffeine in section 3.1.1.1.  
Figure 4.1. A representative TGA thermal profile for caffeine-malonic acid co-crystals prepared 
from  chloroform/methanol (green), acetone/chloroform (blue), ethanol/water (red), and 
acetonitrile (pink) in comparison to unprocessed caffeine (teal) and malonic acid (navy blue). 
 
4.2.2.1.2 DSC analysis 
Caffeine-malonic acid co-crystals were examined using the method described in 
section 2.2.1.2. for the purpose of comparison we will consider the two largest 
endotherms obtained (figure 4.2). The first set is observed at around 133°-
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135°C. These peaks are similar to the melting peak of malonic acid. The second 
major  peak occur around 234°C- 237°C except for that co-crystals prepared 
using acetone/chloroform where it was found at 230°C. This set of peaks can be 
correlated to the melting peak of unprocessed caffeine. The shift in the melting 
peak in the later case may result from the existence of some impurities. A third 
set of common peaks with a wider base are observed at 168°C-171°C. This set 
is similar to the peaks found for recrystallized caffeine in section 3.2.1.1, 
3.2.2.1, and 3.2.3.1. These peaks were identified earlier as caffeine sublimation 
peaks. The shifting of this peak in co-crystals prepared from acetone/chloroform 
to 200°C might be related to the existence of polymorph II of caffeine (Griesser 
et al., 1999 , Emel’yanenko and Verevkin, 2008). Figure 4.2 also shows weak 
intensity wide peaks around 85°C-98°C. These peaks can be correlated to the 
solid transition phase of malonic acid.   
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Figure 4.2. A representative DSC thermal profile for unprocessed caffeine (green), unprocessed 
malonic acid (navy blue), co-crystals prepared from chloroform/methanol (blue), 
acetone/chloroform (red), ethanol/water (pink), and acetonitrile (teal). 
 
Thermal analysis for caffeine-malonic acid co-crystals reveals a similar pattern 
to the unprocessed material thermal profile. The absence of new peaks and the 
existence of the raw materials melting peaks indicate that neither co-crystals 
nor eutectic mixture were formed.  
 
4.2.1.2 Powder X-ray diffraction 
The diffraction patterns of co-crystals prepared with various solvent systems 
were obtained using the method described in section 2.2.2. The collected 
diffraction patterns were compared to unprocessed anhydrous caffeine, 
unprocessed malonic acid, caffeine monohydrate (CSD), and caffeine-malonic 
acid co-crystals (CSD) diffraction patterns (figure 4.3). The last two diffraction 
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patterns were obtained from CSD library. The diffraction patterns of all the co-
crystals show reference peaks at 16.4°, 22.4°, 25°, and 28°. These peaks are 
the reference peaks for caffeine-malonic acid co-crystals (Ibrahim et al., 2010). 
These peaks can also be observed in the diffraction pattern (CSD). 
Consequently, the powder x-ray data confirms the formation of co-crystals from 
all solvent systems. However, co-crystals prepared using acetonitrile showed 
two extra peaks at 12° and 13.4°. These extra peaks can be observed in the 
diffraction pattern of caffeine monohydrate. Hence, it can be stated that the 
product from co-crystallizing caffeine and malonic acid using acetonitrile is a 
combination of the co-crystal and caffeine monohydrate. 
Figure 4.3.  A representative powder x-ray diffraction pattern for co-crystals prepared with: 
acetonitrile (top), ethanol/water (second from top), acetone/chloroform (third from top), 
chloroform methanol (forth from top), standard co-crystals diffraction (fourth from bottom), 
standard anhydrous caffeine diffraction (third from bottom), standard monohydrated caffeine 
diffraction (second from bottom), and standard malonic acid diffraction (bottom). 
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4.2.1.3 FT-IR transmission 
Co-crystals were examined using the method described in section 2.2.3. The 
collected spectra revealed shift in the following peaks: 1692 cm-1 peak to 1699 
cm-1, 1168 cm-1to 1178 cm-1, 962 cm-1 to 957 cm-1, 920 cm-1 to 904 cm-1.(Figure 
4.4) The first peak is assigned for the vibration energy of C=N, NH bond. This 
shift indicates the presence of a hydrogen bond. On the other hand, malonic 
acid has two mirror-image carboxylic acid groups. Thus there are few peaks 
that assign for the C=O, OH bond vibration energy (Bougeard et al., 1988). 
Nevertheless, the observed shifted peaks are some of the peaks that assign for 
these bonds energy. Therefore, the shift can be considered as a result for the 
hydrogen bond that formed between caffeine and malonic acid. Consequently, it 
confirms the successful formation of co-crystals using all the aforementioned 
solvents.  
 
Figure 4.4. A representative FT-IR spectrum for malonic acid (bottom), caffeine (second form 
bottom), co-crystals prepared with: chloroform/methanol (third from bottom), acetone/chloroform 
(forth from bottom), ethanol/water (second from top), and acetonitrile (top). 
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4.3 Co-crystallization of ibuprofen and nicotinamide 
Ibuprofen-nicotinamide co-crystals are one of the two co-crystals to be loaded 
into a polymeric film. The main difference between this system and the other is 
the solubility of the co-crystal components. While both caffeine and malonic acid 
are considered as water soluble drugs, ibuprofen, unlike nicotinamide, is 
considered to be a sparingly soluble one. This difference can create a challenge 
in the film loading process. In order to get a clear image about the 
physicochemical properties of the system, ibuprofen-nicotinamide co-crystals 
will be prepared and characterized using the aforementioned methods. 
Ibuprofen-nicotinamide co-crystals were prepared with acetonitrile using the 
method described in section 2.3.2. the result of their characterization is 
presented below. 
 
4.3.1 Thermal analysis 
TGA & DSC 
The DSC and TGA thermal profiles of ibuprofen-nicotinamide co-crystals were 
obtained using the methods described in sections 2.2.1.1 and 2.2.1.2. The data 
obtained were compared to the thermal profiles of unprocessed ibuprofen and 
nicotinamide (figure 4.5). The TGA thermal profile reveals that this co-crystal 
has a one step thermal degradation in contrast to the two step thermal 
degradation of caffeine-malonic acid (section 4.2.1.1.1). The degradation of the 
co-crystal starts after the degradation of ibuprofen and before the degradation 
of nicotinamide. On the other hand, the DSC profile shows an endothermic peak 
at 94°C. This peak was investigated and it appeared to be related to the melting 
of the co-crystalline system (Friscic and Jones, 2007). Another low-intensity 
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peak was observed on the DSC profile. This peak is observed at 71°C. This 
peak is consistent with the melting of the residual ibuprofen.  
Figure 4.5. A representative TGA and DSC thermal profiles for unprocessed ibuprofen, 
unprocessed nicotinamide, and co-crystals of ibuprofen-nicotinamide.  
 
4.3.2 Powder X-ray diffraction 
The powder x-ray diffraction pattern for the co-crystal was collected using the 
method described in section 2.2.2. The collected pattern was compared to a 
standard diffraction pattern obtained from the CSD library in addition to the 
unprocessed components (figure 4.6). The X-ray diffraction pattern of the co-
crystals reveals three diffraction peaks at 9°, 16°, and 21°. The same peaks can 
be observed in the standard diffraction pattern. In addition, the same peaks are 
not observed in the diffraction pattern of the individual unprocessed ibuprofen 
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and nicotinamide. This indicates that ibuprofen-nicotinamide co-crystals were 
successfully formed. 
Figure 4.6. Representative powder x-ray diffraction patterns for ibuprofen (purple), nicotinamide 
(red), ibuprofen, co-crystals standard diffraction pattern obtained from CSD library (yellow), and 
co-crystals (green). 
 
4.3.3 FT-IR transmission 
The FT-IR spectrum for the ibuprofen-nicotinamide co-crystal was obtained 
using the method described in section 2.2.3. The collected spectrum was 
compared to the FT-IR spectrum for unprocessed ibuprofen and nicotinamide 
(figure 4.7). The co-crystals spectrum reveals two major peaks shifts from 3154 
cm-1 in the unprocessed nicotinamide spectrum and 1704 cm-1 in the 
unprocessed ibuprofen spectrum to 3175 cm-1 and 1698 cm-1 in the co-crystal 
spectrum respectively. The first peak shift is assigned in the literature for C=N, 
NH bond vibrational energy. The second peak is assigned for C=O, OH bond 
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vibrational energy. Both peak shifts are consistent with the formation of a 
hydrogen bond formed between the NH group in nicotinamide and C=O group 
in ibuprofen.  
Figure 4.7. Representative FT-IR spectrum for unprocessed ibuprofen (bottom), unprocessed 
nicotinamide (middle), and co-crystals of ibuprofen and nicotinamide (top).  
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4.4 Co-crystallization of nicotinamide and malonic acid 
Nicotinamide-malonic acid co-crystals were produced during the progress of the 
study. In order to have a deeper insight for general co-crystal-excipient 
interaction (chapter 8), their properties are studied in this chapter. Nicotinamide-
malonic acid co-crystals were not known until very recently (VOGURI, Sep 
2010b). Hence there was an interest for studying this system. Nicotinamide-
malonic acid co-crystals were co-crystallized from acetonitrile using the method 
described in section 2.3.2. Then the co-crystals were characterized using a set 
of analytical instruments. 
 
4.4.1 Thermal analysis 
TGA & DSC 
The TGA and DSC thermal profiles of nicotinamide-malonic acid co-crystals 
were obtained using the methods described in sections 2.2.1.1 and 2.2.1.2. The 
TGA profile shows a two step loss of weight for co-crystals prepared in both 
solvents (figure 4.8). The first step of weight loss commences at around 114°C 
and the second starts around 160°C. The first step is expected to be associated 
with its malonic acid component. This is consistent with the observed fact that 
about 50% weight loss resulted from the first degradation step (malonic acid 
MW is 104g/mol and nicotinamide 122 g/mol and the co-crystals has a 1:1 
stoichiometric ratio).  
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Figure 4.8. Representative TGA thermal profiles for unprocessed malonic acid (pink), 
unprocessed nicotinamide (blue), co-crystals prepared using acetone/chloroform (red), and co-
crystals prepared using acetonitrile (green). 
 
On the other hand, DSC thermal profiles in figure 4.9 reveals the presence of a 
single endothermic peak at 109°C-110°C and the disappearance of the 
nicotinamide and malonic acid melting peaks. This indicates the formation of a 
co-crystalline system of nicotinamide and malonic acid.  
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Figure 4.9. Representative DSC thermal profiles for unprocessed nicotinamide green, 
unprocessed malonic acid (pink), nicotinamide-malonic acid co-crystals prepared using 
acetone/chloroform (red), and co-crystals prepared using acetonitrile (blue). 
 
4.4.2 Powder X-ray diffraction 
The powder x-ray diffraction patterns for co-crystals prepared with both solvents 
were collected using the method described in section 2.2.2. They were 
compared to the diffraction pattern of the raw materials (figure 4.10). The 
diffraction pattern for co-crystals prepared with both solvent systems revealed 
the presence of three new peaks at 9°, 21°, and 22°. The presence of these 
peaks indicates the formation of a new crystalline structure (co-crystal). Since 
this co-crystal system was only recently discovered, no reference pattern was 
included 
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Figure 4.10.  Representative powder x-ray diffraction patterns for unprocessed nicotinamide 
(bottom-red), unprocessed malonic acid (second from bottom- blue), co-crystals prepared using 
acetone/chloroform (second from top-pink), and co-crystals prepared using acetonitrile (top-
teal). 
 
4.4.3 FT-IR transmission 
The FT-IR spectrum for the nicotinamide-malonic acid co-crystal was obtained 
using the method described in section 2.2.3. The spectrum was obtained in 
order to be used as a reference for comparison between ibuprofen-nicotinamide 
and nicotinamide-malonic acid co-crystals. Figure 4.11 shows a peak shift was 
detected in FT-IR transmission pattern from 3366 cm-1 in unprocessed 
nicotinamide spectrum to 3374 cm-1 and 3379 cm-1 in the co-crystal prepared 
with acetone/chloroform and acetonitrile respectively. Additional shifts in two 
other peaks at 1397 and 770 cm-1 in unprocessed malonic acid spectrum 
shifted to 1392 cm-1 and 764 cm-1 in both co-crystal spectra respectively. These 
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peaks were previously assigned for C=N, NH vibration in nicotinamide (3374 
cm-1) (Akalin and Akyuz, 2006 , Hino and Ford, 2001) and C=O, OH (1397 and 
770 cm-1) (Bougeard et al., 1988). The shifts indicate that a hydrogen bond has 
formed between the nicotinamide nitrogen atom (NH) and malonic acid oxygen 
atom (C=O). 
Figure 4.11. Representative FT-IR spectra for unprocessed malonic acid (bottom-blue), 
unprocessed nicotinamide (second from bottom-purple), co-crystals prepared using 
acetone/chloroform, (second from top-red), and co-crystals prepared using acetonitrile (top-
teal). 
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4.5 Summary and Conclusions 
Caffeine-malonic acid co-crystals were prepared using chloroform/methanol as 
previously mentioned in the literature (Trask et al., 2005). In addition, the co-
crystal was prepared using three other solvent systems in order to study the 
effect of formation of caffeine-malonic acid co-crystals with a suitable solvent for 
co-crystals containing film preparation. These solvents were: 
acetone/chloroform, ethanol/water, acetonitrile. The analysis of the resultant co-
crystals prepared with the solvents showed that co-crystal purity was high from 
acetone/chloroform and ethanol/water. However, when co-crystals prepared 
with acetonitrile were analyzed, the product of the preparation process showed 
the presence of some caffeine monohydrate in addition to co-crystals. 
An ibuprofen-nicotinamide co-crystal was successfully prepared as previously 
described in the literature (Berry et al., 2008). Its physicochemical properties 
were characterizd using DSC, X-ray, and FT-IR. The results indicated the co-
crystals formation. 
A third system was studied as well. Nicotinamide-malonic acid co-crystals were 
prepared using acetone/chloroform and acetonitrile with a stoichiometric ratio of 
1:1 mol/mol. Their physicochemical properties were characterized using thermal 
analysis: TGA and DSC, Crystallographic analysis: x-ray diffraction, and 
vibrational analysis: FT-IR spectroscopy. 
Other workers (VOGURI, sep 2010a), have recently identified that nicotinamide 
and malonic acid can form a co-crystal. Thus the previous results indicating co-
crystals formation are consistent with this work. 
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This chapter has identified methods of preparing co-crystals that are suitable for 
use with solvent systems that potentially could allow co-crystals to be cast in 
polymeric films. 
  
 
 
 
 
 
 
 
 
Chapter 5 
Solvent effect on the HPMCAS properties and TEC-
HPMCAS interaction 
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5.1 Introduction 
Studying the relationship between a co-crystal active compound and a 
polymeric vehicle or any other excipients requires at least a basic 
understanding of the behaviour of the unprocessed materials first. This is 
considered an important process in order to obtain a reference point for 
comparison. The starting materials of this project and their relationship with the 
preparation media of the final dosage form were thoroughly studied in chapter 
3. Since the final intended dosage form contains a co-crystal rather than a 
single crystalline drug, investigation of such systems requires a study of the co-
crystals prior to loading into the polymer (chapter 4). A third aspect of the 
project is to study the interaction between each individual component of the co-
crystals with the polymeric vehicle. Moreover, the solvent system might have an 
impact on the drug-polymer interaction. Therefore, this chapter also investigates 
the effect of potential solvent systems on the polymer physical properties. 
 
5.2 Solubility parameters of the raw materials 
Solubility parameters were calculated as a potential prediction of the drug 
behaviour in the polymeric vehicle. They were calculated using Hildebrand 
equation.  
  (equation 5.1(Hildebrand and Scott, 1950)) 
Where  is the heat of vaporization, R is the gas constant, T temperature, 
and Vm molar volume. 
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Some drugs such as malonic acid have the ability to form a dimer. Such 
formation will affect the value for the cohesive energy and consequently it will 
change the solubility parameter value. A correction factor can be introduced to 
the equation to optimize the parameter value for materials possessing this 
property. However, the effect of dimerization on the solubility parameter value 
can be considered small compared to the original value (Barton, 1991). Hence 
the normal equation was used in the calculation (Table 5.1).  
compound solubility parameter (MPa1/2) Pka 
ibuprofen 19.5 4.4 
naproxen 21.9 4.2 
malonic acid 22.47 2.83-5.69 
HPMCAS 24  
flurbiprofen 24.45 4.2 
caffeine 26.52 0.5-1.5 
nicotinamide 27.52 3.6 
TEC 24.78  
Table 5.1. The solubility parameters of the compounds used in the study with their pKa values. 
 
The solubility parameters for solvents were calculated based on the equation 
5.1 then the parameters of the solvent mixtures were calculated using the 
equation provided by (Burke, 1984). The values obtained are detailed in table 
5.2. 
Solvent Solubility parameter 
(MPa1/2) 
chloroform 19 
acetone 20.2 
acetonitirle 24.42 
ethanol 26 
water 47.9 
ethanol/water 30.54 
acetone/chloroform 19.78 
Table5.2. Calculated Solubility Parameters SP MPa
1/2
 of the solvent and solvent combinations 
used in this study. 
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5.3 The effect of solvent on polymer physical properties 
(plasticity) 
Polymers are composed of repeated small units called monomers. These 
monomers are linked together to form chains of various lengths. In amorphous 
polymers, the chains are entangled together in a non-organised state. When the 
polymer is dissolved into a solvent these chains disentangle and chain 
movement increases as they separate from each other. However, when the 
solvent starts to evaporate, the free volume between the chains diminish and 
the chains start to interact with each other and entangle again. The 
conformation of the chain entanglements might depend on the interaction 
between the polymer chains and between the chains and the solvent. A residual 
amount of solvent can still have an impact on the chain dynamics. Solvent 
molecules will interpose between adjacent chains and weaken the interaction 
between those chains thus producing a “plasticizing effect”. Furthermore, this 
effect can be quantified by measurement of the glass transition temperature 
(Tg) of the polymer. 
As defined in section 1.9, the measurement of the Tg will reflect the impact of 
the solvent on the arrangement of the polymer chains. 
 
5.4 Thermal analysis 
Plain HPMCAS films were prepared using acetone/chloroform, ethanol/water, 
and acetonitrile following the method described in section 2.3.3. The Tg values 
of these films revealed a shift from the Tg value reported in the literature 
(Kablitz et al., 2006) (figure 5.1). 
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Figure 5.1. A comparison of films Tg values for unprocessed polymer (Kablitz et al., 2006) 
(purple), films prepared using: acetone/chloroform (blue), ethanol/water (red), and acetonitrile 
(green). DSC thermal profiles are provided in figures AII 10, AII 11, and AII 12. 
 
The effect of the solvent on the interaction between the polymeric chains 
appears clearly in figure 5.1. Acetone/chloroform appears to have the lowest 
effect on the polymeric vehicle. This can be concluded from the higher Tg value 
(for the polymeric film prepared using acetone/chloroform compared to films 
prepared with the other two solvents). Nevertheless, the Tg value of the film 
prepared with acetone/chloroform is lower than the Tg value of the unprocessed 
polymer. On the other hand, films prepared using acetonitrile or ethanol/water 
revealed a close Tg values. This result raises the concern about the effect of 
the solvent system on the loading of the co-crystals into the polymeric film. The 
polarity and the cohesive energy for the system were believed to have an effect. 
Therefore, the solubility parameters of these solvents were measured in order 
to provide an indication for their cohesiveness.  
From the data presented in table 5.1 the solubility parameter calculated for 
acetonitrile is close to the SP value of the polymer (24 MPa1/2). This similarity 
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may explain the preference of the acetonitrile molecule to interact with the 
polymer in a stronger manner compared to the interaction between the other 
two solvents and the polymer. This interaction may have interfered with the 
folding process of the polymeric chains. Hence, the Tg value of the film 
prepared with acetonitrile is lower than the Tg of the film prepared with 
acetone/chloroform. This explanation cannot be extended however on films 
prepared by ethanol/water. 
Ethanol/water has a SP value that is further away from the SP value of the 
polymer than acetone/chloroform or acetonitrile. This behaviour might be 
explained by the fact that water and ethanol have a strong polarity. This polarity 
can trigger the bonding between the solvent mixture and the polymer. Hence, 
the effect of that solvent on the HPMCAS cannot be evaluated using the simple 
SP rule. A more detailed SP that takes into account the polarity and hydrogen 
bond formations might be needed to give a more accurate representation for 
this solvent system. 
In order to expose the effect of the solvent system on the possible interaction 
between a drug and the polymer, the interaction between the polymer and a 
plasticizer using a different solvent was monitored. 
 
5.5 Solvent effect on the plasticizer-polymer interaction 
Tri-ethyl citrate (TEC) is a well known plasticizer that is used in pharmaceutical 
formulations. It is an ester of citric acid. Films containing various concentrations 
of TEC were prepared using acetone/chloroform, ethanol/water, or acetonitrile. 
Tg determination of films prepared using the method described in section 2.3.3 
of these films uncover the question raised by the previous section. The results 
 104 
 
are presented in figure 5.2.  Depending on the concentration of TEC, Tg is 
statistically unaffected by the nature of the solvent.  However at some of the 
levels of TEC employed, the effect of the preparation solvent on the Tg obtained 
is statistically significant. 
It is worthy of mention that the standard error of the measurements was high for 
certain samples as was the case for films containing 13%  (w/w) TEC prepared 
using acetonitrile.  Films prepared with acetonitrile showed a similar or slightly 
lower Tg values to those prepared with ethanol/water. On the other hand, films 
prepared using acetone/chloroform produced the lowest Tg values for films 
containing 4-9% (w/w) and but the Tg obtained was higher than the Tg of films 
prepared with the other two solvents when the TEC concentration was 16.7% 
w/w. Nevertheless in general, films containing 15% (w/w) TEC and cast from 
acetone/chloroform resulted in a film with about a 5°C higher Tg than those 
prepared using the other two solvents (figure 5.2). 
Figure 5.2. Representative Tg values for polymeric films containing various amounts of TEC 
prepared using acetone/chloroform (red square), ethanol/water (green circle), and acetonitrile 
(blue diamond). More details in Appendix AII 13-16. 
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The observed difference in the Tg values for films prepared with the 
aforementioned solvents might be explained by the solubility of the plasticizer in 
each of the previous solvents. When the plasticizer favours to interact with the 
solvent rather than the polymer, it may results in drawing the plasticizer away 
from the polymer during the evaporation stage. This will result in concentrating 
the plasticizer on the upper surface and the sides of the polymer. The strength 
of such interaction will affect the distribution of the plasticizer in the polymer, i.e. 
a strong interaction between the drug and the polymer will results in a higher 
film Tg value than a weak interaction.  
The variation of Tg values of films prepared using acetonitrile and 
acetone/chloroform is worthy of comment.  To explain the differences in the Tg 
values obtained, the solubility parameters of the solvent systems and TEC were 
compared. The theory we wish to test here is that if the solubility parameter 
value of the TEC or the polymer is closer to the SP value of the solvent, then 
either of the two will favour interacting with the solvent more than interacting 
with each other. On the other hand, if the SP value of TEC and HPMCAS is 
closer to each other than the SP value of the solvent, the interaction between 
them will be stronger and consequently the plasticization effect will be greater. 
TEC has a SP value of 24.78 MPa1/2. Acetonitrile is the only solvent with SP 
value that is closer to the TEC than the polymer. Hence, it is expected that the 
solvent will interact/dissolve TEC in a strong manner and that the interaction will 
interfere with the dispersion and the interaction of the TEC with the polymer. 
Such behaviour would result in high Tg values being observed with these films. 
On the other hand, acetone/chloroform has a solubility parameter that is 
considered far from both polymer and plasticizer. Therefore, theory would be 
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predicted the film to have a lower Tg values from films prepared using 
acetone/chloroform. However, films prepared with ethanol/water presents an 
unusual behaviour. Ethanol/water has SP value of 30.54. This value is remote 
from the SP values for both the polymer and plasticizer. Thus, it would be 
expected to observe low Tg values for these films. On the contrary, these films 
revealed high Tg values. This behaviour might be related to the fact that ethanol 
and water are quite miscible with each other. They interact in a strong manner 
that changes their polarity and final SP value. This was observed by Hildebrand 
and a new method was placed to calculate the SP parameter for liquids that 
interact in  a similar manner (Barton, 1991). 
Additionally the SP calculated in this thesis is a hybrid value of the two solvents 
mixed together and does not reflect differential evaporation of one of the 
solvents over the other and thus cannot be expected to reflect the complexity in 
the experimental film production. Furthermore, it is well documented that the 
amount of the residual solvent in the film can affect the Tg value of that film 
(Lopez and Mijangos, 1994). However, samples were kept at 100°C for 5 
minutes in order to evaporate the residual solvent. Nevertheless, the thermal 
TGA profile of the previous films were collected and revealed the existence of 
the 2% weight loss between 30-100°C that can be found in unprocessed 
HPMCAS and is due to evaporation of the residual moisture (figure AI 7-9). 
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5.6 Summary and conclusion 
Plain films casted using acetone/chloroform, ethanol/water, and acetonitrile 
showed a different Tg values than the unprocessed HPMCAS. Films prepared 
using ethanol/water or acetonitrile showed almost the same Tg values around 
118°C. However, films prepared using acetone/chloroform showed a higher Tg 
value of about 120°C. This difference in the Tg value was correlated to the 
effect of solvent on the polymeric chain entanglement. On the other hand, this 
difference can be explained according to solubility parameter values presented 
in tables 5.1 and 5.2, the SP value of acetone/chloroform can be considered 
remote to that of acetonitrile. This reflects the lower affinity for the 
acetone/chloroform to interact with the polymer chains. Nevertheless, this rule 
cannot be applied on the calculated SP value of ethanol/water. The 
aforementioned solvent has a remote SP value to the polymer. However, the Tg 
of films casted using that solvent is similar to those prepared using acetonitrile. 
It is worthy to mention that the equation used to calculate the SP values for 
solvents and their combination is considered a simple equation and doesn’t 
include the effect of the interactions in the solvent mixtures. Hence, the 
calculated SP value for ethanol/water might be far away from the true SP value 
of this solvent. 
On the other hand, it was noticed that the use of various solvents in casting 
films containing the same amount of TEC resulted in the observation of 
difference in the Tg values. This difference was linked to the SP values of the 
solvent systems, HPMCAS, and TEC. A theory was developed after monitoring 
the behaviour of films prepared with the aforementioned solvents. It states that 
if the polymer and the plasticizer have a closer SP values to each other than the 
solvent used, then the solvent effect will be lower than the solvent with a closer 
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SP value to any of them. In other words, the closeness in the SP values reflects 
the affinity of the materials to interact with each others. This theory explained 
the behaviour of films prepared using acetonitrile and acetone/chloroform. 
Acetone/chloroform has a remote SP value to the polymer and the plasticizer 
than acetonitrile. Therefore, the effect of acetone/chloroform on the interaction 
between HPMCAS and TEC is lower than the effect of acetonitrile. Hence, films 
prepared using acetone/chloroform showed lower Tg values. However, this 
theory cannot be applied in the case of films prepared using ethanol/water as 
they showed almost a similar Tg values to those prepared using acetonitrile. 
On the other hand, this phenomenon can be explained by the solubility of the 
TEC and the polymer in those solvents. The higher the difference in solubility 
between them, the more phase separation will be. Therefore, it worth to 
measure the solubility of HPMCAS and TEC in each of the aforementioned 
solvents in order to clarify the reason for the Tg difference between films 
prepared with each of them. 
  
 
 
 
 
 
 
 
 
Chapter 6 
Preparation and characterisation of HPCMAS films containing 
acidic drugs/species 
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6.1 Introduction 
Understanding the interaction between the polymeric vehicle and the individual 
components of the co-crystals would be the next step towards understanding 
the interactions between the co-crystals and the polymer.  Studying the 
unprocessed materials and the effect of the preparation media on their re-
crystallization have been investigated in chapters 3 and 4 respectively.  
Moreover, the findings presented in chapter 5 revealed that the solvent system 
has a noticeable effect on the interaction between the polymer and a plasticizer. 
Hence, the study of drug-polymer interaction in this chapter will include the 
study of the effect of using different solvents on these interactions.  Drug-
polymer interactions have been well documented in the literature. It has been 
identified that such interaction might cause a delay of the drug release. 
However, this property was useful in controlling the release of drug in sustained 
or controlled release dosage forms (Puttipipatkhachorn et al., 2001 , Murdande 
et al., 2011 , Huang et al., 2008 , Lin et al., 1995 , Feely and Davis, 1988). 
Moreover, there are few reported cases of drug-HPMCAS interactions 
(Yamaguchi and Tominaga, 2008 , Dong and Choi, 2008 , Tanno et al., 2004 , 
Riedel and Leopold, 2005 , Yamaguchi and Tominaga, 2006). These studies 
revealed the ability of HPMCAS to interact or adhere to the surface of drug 
crystals, inhibiting their growth and may convert them into amorphous materials. 
The interaction of HPMCAS with drugs was used in a controlled release drug. 
Drug-containing films were prepared by the method described in section 2.3.3. 
In this chapter we consider the interaction of acidic materials with HPMCAS. 
Namely malonic acid, ibuprofen, naproxen, and flurbiprofen were investigated 
with the interaction of malonic acid and ibuprofen with the polymer being more 
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extensively studied. Naproxen and flurbiprofen were used in a limited 
assessment of a drug substitution theory (where two acidic materials are 
simultaneously cast in a polymeric film). The other category includes the basic 
drugs such as caffeine and nicotinamide which will be investigated in a later 
chapter.  
 
6.2 Preparation and characterisation of HPCMAS films 
containing a single acidic drug/species 
HPMCAS is known to interact with acidic drugs (Dong and Choi, 2008, Tanno et 
al., 2004, Riedel and Leopold, 2005). However, there are few reported cases of 
the interaction between basic drugs and HPMCAS (Yamaguchi and Tominaga, 
2006 , Yamaguchi and Tominaga, 2008).  
Films containing acidic drugs were prepared using the method described in 
section 2.3.3. Malonic acid and ibuprofen interactions with HPMCAS were 
independently studied thoroughly because of their subsequent use in the 
incorporation of their co-crystal in the film.  
 
6.2.1 Malonic acid 
Various concentrations of malonic acid (1:100-60:100 w/w malonic 
acid/HPMCAS) were loaded into polymeric films in order to see the effect of 
malonic acid on the polymer physical properties. 
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6.2.1.1 General analysis 
Films containing low concentrations of malonic acid (1:100-30:100 w/w malonic 
acid/HPMCAS) were visually similar to a 100% HPMCAS film. On the other 
hand, the flexibility of the film measured by hand increased with increasing the 
malonic acid concentrations from 1-30:100 w/w malonic acid/HPMCAS. This 
increase in flexibility was not accompanied by a change in the film 
transparency. When the concentration of malonic acid goes above 30:100 w/w 
malonic acid/HPMCAS, the polymer starts to show some opacity. At that point, 
the flexibility of the films stopped increasing and became independent on the 
malonic acid concentration in the film. When the concentration of malonic acid 
reaches 40:100 w/w, it was hard to detect a Tg value on the thermal DSC profile 
(appendix AII 23). Nevertheless, exceeding 40% revealed a lower flexibility in 
the film and the growth of large malonic acid crystals through all the film. The 
growth of these crystals might have affected the overall flexibility and made the 
film brittle. 
 
6.2.1.2 Thermal analysis 
TGA and DSC 
The thermal profiles of HPMCAS films containing various concentrations of 
malonic acid were obtained using the method described in section 2.2.1.1. A 2-
6 % weight loss can be observed between 25°-100°C (figure 6.1 and AI 2). A 
similar weight loss (3%) can be observed with the unprocessed HPMCAS. the 
extra weight loss can be either correlated to extra moisture trapped in 30:100 
and 50:100 w/w malonic acid/HPMCAS films as 60:100 w/w malonic 
acid/HPMCAS. However, the first heating cycle in the DSC should evaporate 
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this extra moisture. This loss was linked to the evaporation of the residual 
solvent and moisture in the sample. The main weight loss of the sample can be 
divided into two stages. The first commences at about 130°C and involves a 
weight loss of around 25%. This weight loss can be linked to the thermal 
degradation of malonic acid in the film as unprocessed malonic acid thermal 
profile reveals the weight loss caused by the thermal degradation starting at 
around 140°C. The second commences at 300°C and almost results in a total 
weight loss. The second step can be correlated to the thermal degradation of 
the polymer as the weight loss caused by heating the film is similar to that of the 
unprocessed HPMCAS. 
Figure 6.1. Representative TGA thermal profile for unprocessed malonic acid (green), 
unprocessed HPMCAS (pink), HPMCAS film prepared with acetonitrile (red), and a film 
containing 25% w/w malonic acid prepared with acetonitrile (blue). 
 
The thermal DSC profiles for the films revealed a shift in the Tg value of the 
polymer (appendix AII 24). It can be observed that films prepared using 
ethanol/water gave the highest Tg values among other films (figure 6.2) 
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whereas, in general, films prepared using acetonitrile revealed the lowest Tg 
values. Applying the solubility parameter theory shows that the observed results 
do not conform to the expected behaviour based on the solubility parameter 
values of solvents, malonic acid and HPMCAS. According to the SP values of 
the aforementioned materials acetonitrile is expected to more strongly interact 
with malonic acid as it has a closer SP value to that of malonic acid. Thus it can 
be anticipated that acetonitrile will act to promote the migration of malonic acid 
molecules to the surface of the polymeric film when it evaporates. On the other 
hand, films produced with acetone/chloroform should reveal low Tg based on 
their far SP value compared to malonic acid and the polymer. Thus, it can be 
concluded that the solvent effect on malonic acid-HPMCAS interaction is 
different from the observed behaviour in section 5.4. However, it is worth 
mentioning that SP values of solvent systems were calculated without taking the 
interaction between solvents into consideration. Ethanol and water are known to 
interact with each other. This interaction will affect the polarity of their mixture. 
Therefore, the SP values of the solvent systems are not accurate. On the other 
hand, the previous behaviour could be explained based on the difference of 
solubility between malonic acid and HPMCAS in the solvent used. Malonic acid 
is highly soluble in water. However, HPMCAS is considered as a sparingly 
soluble in it. Thus, malonic acid will prefer to interact with water rather than the 
polymer. Ethanol/water has a good solubility for malonic acid and the polymer. 
However, the solubility of malonic acid in that solvent system is expected to be 
higher than the affinity of malonic acid to HPMCAS. The polarity of 
ethanol/water plays a rule in increasing such interaction. On the other hand, 
acetonitrile has a weak polarity that doesn’t allow for a strong interaction to take 
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a place, therefore, the effect of acetonitrile on malonic acid-HPMCAS is weaker. 
Chloroform and acetone are known to have a moderate polarity. Hence, their 
effect lies between the effect of ethanol/water and acetonitrile (figure 6.2). The 
solvent effect on the Tg value of polymer was studied for polyvinyl chloride and 
it was found that solvent type plays a role in the Tg value of that polymer (López 
and Mijangos, 1994).   
Figure 6.2. Graph to show the relation between the Tg and the percentage weight concentration 
of malonic acid in HPMCAS films cast from different solvent systems. 
 
6.2.1.3 Powder X-ray diffraction 
The powder x-ray diffraction patterns for films containing malonic acid were 
obtained using the method described in section 2.2.2. However, the patterns 
collected showed a high noise/signal ratio and an amorphous peak. Hence, it 
was not possible to distinguish the existence of malonic acid diffraction peaks 
with films containing low concentrations of malonic acid. Films containing 30% 
malonic acid and higher revealed the existence of some peaks that can be 
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found in the diffraction pattern of unprocessed malonic acid. A representative 
for the diffraction pattern is provided in figure AIII 3. 
  
6.2.1.4 FT-IR transmission 
The FT-IR spectra obtained for the polymeric films using the method described 
in section 2.2.3 revealed a low signal/noise ratio (figure 6.3). Additionally, films 
with a malonic acid concentration below 25:100 w/w malonic acid/HPMCAS 
produced transmission spectra similar to that of a plain film. However, films 
containing high concentrations (30% w/w) of malonic acid revealed clear 
transmission peaks similar to the ones found in the spectrum of unprocessed 
malonic acid. This indicates that the FT-IR microscope is sensitive enough to 
detect the presence of malonic acid crystals in films containing 25:100 w/w 
malonic acid/HPMCAS or less. 
Figure 6.3. Representative FT-IR spectra for HPMCAS film cast using acetonitrile (red), 
unprocessed malonic acid (blue), a film containing 1:4 w/w malonic acid/HPMCAS (green), and 
a film containing 3:10 w/w malonic acid/HPMCAS (yellow). 
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6.2.1.5 Hot Stage Microscopy 
Cast films were examined by HSM following the method described in section 
2.2.4.2. The events that occurred during the analysis of HPMCAS films 
containing 40:100 w/w malonic acid/HPMCAS cast using acetone/chloroform. It 
was noted that the crystals in the film were heavily condensed in a way that 
blocked the light from passing through. When the heating started, the polymeric 
matrix started to expand causing a change in the focal length of the observed 
field. Malonic acid crystals were observed to melt with an onset of around 
118°C (figure 6.4). This temperature is low compared to the melting point of the 
unprocessed malonic acid. However, the dispersion of malonic acid in the 
polymeric film can cause such a depression in melting point. The depression of 
melting point of drugs dispersed in the polymer has been observed before in the 
literature and linked to Flory-Huggins lattice theory (Marsac et al., 2009). The 
melted malonic acid continued to occupy the cavities in the polymer where the 
crystals previously used to be. At higher temperatures the liquid malonic acid 
was observed to diffuse through the polymeric matrix and mix with it forming a 
homogenous phase. Cooling the sample to room temperature did not induce 
recrystallization during the time frame of the experiment. Thus it can be 
concluded that the crystals converted into an amorphous material in the 
polymeric film.  
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Figure 6.4. Representative HSM images for films 40% w/w malonic acid/HPMCAS at: (A) 24°, 
(B) 87°, (C) 95°, (D) 107°, (E) 112°, (F) 120°, (G) 124°, (H) 134°, and (I) 136°C  all using x10 
magnification power. 
 
 
6.2.1.6 SEM 
Films containing malonic acid crystals were analyzed using the SEM in order to 
obtain a good image for the crystal shape. SEM imaging was performed using 
the method described in section 2.2.4.1. Malonic acid crystals were typically 
observed to have the length of 30-60 micrometers as exemplified in figure 6.5.  
Figure 6.5. Representative SEM images for films containing different concentrations of malonic 
acid with magnification powers: x1600 (top left), x3180 (top right), x1800 (bottom left), and 
x3000 (bottom right). 
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6.2.2 Ibuprofen   
Ibuprofen-polymer interaction is well documented in the literature (Kazarian and 
Martirosyan, 2002 , Nakayama et al., 2009 , Whelan et al., 2002). The polymer 
inhibits the growth of ibuprofen crystals. It deposits on the active growing 
surfaces of the crystal inhibiting its growth. In order to characterize the effect of 
such interaction on the loading process of ibuprofen-nicotinamide co-crystals 
into the polymeric film, films containing various concentrations of ibuprofen were 
prepared using the method described in section 2.3.3. Films were prepared 
using acetone/chloroform and/or acetonitrile as a solvent system.  
 
6.2.2.1 Thermal analysis 
6.2.2.1.1 TGA 
In order to characterise the amount of moisture or residual solvent in the 
prepared films, the thermal profiles for films containing ibuprofen were collected 
using the method described in section 2.2.1.1. The collected data were 
compared to the thermal profile for unprocessed ibuprofen and unprocessed 
HPMCAS (figure 6.6). It can be noticed that the weight loss due to the thermal 
degradation of the films passes through two steps. The first step commences 
around 170°C. This step can be correlated to the weight loss resulted from the 
thermal degradation of ibuprofen in the film as the thermal profile of the 
unprocessed ibuprofen revealed the same weight loss pattern that commences 
around 150°C and the observed weight loss at the end of this stage is 
consistent with the percentage of ibuprofen concentration in the film. The 
second stage commences around 300°C which can be correlated to the thermal 
degradation of the polymer as the weight loss at the end of this step is 
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consistent with the weight loss observed in the thermal profile of the 
unprocessed polymer. It can be observed that films containing ibuprofen have 
lost less than 2% weight at 100°C. A similar weight loss can be observed in the 
thermal profile of unprocessed HPMCAS. thus it is expected to be the result of 
the evaporation of residual moisture.  
Figure 6.6. Representative TGA thermal profiles for unprocessed ibuprofen (blue), HPMCAS 
cast from acetonitrile (red), a film containing 3:10 w/w ibuprofen/HPMCAS (green), and a film 
containing 3:5 w/w ibuprofen/HPMCAS (pink). 
 
 
6.2.2.1.2 DSC 
The thermal profiles for films containing various concentrations of ibuprofen 
were collected using the method described in section 2.2.1.2. The Tg values 
were obtained from the thermal data and plotted against the concentration of 
ibuprofen and compared to the Tg of films containing various concentrations of 
malonic acid (section 6.2.1.2.2) in figure 6.7.  
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Figure 6.7. A chart of polymer Tg against the concentrations of ibuprofen (blue diamond) and 
malonic acid (red circle) in polymeric films separately. 
 
It can be noted from figure 6.7 that the malonic acid has plasticized the polymer 
in almost a similar manner to that produced by using ibuprofen, using the same 
solvent (acetonitrile).  
 
 6.2.2.2 Powder X-ray diffraction 
The diffraction patterns of films containing ibuprofen were collected using the 
method described in section 2.2.2. The diffraction pattern of a film containing 
60% w/w ibuprofen/HPMCAS displays the appearance of an amorphous peak 
between 5°-20°. The pattern in figure 6.8 reveals a high noise/signal ratio, yet, 
there are some clear diffraction peaks that can be observed.  The diffraction 
pattern reveals some peaks at 6°, 12°, 16°, 18°, 19°, 19.8°, 20°, 22°, 25°, and 
27° in addition to other peaks (figure 6.8). The above peaks can be observed in 
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the standard diffraction pattern of ibuprofen RS. Consequently, the ibuprofen 
isomerism didn’t change after loading it into the polymer and the films contained 
some crystalline ibuprofen. 
Figure 6.8. Representative powder x-ray diffraction patterns for unprocessed ibuprofen (purple), 
standard diffraction pattern for S-ibuprofen CSD (red), RS- ibuprofen CSD (green), and a film 
containing 6:10 w/w ibuprofen/HPMCAS prepared using acetonitrile (blue). 
 
6.2.2.3 FT-IR transmission 
FT-IR spectra for films containing ibuprofen were obtained in order to detect any 
peak shifts in the spectrum resulting from hydrogen bond formation between the 
polymer and ibuprofen. The spectrum was obtained using the method described 
in section 2.2.3. The FT-IR spectrum in figure 6.9 revealed a shift in the 1700 
cm-1 peak to 1715 cm-1. In addition to that, it can be noticed that in films 
containing 5:10 ibuprofen/HPMCAS there are two peaks at 1699 and 1715 cm-1. 
This peak was noticed to be assigning for the C=O, OH vibration energy in 
section 3.1.3.3. However, C=O, OH peaks usually shift to a lower wavenumber 
when they participate in hydrogen bonding. Hence, this shifting might or might 
not be related to the formation of a hydrogen bond.  
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Figure 6.9. Representative FT-IR spectra for unprocessed HPMCAS (dark red), unprocessed 
ibuprofen RS (yellow), a film containing 3:10 w/w ibuprofen/HPMCAS (light red), and a film 
containing 1:2 ibuprofen/HPMCAS (blue) both films prepared using acetonitrile. 
 
 
6.2.2.4 Hot stage microscopy 
In order to characterize the behaviour of ibuprofen crystals inside the polymeric 
film, a sample of a film containing 3:5 w/w ibuprofen:HPMCAS was analyzed 
using the hot stage microscope following the method described in section 
2.2.4.2. The sample was heated to around 95°C (figure 6.10). A magnification 
power of x10 was used to capture the film images up to 70°C then X20 
magnification power was used to get detailed images for the crystals melting. 
The crystals appeared small using X10 magnification power. This behaviour can 
be correlated to the ability of the polymer to inhibit the crystal growth of drugs. It 
can be observed from figure 6.10 that ibuprofen crystals start to melt at around 
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75°C. The melting of the crystals was noticed to end at around 78°C. Increasing 
the temperature was noted to causes the polymeric matrix to expand and the 
liquefied ibuprofen to penetrate into the polymer matrix and form a 
homogeneous system.  
Figure 6.10. A representative HSM scan of a film containing 3:5 w/w ibuprofen/HPMCAS at: (A) 
25°, (B) 66°, (C) 69°, (D) 71°, (E) 73°, (F) 75°, (G) 76°C, (H) 78°C, and (I) 90°C. Magnification 
power is x10 (A) to (D) and x20 from (E) to (I). 
 
Films containing naproxen and flurbiprofen were not extensively studied 
separately as the two aforementioned drugs were used to investigate a 
displacement hypothesis only (section 6.3.1.2 and 6.3.3). 
 
6.3 Characterisation of films containing two different acidic 
species/drugs 
6.3.1 Films containing malonic acid with ibuprofen 
To this point this thesis has evaluated the behaviour of films cast to contain a 
single material.  It has also evaluated the films prepared from different solvents. 
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The effect of introducing a second acidic system to the same film is an 
interesting and novel area to study.  
Films containing two acidic species were prepared using the method described 
in section (2.3.3). In summary, the method involved casting films containing 
2:2:10, 3:2:10, 3:3:10, and 3:4:10 w/w/w ibuprofen/malonic acid/HPMCAS. Two 
solvent systems identified to prepare these films were acetonitrile and 
acetone/chloroform. 
 
6.3.1.1 Thermal analysis 
6.3.1.1.1 TGA 
Thermal profiles for films containing ibuprofen and malonic acid were obtained 
using the method described in section 2.2.1.1. Collected thermal data of 
polymeric films containing 3:2:10 and 3:4:10 w/w/w ibuprofen/malonic acid/ 
HPMCAS revealed that the weight loss in their thermal TGA profile can be 
divided into three steps (Figure 6.11). The first step commences at around 
130°C. This step can be easily correlated to the weight loss resulted from the 
thermal degradation of malonic acid (sections 3.1.2.1 and 3.2.2.1). The second 
step commences at around 180°C which can be correlated to the weight loss 
resulted from the thermal degradation of ibuprofen (section 3.1.3.1). The third 
step commences at around 250°C and it can be correlated to HPMCAS thermal 
degradation (section 3.1.7.1). It can be noted from figure 6.11 that the film has 
lost less than 5% of total weight between 30-100°C. This loss was observed in 
films containing malonic acid (3:10 and 5:10 w/w). This extra percentage might 
indicate that the solvent has not evaporated completely. Nevertheless, the 
amount of residual moisture is small to affect the crystallization or the 
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interaction with the polymer. In addition, malonic acid is considered as a 
hygroscopic material and that might have caused the increase in the amount of 
residual moisture. Thus these films might have additional moisture.  
Figure 6.11. Representative TGA thermal profiles for unprocessed ibuprofen (teal), 
unprocessed malonic acid (green), HPMCAS film prepared with acetonitrile (blue), and films 
containing 3:2:10 and 3:4:10 w/w/w ibuprofen/malonic acid/HPMCAS (red and pink 
respectively). 
 
6.3.1.1.2 DSC 
Thermal profiles for films containing ibuprofen and malonic acid were obtained 
using the method described in section 2.2.1.2.Collected thermal data revealed 
the existence of an endothermic peak in the first heating run on the DSC chart 
as in figure 6.12. This peak appears at 61°C. This peak relates to the melting of 
ibuprofen crystals in the polymeric film. The reduction in the melting point 
results from the impurity effect of the polymer on the ibuprofen melting point. In 
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order to have clear evidence, other films containing malonic acid and a higher 
concentration of ibuprofen were analyzed. The collected data showed a higher 
area under the curve for the same peak indicating that this peak is related to a 
thermal transition for at least a part of the ibuprofen content. 
Figure 6.12. DSC scan of films containing 3:2:10 (green), 2:3:10 (pink), 1:2.5:10 (blue), and 
1:1:5 (red) ibuprofen/malonic acid/HPMCAS w/w/w. 
Cooling the sample and reheating it revealed a flat thermal profile indicating that 
ibuprofen crystals melted on the first heat and remained amorphous or liquefied 
in the polymeric film (figure AII 19-21). 
Interestingly, the thermal profiles showed no other peak at or near the melting 
point of malonic acid. Malonic acid would therefore be molecularly dispersed in 
the film and not in a crystalline state.  
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6.3.1.2 powder X-ray diffraction 
Powder x-ray diffraction data was collected using the method described in 
section 2.2.2. The diffraction pattern for films containing 3:4:10, 3:3:10, and 
3:2:10 ibuprofen/malonic acid/HPMCAS w/w/w revealed the existence of three 
characteristic diffraction peaks at 6°, 12°, and 24°. These peaks can be 
observed in the diffraction pattern of ibuprofen RS. Therefore, it can be 
concluded that ibuprofen is present in a crystalline state in the film. On the other 
hand, the absence of any peaks that can be correlated to crystalline malonic 
acid diffraction pattern was noted. This result conforms to the result obtained in 
section 6.3.1.1.2. Therefore, it can be concluded that malonic acid was 
predominantly molecularly dispersed while ibuprofen crystallized in the 
polymeric film. 
Figure 6.14. Representative powder x-ray diffraction pattern for unprocessed malonic acid 
(blue), unprocessed ibuprofen RS (red), a film containing 3:4:10 ibuprofen/malonic 
acid/HPMCAS w/w/w (pink), 3:3:10 (light red), and 3:2:10 (teal). 
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6.3.1.3 FT-IR transmission 
The FT-IR spectra for a film containing 3:4:10 w/w/w ibuprofen/malonic 
acid/HPMCAS were collected using the method described in section 2.2.3. The 
collected spectrum revealed a similar FT-IR transmission pattern to the 
unprocessed ibuprofen (figure 6.15). The spectrum revealed a transmission 
peak at 1698 cm-1. This peak was previously assign to C=O, OH vibration 
energy. There was no obvious shifting for this peak. This might reflect the 
existence of no bonding between ibuprofen crystals and HPMCAS. On the other 
hand, the FT-IR could not detect the existence of malonic acid. This might 
happen due to the small size of malonic acid crystals that hindered the 
detection by the FT-IR.  
Figure 6.15. Representative FT-IR spectrum for unprocessed HPMCAS (bottom), unprocessed 
malonic acid (pink), unprocessed ibuprofen (blue), film containing malonic acid (teal), and a film 
containing 3:4:10 w/w/w ibuprofen/malonic acid/HPMCAS (red). 
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6.3.1.4 Hot Stage Microscopy 
Hot stage microscopy was performed in order to have visual evidence that 
supports the results obtained using DSC. A film containing 3:3:10 w/w/w 
ibuprofen/malonic acid/HPMCAS was analyzed using the method described in 
section 2.2.4.2. The film was heated with a heating rate of 2°C/min to 100°C 
then cooled to room temperature using the same rate (figure 6.16).  
Figure 6.16. Hot Stage Microscope scan of a film containing 3:3:10 w/w/w ibuprofen/malonic 
acid/HPMCAS prepared with ethanol/water at: (A) 62°C, (B) 65°C, (C) 75°C, (D) 76°C, (E) 79°C, 
(F) 83°C, (G) 100°C, (H) 50°C, (I) 80°C. Magnification was x10 for all cases. 
 
A large amount of crystals were observed in the film at room temperature. 
When commencing heating, the polymeric film expanded. The melting 
sequence of the crystals started at around 65°C and it lasted until the 
temperature reached 67°C. After that, the melt was observed to diffuse through 
the polymeric film and form a homogenous structure. The cooling sequence 
revealed that re-crystallisation did not occur within the experimental time frame. 
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The HSM behaviour of the film is consistent with the endothermic peak found in 
the DSC thermal profile. The crystals observed in the film to melt can be 
identified as ibuprofen crystals that phase separated from the polymer. 
Ibuprofen alone in HPMCAS did not crystallise at this concentration. 
Only above 60:100 w/w ibuprofen/HPMCAS was this behaviour observed. The 
finding indicates that the addition of malonic acid lowers the saturation 
concentration for ibuprofen with HPMCAS. The finding is also consistent with 
malonic acid having a greater affinity to interact with HPMCAS than ibuprofen. 
According to the solubility parameter values of malonic acid, ibuprofen, and 
HPMCAS obtained from table 5.1 and 5.2. Malonic acid has a closer SP value 
(22.4) to the polymer (24) than ibuprofen (19).  This observation if universally 
applicable might open the road towards finding a theoretical method for 
predicting and controlling the interactions between acidic drugs and HPMCAS. 
To test the validity of the above finding for other systems, naproxen and 
flurbiprofen were used to test the applicability of the previous conclusion.  
 
6.3.2 Investigation of HPMCAS films containing malonic acid and 
naproxen 
A film containing 20:20:100 w/w/w naproxen/malonic acid/HPMCAS was 
prepared using acetonitrile and following the method described in section 2.3.3.  
Malonic acid has a solubility parameter (22.47) that is relatively closer to 
HPMCAS parameter value (24) than naproxen (21.9). Hence, from the SP 
theory it was expected that malonic acid should dispersed in the polymer 
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reducing the saturation point for naproxen. Consequently, naproxen crystals 
should be observed in the polymeric films.  
6.3.2.1 Thermal analysis 
6.3.2.1.1 TGA 
TGA thermal profile for the aforementioned film was obtained using the method 
described in section 2.2.1.1. A weight loss of around 2% was found between 
30-100°C (figure 6.17). A similar weight loss was observed in the thermal profile 
of unprocessed HPMCAS and it was correlated to evaporation of residual 
moisture. 
Figure 6.17. Representative TGA thermal profile for unprocessed naproxen (green), 
unprocessed malonic acid (blue), HPMCAS film (teal), film containing 3:10 w/w 
naproxen/HPMCAS (pink), and film containing 1:1:5 naproxen/malonic acid/ HPMCAS (red).  
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6.3.2.1.2 DSC 
The DSC thermal profiles for films containing naproxen and malonic acid were 
obtained using the method described in section 2.2.1.2. The collected data 
reveals an endothermic peak appears in the analysis of films containing 3:10 
naproxen/HPMCAS and a film containing 1:1:10 naproxen/malonic 
acid/HPMCAS. This peak can be observed at 153°C (figure 6.18). Hence, this 
peak can be correlated to the melting of naproxen crystals in the film. A weak 
intensity, yet wide endothermic peak can be observed around 100°C. This peak 
is believed to be related to the evaporation of the residual moisture in the film.  
Figure 6.18. Representative DSC thermal profiles for a film containing 3:10 naproxen/HPMCAS 
prepared with ethanol/water (green) and a film containing 1:1:5 naproxen/malonic 
acid/HPMCAS prepared with acetone/chloroform (blue). 
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6.3.2.2 Powder X-ray diffraction 
The powder x-ray diffraction patterns for films containing 1:1:5 w/w/w 
naproxen/malonic acid/HPMCAS, 3:10 w/w naproxen/HPMCAS, and 1:5 
naproxen/HPMCAS were obtained using the method described in section 2.2.2. 
The collected diffraction pattern shown in figure 6.19 reveals the existence of a 
broad amorphous peak around 10°. It can be noticed that the patterns reveals a 
high noise/signal ratio. However, a number of peaks can be observed in the film 
diffraction pattern. Those peaks can be found at 16°, 19°, 20°, and 23°. These 
peaks can be easily observed in the diffraction pattern of unprocessed 
naproxen. On the other hand, none of the detected peaks can be correlated to 
the diffraction pattern of malonic acid.  
Figure 6.19. X-ray scan of malonic acid, naproxen, a film containing 1:1:5 naproxen/malonic 
acid/HPMCAS w/w/w, film containing 3:10 naproxen/HPMCAS, and a film containing 1:5 
naproxen/HPMCAS. All films were prepared using acetone/chloroform. 
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6.3.2.3 Hot Stage Microscopy 
A film containing 20:100 w/w naproxen/HPMCAS was analyzed using hot stage 
microscopy in order to monitor the behaviour of naproxen crystals. The analysis 
was performed using the method described in section 2.2.4.2. Figure 6.20 
reveals that naproxen crystals started to melt around 126°C.  
Figure 6.20. A representative Hot Stage Microscope analysis for a film containing 20:100 w/w 
naproxen/HPMCAS prepared with acetonitrile at: (A)  49°, (B) 110°, (C) 112°, (D) 126°, (E) 
133°, (F) 139°, (G) 161°, (H) 150°, (I) 59°C.  Magnification power of x10 was used. 
 
In addition, a film containing 20:20:100 w/w/w naproxen/malonic acid/HPMCAS 
was analyzed by HSM (figure 6.21). 
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Figure 6.21. A representative Hot Stage Microscope analysis for a film containing 20:20:100 
w/w/w naproxen/malonic acid/HPMCAS prepared with acetone/chloroform at: (A)  112°, (B) 
131°, (C) 134°, (D) 140°, (E) 147°, (F) 167°. Magnification power of x10 was used. 
 
It was observed that crystals started to melt around 130°C. It was observed that 
crystals in both films were behaving similarly. Hence, the scan of those films 
conforms to the results obtained from the DSC scan indicating the existence of 
naproxen crystals in both films. On the other hand, the characteristic melting of 
malonic acid crystals could not been detected. Hence, it is expected that it 
malonic acid is once again molecularly dispersed in the polymer and acts to 
reduce the saturation concentration for naproxen in the polymer.  
This result confirms the expected behaviour according to SP theory of malonic 
acid and naproxen in the polymeric film. 
In order to test the applicability of using the solubility parameters to predict the 
behaviour of two acidic drugs in a polymer, other drug combinations were tested 
in the next section. 
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6.3.3 Flurbiprofen as a blocker of the acidic drug-polymer interaction 
Flurbiprofen is characterized by having a SP value very close to that of 
HPMCAS (table 5.1). Hence, according to the previous conclusion and in line 
with SP theory flurbiprofen should preferably interact with HPMAS reducing the 
saturation point for the other acidic materials and resulting in their preferential 
crystallisation. Films containing flurbiprofen and one of the other acids (malonic 
acid, naproxen, and ibuprofen) were prepared using the method described in 
section 2.3.3. 
Despite the different effect that might arise from adding two acidic drugs to the 
polymeric matrix, films were analyzed to identify the type of the crystals that 
might grow inside. 
  
6.3.3.1 General analysis 
Films were prepared using the following concentrations: 800 mg (malonic acid, 
naproxen, or ibuprofen), 800mg flurbiprofen, and 4000 mg HPMCAS using 
acetonitrile as the preparation solvent. The visual inspection for films containing 
malonic acid or naproxen became relatively opaque and the change of their 
flexibility compared to plain HPMCAS films. However, films containing ibuprofen 
stayed relatively transparent even when 1200 mg of ibuprofen used instead of 
800 mg.  
 
6.3.3.2 Powder X-ray diffraction 
A sample of each film was analyzed using the x-ray diffractometer in order to 
identify the crystalline material that caused the film opacity. The diffraction data 
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were obtained using the method described in section 2.2.2. The diffraction 
patterns obtained from films containing malonic acid and flurbiprofen (figure 
6.22) reveals the existence of diffraction peaks at 17, 19, 23.4, 23.9, 25°. These 
peaks can be observed in the diffraction pattern of unprocessed malonic acid. 
However, there is a low intensity peak at 21° that matches one found in the 
diffraction pattern of flurbiprofen. Thus it can be concluded that the majority of 
flurbiprofen has been molecularly dispersed in the polymer and acts to promote 
malonic acid crystallization in line with the SP theory being developed in this 
thesis. 
Figure 6.22. Representative powder x-ray diffraction patterns for unprocessed malonic acid 
(green), unprocessed flurbiprofen (red), and a film containing flurbiprofen and malonic acid 
(blue). 
The diffraction pattern obtained from films containing flurbiprofen and naproxen 
reveals some peaks at (6°, 12°, 13°, 17°, 19°, 22°, and 24° (2 theta)). These 
peaks can be easily distinguished in the diffraction pattern of unprocessed 
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naproxen (figure 6.23). It was difficult to confirm the existence of flurbiprofen 
crystals in the diffraction pattern, in addition to a high noise/signal ratio. Hence, 
there may or may not be some flurbiprofen crystals in the films. However, it can 
be concluded that most of the crystalline phase in the polymeric film can be 
correlated to naproxen crystals. 
Figure 6.23. Representative powder x-ray diffraction pattern for unprocessed naproxen (red), 
unprocessed flurbiprofen (purple), and a film containing flurbiprofen and naproxen (green). 
 
Both results obtained from the diffraction patterns of films containing flurbiprofen 
and either naproxen or malonic acid conform to the previous expectations 
observed from the solubility parameters of the three materials. 
The diffraction pattern of a film containing 20:20:100 w/w/w 
flurbiprofen/ibuprofen/HPMCAS revealed a low signal/noise ratio. This indicate 
that the diffractometer couldn’t detect the presence of neither flurbiprofen nor 
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ibuprofen crystals. Hence, the flurbiprofen and ibuprofen might be in the 
amorphous state or their crystals are too small to be detected by the x-ray. 
Figure 6.24. Representative powder x-ray diffraction patterns for unprocessed ibuprofen (red), 
unprocessed flurbiprofen (purple), and a film containing 20:20:100 w/w/w 
flurbiprofen/ibuprofen/HPMCAS prepared using acetonitrile (blue). 
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6.4 Summary and Conclusion 
The acidic materials malonic acid and ibuprofen were found to interact with 
HPMCAS as shown by a reduction in its Tg value. Difficulties in signal to noise 
ratios meant that the exact nature of the malonic acid interaction with the 
polymer was not identified. It might be a hydrogen bond interaction or Van der 
Waals interaction. Such interactions for acidic drugs have been observed in the 
literature (Patrick et al., 1998 , Bharate et al., 2010 , Dong and Choi, 2008 , 
Konno and Taylor, 2006). Interestingly, the study showed that the nature of the 
solvent system used to produce the films affected the degree of interaction 
between malonic acid and HPMCAS. Ethanol/water was found to interfere with 
this interaction as observed with the high Tg values of films prepared using 
ethanol/water in comparison to those prepared using other solvents. This might 
be due to the interaction between the solvent and malonic acid that competed 
with malonic acid-HPMCAS interaction. On the other hand, acetonitrile and 
chloroform has less effect on malonic acid-HPMCAS interaction. The findings 
were consistent in accordance with the polarity of the solvent used. High 
polarity solvents (e.g ethanol/water) form a bond with either the acidic 
component or the polymer and interfere with their interaction. On the other 
hand, weakly polar solvents did not compete or interfere with acidic drug-
HPMCAS interaction. 
Increasing the concentration of the acidic species resulted in their saturation of 
the polymer accompanied by the growth of large crystals as indicated by HSM. 
The addition of both malonic acid and ibuprofen to the polymer resulted in the 
growth of large ibuprofen crystals at lower ibuprofen concentrations than were 
observed without the presence of malonic acid. Similar behaviour was noticed 
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with films containing malonic acid and naproxen where naproxen crystals were 
observed in the film. A theory to explain this behaviour was put forward and 
involved the competition between malonic acid and ibuprofen for interaction with 
the polymer. The behaviour of two acidic materials in the polymer can be 
correlated to their SP values. Malonic acid has the closest SP value to that of 
the polymer. Hence, it can be concluded from the previous experiments that the 
closer the SP value for the drug to a polymeric vehicle, the more potential for 
that material to preferably interact with the polymer and thus lower the apparent 
solubility of the other acidic component in HPMCAS and thus facilitate its 
apparent earlier onset of crystallisation. 
In addition, flurbiprofen was used to prove the aforementioned theory as it has a 
unique SP value of 24.45 MPa1/2. This value is considered to be the closest 
value to that of HPMCAS than other acidic drugs. The diffraction patterns of 
films containing flurbiprofen with either malonic acid or naproxen show the 
presence of malonic acid or naproxen crystals. However, flurbiprofen crystals 
couldn’t be detected. This result conforms to the expected behaviour based on 
the aforementioned theory considering that both malonic acid and naproxen 
have a remote SP values from that of HPMCAS in comparison to the SP value 
of flurbiprofen. However, the diffraction pattern of a film containing flurbiprofen 
and ibuprofen revealed a low signal/noise ratio with no appearance for any 
diffraction peaks. This indicates that both flurbiprofen and ibuprofen are in the 
amorphous state or their crystals were too small to be detected by x-ray 
diffractometer. The result obtained with the last film doesn’t conform to the 
previous theory. The presence of flurbiprofen might have increased the 
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solubility of ibuprofen in the polymer. Therefore, further investigations are 
needed. 
  
 
 
 
 
 
 
 
Chapter 7 
Films containing basic drugs and their 
physicochemical properties 
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7.1 Introduction 
Acidic drugs interaction with HPMCAS has been studied in chapter 6. This 
chapter focuses on the interaction between caffeine and nicotinamide with 
HPMCAS. It also studies the possible effect of the preparation media on that 
interaction. HPMCAS is reported to interact with some basic drugs such as 
indomethacin and omeprazole (Bharate et al., 2010 , Stroyer et al., 2006). 
Therefore it is essential to study the relationship between the basic drugs used 
in this project with the polymer. 
Films containing alkaline drugs were prepared using the method described in 
section 2.3.3. Various solvent systems were used in order to identify the 
possible effects of the preparation media on the aforementioned interaction. 
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7.2 Films containing caffeine 
Films containing caffeine were prepared using the method described in section 
2.3.3. Three solvent systems were used as film preparation media: acetonitrile, 
acetone/chloroform, and ethanol/water.  
 
7.2.1 General analysis 
Films containing low concentrations of caffeine (up to 3:50 caffeine/HPMCAS 
w/w) were noted to be transparent and brittle. However, when caffeine 
concentration increased, the film became more flexible, less brittle and more 
opaque. It was noted that caffeine crystals started to grow on the external 
edges of the film initially. Then the growth continued inward with increasing 
caffeine concentration. Unlike malonic acid, a film containing 2:25 
caffeine/HPMCAS w/w was fully opaque whereas a concentration of 3:5 w/w 
malonic acid/HPMCAS was required to achieve the same outcome.  
 
7.2.2 Thermal analysis 
7.2.2.1 TGA 
The TGA thermal profiles for films containing caffeine were obtained using the 
method described in section 2.2.1.1. It can be observed in figure 7.1 that films 
containing caffeine lost around 3% of the total weight between 30-100°C. This 
weight loss was found in the thermal profile of unprocessed HPMCAS and it 
was considered to be due to the residual moisture in the film. The weight loss 
accelerated above 110°C as a result of caffeine and HPMCAS degradation. It 
has to be noted that the degradation of the film containing caffeine starts at 
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lower temperature than caffeine or HPMCAS alone. This might indicate that the 
polymer is accelerating the degradation of caffeine. 
Figure 7.1. Representative TGA thermal profiles for unprocessed caffeine (blue), unprocessed 
HPMCAS (red), and a film containing 1:10 caffeine/HPMCAS. 
 
 
7.2.2.2 DSC 
The DSC thermal profiles for films containing various amounts of caffeine were 
obtained using the three solvent systems according to the method described in 
section 2.2.1.2. Thermal data were used to obtain the Tg values for these films. 
The Tg values were plotted against the concentration of caffeine in the film 
using the aforementioned solvents. Figure 7.2 reveals that films prepared with 
ethanol/water have the highest Tg values independent of the caffeine 
concentration in the film. On the other hand, films prepared with 
acetone/chloroform shows the lowest values for the Tg. This behaviour can be 
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explained by the affinity of the solvent to form a bond with the polymer/drug and 
consequently interfering with the drug-polymer interaction. In addition to that, 
the value of the Tg was more or less constant when a concentration of 1:10 w/w 
caffeine/HPMCAS or more was added to the film. This might indicate that the 
polymer became saturated with caffeine molecules. Hence any additional  
caffeine molecules will not affect the Tg or the plasticity of the polymer. 
Figure 7.2. Graph to show the relation between the Tg and the percentage weight concentration 
of caffeine in HPMCAS films cast from different solvent systems 
 
 
7.2.3 Powder X-ray diffraction 
The powder x-ray diffraction data were obtained using the method described in 
section 2.2.2. The diffraction pattern revealed a high noise/signal ratio (figure 
7.3). However, it is possible to observe a diffraction peak at 11.9°. This peak 
can be seen as well in the diffraction pattern of unprocessed caffeine. Hence, it 
indicates the presence of crystalline caffeine in the film. 
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Figure 7.3. Representative powder x-ray diffraction patterns for unprocessed caffeine(red), a 
film containing 1:10 caffeine/HPMCAS prepared with ethanol/water (purple), and a film 
containing 1:10 caffeine/HPMCAS prepared with acetone/chloroform (blue). 
 
 
7.2.4 FT-IR transmission 
The FT-IR spectra for films containing 7:100 w/w caffeine/HPMCAS prepared 
using the aforementioned solvent systems were collected using the method 
described in section 2.2.3 in order to identify the presence of any potential 
interaction between caffeine and HPMCAS. The FT-IR spectra for films 
containing various amounts of caffeine revealed a shift in the 1692 cm-1 peak. 
This peak was assigned to C=N, NH vibrational energy (section 3.1.1.3). It can 
be noticed that this peak has shifted to around 1704-1709 cm-1. This indicates 
that the NH group is participating in the bond between caffeine and HPMCAS 
through a hydrogen bond. 
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Figure 7.4. representative FT-IR spectra for unprocessed HPMCAS (teal), unprocessed caffeine 
(red), film containing 9:100 w/w caffeine/HPMCAS prepared using acetone/chloroform (teal), 
film containing 7:100 w/w caffeine prepared with ethanol/water (pink), and a film containing 1:10 
w/w caffeine prepared with acetonitrile (red). 
 
 
7.2.5 SEM 
Films containing malonic acid crystals were analyzed using the SEM in order to 
obtain a good image for the crystal shape. SEM imaging was performed using 
the method described in section 2.2.4.1. The collected data revealed that 
crystals had a diameter of around 50 micrometer (figure 7.5). Some small 
particles appeared to cluster around the crystals. These particles might be 
some carbon dust resulting from the carbon coating of the sample that was 
needed due to the high electrostatic charge of the films. On the other hand, 
those particles might be HPMCAS particles that are adhering to the edges of 
the caffeine crystals. 
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Figure 7.5. SEM scan of films containing 1:100 w/w caffeine/HPMCAS with magnification 
powers of X3000 (top left), X1400 (top middle), X2600 (top right), X1600 (bottom left), X4000 
(bottom middle), and X2200 (bottom right). 
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7.3 Films containing nicotinamide 
Nicotinamide was planned to be used as a co-crystal former with ibuprofen. A 
possible nicotinamide-HPMCAS interaction was studied by analyzing films 
containing various amount of nicotinamide. These films were prepared using the 
method described in section 2.3.3.  
 
7.3.1 Thermal analysis 
7.3.1.1 TGA analysis 
The TGA thermal profile for a film containing 1:5 nicotinamide/HPMCAS was 
collected using the method described in section 2.2.1.1. The data obtained in 
the profile reveal a weight loss of about 2% between 30-100°C. A similar weight 
loss was observed in the thermal profile of unprocessed HPMCAS and was 
correlated to the evaporation of the residual moisture in the film (figure 7.6). It is 
noted that the weight loss in the film containing nicotinamide starts earlier than 
the degradation of the unprocessed polymer or the API. This might indicate that 
the interaction between the two components is accelerating the degradation of 
the nicotinamide. 
 152 
 
Figure 7.6. Representative TGA thermal profiles for unprocessed nicotinamide (green), 
unprocessed HPMCAS (blue), and a film containing 1:5 w/w nicotinamide/HPMCAS prepared 
with acetonitrile (red). 
 
7.3.1.2 DSC analysis 
The DSC thermal profiles for films containing various amount of nicotinamide 
were obtained using the method described in section 2.2.1.2. The collected data 
were used to calculate the Tg values for these films. Then the Tg values were 
plotted against nicotinamide concentration in films (figure 7.7). It can be noticed 
from figure 7.7 that the Tg values decrease as the concentration of nicotinamide 
increase. However when the nicotinamide concentration exceeds 15:100 w/w in 
the film, the change in the Tg values becomes minimal. The plateau effect might 
be related to a saturation point of nicotinamide in the film. 
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Figure 7.7. A representative plot for the polymeric film Tg values against nicotinamide 
concentrations in these films. 
 
7.3.2 FT-IR transmission 
The FT-IR spectra of films containing 15:100 and 20:100 w/w 
nicotinamide/HPMCAS of nicotinamide were collected following the method 
described in section 2.2.3. It can be noticed in figure 7.8 the presence of a peak 
shift from 3348 cm-1 in nicotinamide to around 3358 cm-1 in films containing 
nicotinamide. This peak was assigned for the C=N, NH vibrational energy in 
nicotinamide (section 3.1.4.3). Consequently, it can be concluded that 
nicotinamide NH group is participating in hydrogen bonding with HPMCAS.  
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Figure 7.8. Representative FT-IR spectra for unprocessed HPMCAS (red), unprocessed 
nicotinamide (purple), film containing 15:100 w/w nicotinamide/HPMCAS (blue), and film 
containing 1:5 w/w nicotinamide/HPMCAS (teal). 
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7.4 Characterisation of films prepared containing one acidic 
and one basic species/drug 
In chapter 6, it was found that adding two acidic drugs to the film resulted in one 
being “salted out” by the other. However, in this chapter, it was decided to 
investigate the effect of including two drugs in the polymer, one is acidic and 
one is basic. . The acidic compound used here is malonic acid and the basic 
counterparts are caffeine and nicotinamide. The films were prepared using the 
method described in section 2.3.3. 
Caffeine and malonic acid are known to form a co-crystalline system (section 
4.2). This system might be affected by the interaction of either one or both of 
them with the polymer. Solubility parameter data were employed in order to 
predict the behaviour of those drugs inside the polymeric film. it can be noticed 
by looking to table 5.1 and 5.2 that both caffeine and malonic acid have SP 
values that are closer to that of HPMCAS than each other. Therefore, 
theoretically, malonic acid and caffeine will preferably interact with the polymer 
rather than interacting with each other. Similar behaviour is expected between 
nicotinamide and malonic acid.  
 
7.4.1 Films containing caffeine and malonic acid 
In order to monitor the interaction affinity of caffeine and malonic acid, both 
materials were added to the film using the same stoichiometric ratio required for 
their co-crystal formation.  
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7.4.1.1 Thermal analysis 
TGA & DSC 
Thermal profiles for films containing various concentrations of caffeine and 
malonic acid were obtained using the methods described in sections 2.2.1.1 
and 2.2.1.2. The TGA thermal profile reveals a weight loss of 2% between 30-
100°C. A similar weight loss was found in the thermal profile of unprocessed 
HPMCAS and was correlated to the evaporation of the residual moisture. On 
the other hand, DSC thermal profiles were used to calculate the Tg values for 
these films (table 7.1). The Tg values of films prepared with acetone/chloroform 
appeared to be higher than those prepared using ethanol/water independent of 
the caffeine and malonic acid concentrations. On the other hand, the Tg of the 
films containing mixture of caffeine and malonic acid revealed Tg values in 
between the Tg values of the films containing caffeine alone or malonic acid 
alone previously discussed in sections 7.2.2 and 6.2.1.2. 
The Tg values of the previous films are less than it would be expected to be for 
films containing mixtures of caffeine and malonic acid behaviour of the Tg can 
be explained by the presence of an interaction between some molecules of 
caffeine and malonic acid. Hence, the effect on the Tg is not linear or additive. 
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Films prepared by acetone/chloroform 
Average Tg value 
(°C) 
Standard 
deviation Malonic acid concentration 
(w%) 
Caffeine concentration 
(W%) 
0 0 119.79 0.3748 
1.4 4.8 82.097 2.1093 
2.6 9.2 74.815 1.5452 
5.3 16.8 64.438 2.2596 
Films prepared by ethanol/water   
Malonic acid concentration Caffeine concentration Average Tg value 
Standard 
deviation 
0 0 118.63 0.5769 
0.2 0.8 114.92 2.0141 
1.3 5 92.997 2.0740 
2.6 9.2 88.477 1.2050 
5.2 16.8 73.863 0.8680 
Table 7.1. Tg values for HPMCAS films containing various concentrations of caffeine and 
malonic acid prepared by acetone/chloroform and ethanol/water. 
 
7.4.1.2 Powder X-ray diffraction 
Powder x-ray diffraction patterns for films containing both caffeine and malonic 
acid were obtained using the method described in section 2.2.2. The diffraction 
patterns (figure 7.9) revealed a high noise/signal ratio, probably due to the high 
amorphous content of the film. However, a peak was observed at 11°. This 
peak was found to exist in unprocessed caffeine diffraction pattern. On the other 
hand, a co-crystal formation peak at 8° was not observed. This indicates that 
caffeine and malonic acid might have not formed a co-crystalline system in the 
polymer or that their co-crystal concentration was below the detection limit. 
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Figure 7.10. A representative powder x-ray diffraction patterns for unprocessed malonic acid 
(red), unprocessed caffeine (purple), co-crystals of both (blue), a film containing 2:9:100 
malonic acid/caffeine/HPMCAS (teal), and a film containing 8:25:100 malonic 
acid/caffeine/HPMCAS (yellow). The last three were prepared using ethanol/water. 
 
7.4.1.3 FT-IR transmission 
The FT-IR transmission spectrum for a film containing 10:3:100 w/w/w 
caffeine/malonic acid/HPMCAS was obtained following the method described in 
section 2.2.3. The collected spectrum reveals a shift in 1692 cm-1 peak in 
caffeine to 1705 cm-1 in the film containing the mixture (figure 7.10). This shift is 
similar to that observed in films containing caffeine alone. This indicates that at 
least some of the caffeine in these films is not forming a bond with malonic acid. 
11 
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Figure 7.10. Representative FT-IR spectra for plain HPMCAS film (red), unprocessed caffeine 
(teal), unprocessed malonic acid (dark red), co-crystals prepared using acetone/chloroform 
(blue), film containing 7:100 w/w caffeine/HPMCAS (pink), and film containing 10:3:100 
caffeine/malonic acid/HPMCAS (green). 
 
It can be concluded that caffeine and malonic acid have interacted with the 
polymer and plasticized it. However, there is a possibility that some particles 
might have formed co-crystals as the observed Tg values of the film were 
lowered than expected for films containing caffeine malonic acid mixture.  
Nevertheless, the thermal profile of the co-crystals appeared in section 4.2.2.1.2 
to be hard to measure. Hence, it cannot be used as an identification tool. 
 
7.4.1.4 Hot stage microscopy  
A film containing 1.4:4.8:100 w/w/w malonic acid/caffeine/HPMCAS was 
examined by HSM following the method described in section 2.2.4.2. The 
 160 
 
crystals inside the polymer revealed a thin and long shape. It can be noticed 
that the crystals spread through all the layers of the film (figure 7.12). 
Figure 7.12. A representative HSM imaging for a film containing 1.4:4.8:100 w/w/w malonic 
acid/caffeine/HPMCAS with different magnification power: X10 (top and bottom left), X20 (top 
right), and X50 (bottom right). 
 
In summary: loading malonic acid and caffeine in the film resulted in their 
interaction with the polymer. This result conforms to the expected behaviour of 
both drugs obtained from their SP values. However, there was a possibility of 
growing the co-crystals after they reach their saturation concentration. 
Therefore, films containing 8:15:100, 8:20:100, and 8:25:100 w/w/w 
caffeine/malonic acid/HPMCAS were prepared. Acetonitrile was used as a 
solvent system. Films were analyzed using the X-ray diffractometer following 
the method described in section 2.2.2 (figure 7.13). The diffraction patterns 
revealed the presence of diffraction peaks at 16° for all the films. The film 
containing 8:25:100 w/w/w caffeine/malonic acid/HPMCAS revealed the 
presence of two other significant peaks at 22.8° and 25.6°. These peaks 
collectively are considered as the characteristic peaks for caffeine-malonic acid 
co-crystals. On the other hand, films prepared with acetonitrile showed the 
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conversion of anhydrous caffeine into caffeine monohydrate. However, the x-ray 
diffraction pattern did not detect caffeine monohydrate in the film. 
Figure 7.13. Representative powder x-ray diffraction patterns for unprocessed malonic acid 
(red), unprocessed caffeine (green), co-crystal (CSD) (yellow), 8:25:100 (green), 8:20:100 
(purple), and 8:15:100 w/w/w caffeine/malonic acid/HPMCAS (blue). 
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7.4.2 Films containing nicotinamide and malonic acid 
Films containing malonic acid and nicotinamide were prepared using the 
method described in section 2.3.3. Films were analyzed in order to identify the 
molecular interactions that occurred within the film. 
 
7.4.2.1 Thermal analysis 
7.4.2.1.1 TGA 
The thermal profiles for films containing nicotinamide and malonic acid were 
obtained using the method described in section 2.2.1.1. The data collected 
reveals a 2% weight loss between 30-100°C. A similar weight loss was also 
observed in the thermal profile of unprocessed HPMCAS and was correlated to 
the evaporation of residual moisture (figure 7.13).  
Figure 7.13. Representative TGA thermal profiles for unprocessed malonic acid (red), 
unprocessed nicotinamide (pink), HPMCAS film (teal), a film containing 15:100 w/w 
nicotinamide/HPMCAS (blue), and a film containing 1:1:5 nicotinamide/malonic acid/HPMCAS 
(green). 
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7.4.2.1.2 DSC analysis 
Thermal profiles for films containing nicotinamide and malonic acid were 
collected using the DSC following the method described in section 2.2.1.2. The 
collected data reveals the existence of a strong intensity peak at 109°C (figure 
7.14). This peak might be related to the melting of either malonic acid or 
nicotinamide crystals inside the polymer. On the other hand, a new system 
might have formed inside the film and this endothermic peak is the melting peak 
for that system. Another small peak can be noticed at 92°C. This peak might be 
an indication for the presence of some impurities. 
Figure 7.14. A representative thermal DSC profile for a film containing 1:1:5 w/w/w 
nicotinamide/malonic acid/HPMCAS and prepared with acetone/chloroform. 
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7.4.2.2 Powder X-ray diffraction 
The powder diffraction patterns for films containing malonic acid and 
nicotinamide were obtained using the method described in section 2.2.2. The 
diffraction pattern reveals the existence of new peaks at 21° and 28° (figure 
7.15). These two peaks have no matching in the diffraction pattern of 
unprocessed nicotinamide or malonic acid diffraction pattern. However, these 
peaks were observed in the diffraction pattern of malonic acid-nicotinamide co-
crystals (section 4.4.2). Consequently, it can be concluded that part of the two 
drugs may have formed a co-crystalline system inside the polymeric film.  
Figure 7.15. Representative powder x-ray diffraction patterns for unprocessed nicotinamide 
(yellow), unprocessed malonic acid (blue), and a film containing 1:1:5 w/w/w 
nicotinamide/malonic acid/HPMCAS (red). 
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7.4.2.3 FT-IR transmission 
The FT-IR spectra for films containing malonic acid and nicotinamide were 
obtained using the method described in section 2.2.3. The resulting spectrum 
reveals a shift in the 3354 cm-1 peak to 3372 cm-1(figure 7.16). This peak was 
previously assigned to the C=N, NH vibration in nicotinamide (section 4.4.3). 
The shift indicates the participation of this group in a bond between 
nicotinamide and either HPMCAS or malonic acid. However, the x-ray 
diffraction pattern showed the existence of new peaks that were observed with 
the diffraction pattern of nicotinamide-malonic acid co-crystals. In addition the 
similarity of this shift with the FT-IR shift in the co-crystals spectrum. Hence, the 
shift might be another indication for the formation of nicotinamide-malonic acid 
co-crystals in the film.  
Figure 7.16. Representative FT-IR spectra for a plain HPMCAS film (red), unprocessed malonic 
acid (yellow), unprocessed nicotinamide (blue), a film containing 1:5 nicotnamide/HPMCAS 
(teal), and a film containing 1:1:5 w/w/w nicotinamide/malonic acid/HPMCAS (green). 
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7.5 Summary and conclusion 
Basic drugs interacted with HPMCAS affecting its plasticity. However, unlike the 
case for acidic additives, a relatively small amount of caffeine or nicotinamide 
amount was enough to saturate the polymer. In addition a slightly lower effect 
on the Tg reduction was observed in comparison to acidic drugs. This can be 
demonstrated by comparing the effect of each of malonic acid, caffeine, and 
nicotinamide on the Tg of the polymer (figure 7.17). It can be seen that caffeine 
has affected the Tg to almost a similar manner like nicotinamide. However, a 
smaller amount of caffeine was enough to produce the saturation concentration. 
Figure 7.17. A comparison between the Tg values of films containing: caffeine, nicotinamide, or 
malonic acid against the concentrations of these drugs in the film. 
 
FT-IR spectra for films containing caffeine or nicotinamide revealed a shift in the 
peak  assigned for the C=N, NH vibration in both of the compounds. This 
indicates that each of them is formed a hydrogen bond with the polymeric 
matrix. 
 167 
 
When films containing caffeine were prepared using various solvent systems, it 
was noticed that the high polarity solvent system (ethanol/water) interfered with 
the drug-polymer interaction. On the other hand, the low polarity solvent 
(acetonitrile) had less effect on that interaction and resulted in a low Tg values 
expected.   
Malonic acid was used to study the effect of loading an acidic and a basic drug 
into the polymeric film. Despite that solubility parameter values provided in table 
5.1 indicated that malonic acid and nicotinamide or caffeine would theoretically 
favour to interact with the polymer rather than interacting with each other, 
malonic acid managed to form a bond with caffeine and nicotinamide forming a 
co-crystalline system during the loading of the two materials (malonic acid-
nicotinamide and/or malonic acid- caffeine) into a polymeric film. However, a 
smaller amount of malonic acid was needed to interact with nicotinamide than 
that needed to interact with caffeine. The excess amount in the second case 
appeared to be needed to saturate the polymer first and bring the interaction 
favour toward caffeine. This result doesn’t conform to the proposed theory of 
interaction affinity prediction based on the closeness of the solubility parameter 
values of the drugs and the polymer. This difference can be explained by the 
affinity factor between the acidic and basic compounds to interact which has not 
been taken into consideration in the proposed theory.  
It can be concluded from the previous observation that increasing the 
concentration of the acidic part of the co-crystal system can be considered as a 
technique to grow co-crystals in a polymeric carrier of HPMCAS. this technique 
proved itself in the case of caffeine-malonic acid co-crystals in HPMCAS film. 
however, this technique cannot be considered as a general rule as it may 
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resulted in the use of an excess amount of the drug over its therapeutic level as 
in the case of ibuprofen-nicotinamide were ibuprofen is the acidic part of the 
drug.
  
 
 
 
 
 
 
 
 
 
Chapter 8 
Manufacture and stability of co-crystals in a polymeric carrier 
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8.1 Introduction 
This chapter examines the loading process of co-crystals (caffeine-malonic acid 
and ibuprofen-nicotinamide) into a polymeric vehicle (HPMCAS). It will also 
investigate the factors that affect this process and study the dissolution release 
and stability of the co-crystals in the film. 
Caffeine-malonic acid co-crystals can be grown in the polymeric film by using 
an excess above their saturation concentrations. Therefore, the excess amount 
of the acidic moiety of the co-crystals was used in chapter 7 to saturate the 
polymer for the acidic drug. This in turn has allowed the growth of free crystals 
in the film that have the ability to interact with the basic moiety and form a co-
crystal (as in caffeine-malonic acid co-crystal formation in chapter 7). However, 
the increase in the acidic moiety may not always be possible for the rest of co-
crystalline systems, e.g. Ibuprofen-nicotinamide co-crystals are one of the 
examples were the API is the acidic moiety. Increasing the ibuprofen 
concentration to reach the saturation concentration may not be possible as it 
will result in overdosing. 
Therefore, it was necessary to find a method that can preserve the 
concentrations around their acceptable therapeutic concentrations. 
The possibility of loading the co-crystals without increasing the acidic moiety 
concentration was investigated. Therefore, the co-crystals of caffeine-malonic 
acid and ibuprofen-nicotinamide were prepared and then dispersed in a 
HPMCAS solution. 
The solvent effect on the loading process and on co-crystal integrity was 
evaluated through the use of different solvents for the loading process. 
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It was revealed in chapter 7 that the HPMC-AS film has a higher affinity to 
interact with the acidic moiety of the co-crystal, therefore the approach of using 
another acidic drug with a closer SP to that of the polymer was investigated to 
verify if it can reduce the saturation concentration of the co-crystal acidic moiety 
and therefore protect the co-crystal integrity. 
Two co-crystal systems were studied, caffeine-malonic acid and ibuprofen-
nicotinamide. 
 
8.2 HPMCAS films containing co-crystals of caffeine and malonic 
acid 
Films designed to contain 500 mg caffeine-malonic acid co-crystal in 4000 mg 
HPMCAS were prepared using the method described in section 2.3.4. Two 
solvent systems were used for the loading process: acetonitrile and 
acetone/chloroform. The resulting films were analyzed in order to confirm co-
crystal integrity. 
 
8.2.1 Thermal analysis 
TGA & DSC 
Films containing 500 mg of caffeine-malonic acid co-crystals prepared and cast 
using acetonitrile or acetone/chloroform were analysed using TGA and DSC to 
obtain their thermal profiles. The moisture content of the film was similar to the 
moisture content of unprocessed HPMCAS (section 3.1.7.1) around 2% 
between 30-100°C (Appendix AI 10).  
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The thermal DSC profile for films containing co-crystals didn’t reveal any of the 
melting peaks observed in the thermal profile of caffeine-malonic acid co-
crystals (figure 4.1 and 4.2). In addition to that, the Tg values of films containing 
co-crystals prepared using acetone/chloroform was difficult to measure.  
However, the two measureable Tg values (91.52° and 35.73°C) are lower than 
those observed with films prepared using acetonitrile (110.37° and 72.73°C). 
This may reflect that the type of materials interacting with the polymer is 
different between the two films. It was noticed that malonic acid (or acidic drugs 
generally) causes more depression for the Tg of the polymer than basic ones. 
Therefore, this might suggests that the amount of free malonic acid in the film 
prepared using acetone/chloroform is higher than that in a film prepared using 
acetonitrile (figure 8.1). 
Nevertheless, it is unclear if the Tg shift is the result of the interaction between 
the co-crystals and the polymer or the caffeine and malonic acid interaction with 
the polymer. Consequently, detecting Tg changes to quantify drug interaction 
with the polymer and compare the effect of using various solvents on such 
interaction was not practical.  
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Figure 8.1. Representative thermal DSC profiles for films containing caffeine-malonic acid co-
crystals prepared using acetone/chloroform (green) and acetonitrile (blue). 
 
8.2.2 Powder X-ray diffraction 
The diffraction pattern obtained from a film containing co-crystals prepared 
using acetonitrile revealed two diffraction peaks at 12.5° and 27.4°. The second 
diffraction peak can be correlated to the diffraction pattern of caffeine- malonic 
acid co-crystals (section 4.2.1.2). On the other hand, the diffraction pattern 
obtained from films prepared using acetone/chloroform revealed a high 
noise/signal ratio with a weak diffraction peak appeared at 12°. Therefore, it 
was not possible to confirm conclusively the co-crystals presence in these films 
(figure 8.2).  
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Figure 8.2. Representative x-ray diffraction patterns for unprocessed malonic acid (purple), 
unprocessed caffeine (blue), co-crystals diffraction pattern obtained from CSD (green), a film 
containing co-crystals prepared using acetone/chloroform (teal), and a film containing caffeine-
malonic acid co-crystals prepared using acetonitrile (red). 
 
8.2.2 FT-IR transmission 
The collected FT-IR spectra using the method described in section 3.2.3 
revealed a shift in caffeine C=N, NH peak from 1692 cm-1 to 1699 cm-1 and 
1705 cm-1 in films containing co-crystals prepared with acetonitrile and 
acetone/chloroform respectively. The shift of C=N, NH peak from 1692 to 1698 
cm-1 was observed previously in the FT-IR transmission pattern of caffeine-
malonic acid co-crystals (section 4.2.1.3). As the degree of shifting reflects the 
change of the vibrational energy of the system, therefore it can be concluded 
that the films prepared using acetonitrile reveals the presence of co-crystals. On 
the other hand, the observed shift in films containing 500 mg co-crystals and 
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prepared using acetone/chloroform is similar to the shift in films containing 
caffeine alone. In addition, this shift is higher than the shift resulting from co-
crystal formation. Therefore, it can be concluded that a shift of the C=N, NH 
peak in the analysis of films prepared using acetone/chloroform is an indication 
of the bond formed between caffeine and HPMCAS which in turns reflect the 
absence of co-crystals in the scanned spot (figure 8.3). It was difficult to identify 
the shift in malonic acid C=O, OH representative peaks as the polymer 
transmission pattern was covering a wide range of the chart and due to the high 
number of peaks that assign for that particular functional group. Therefore, the 
vibrational energy in the C=N, NH bond was used as an indicator for the 
presence of caffeine-HPMCAS or caffeine-malonic acid interaction. It is worth 
mentioning that films prepared using both solvents showed the presence of both 
co-crystals and caffeine-HPMCAS interaction. However, it was easier to find co-
crystals in films prepared using acetonitrile than those prepared using 
acetone/chloroform. Nevertheless, since the FT-IR microscopy is a single spot 
scan therefore it is difficult to quantify the co-crystals/crystals ratio in each film.  
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Figure 8.3. Representative FT-IR spectra for unprocessed HPMCAS (red), unprocessed 
malonic acid (teal), unprocessed caffeine (yellow), a film containing 1:10 caffeine/HPMCAS 
(blue), co-crystals prepared using acetone/chloroform (brown), film containing co-crystals 
prepared using acetone/chloroform (purple), and a film containing co-crystals prepared using 
acetonitrile (green). 
 
 
It can be concluded that caffeine-malonic acid co-crystals were successfully 
loaded into the polymer and that some of them stayed intact. A quantitative 
study for the co-crystals/constituents ratio was difficult to perform; therefore no 
blocker was used as its effect cannot be measured. 
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8.3 Films containing co-crystals of ibuprofen and nicotinamide 
Films containing 500 mg ibuprofen-nicotinamide co-crystals were prepared 
using the method described in section 2.3.4. Acetonitrile and 
acetone/chloroform were used for the loading of these co-crystals in the 
polymeric film.  
 
8.3.1 Thermal analysis 
TGA and DSC 
The thermal profiles of films containing ibuprofen-nicotinamide co-crystals 
prepared with acetone/chloroform and/or acetonitrile reveal a weight loss 
around 2% between 30-100°C which was similarly observed in the thermal 
profile of unprocessed HPMCAS. This weight loss was correlated to the 
evaporation of the residual moisture in the film (Appendix AI 11). A shift of the 
polymer Tg can be observed as well. From figure 8.4, the Tg values were 53° 
and 41°C for films prepared using acetonitrile and acetone/chloroform 
respectively. Comparing these values to the values observed in films containing 
ibuprofen and nicotinamide separately reveals that the observed Tg shift in films 
loaded with ibuprofen-nicotinamide co-crystals might be due to the plasticizing 
effect produced by the effect of the constituents on the polymer. Hence, free 
ibuprofen and nicotinamide were detected (figure 8.4). On the other hand, this 
change in Tg value might be the result of co-crystals interaction with the 
polymer. 
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Figure 8.4. Representative DSC thermal profiles for a film containing 1:10 w/w 
ibuprofen/HPMCAS (green), 1:10 w/w nicotinamide/HPMCAS (blue), a film containing co-
crystals prepared with acetone chloroform (1) (red), and acetonitrile (2) (purple). 
 
8.3.2 powder X-ray diffraction 
The diffraction pattern obtained from films containing ibuprofen-nicotinamide co-
crystals prepared using acetonitrile revealed the existence of three peaks at 3°, 
16°, and 17°. The presence of these peaks is confirmatory of the presence of 
co-crystal inside the polymer. On the other hand, the diffraction pattern of the 
film prepared using acetone/chloroform failed to provide any diffraction peak 
due to the low signal/noise ratio due to the domination of the amorphous peaks 
related to the polymeric matrix (figure 8.5). 
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Figure 8.5. representative powder x-ray diffraction pattern for unprocessed nicotinamide (black), 
unprocessed ibuprofen (red), co-crystals (silver), a film containing co-crystals prepared using 
acetone/chloroform (teal), and a film containing co-crystals prepared using acetonitrile (green). 
 
This result doesn’t prove or disprove the existence of ibuprofen-nicotinamide 
co-crystals in films prepared using acetone/chloroform. Therefore, FT-IR 
microscopy was used to provide supporting evidence for identifying the type of 
crystal in the film. 
 
8.3.3 FT-IR transmission 
Analysis of the data in figure 8.6 revealed that it was difficult to detect the shift 
in films containing ibuprofen-nicotinamide co-crystals. This is due to the nature 
of the polymer that has wide range of interfering vibrations. 
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Figure 8.6. Representative FT-IR spectra for, unprocessed ibuprofen RS (green), unprocessed 
nicotinamide (blue), co-crystals (pink), a film containing co-crystals prepared using 
acetone/chloroform (red), and a film containing co-crystals prepared using acetonitrile (silver). 
 
The results collected from the DSC, X-ray, and FT-IR indicate the presence of 
some ibuprofen-nicotinamide co-crystals in the film prepared using acetonitrile, 
contrary to films prepared using acetone/chloroform. However, the co-crystal 
percentage appeared to be lower than that that the DSC can detect. The FT-IR 
data revealed no shifting in the analyzed spots. Hence, it can be concluded that 
free nicotinamide and ibuprofen are present in the film. Thermal analysis of both 
films revealed the presence of an interaction between the drug, crystalline/co-
crystalline, and the polymeric matrix. This interaction caused the depression 
noticed in the Tg value of the polymer. 
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HPMCAS is known to have a preferential interaction with acidic drugs. Hence, 
in order to prevent such an interaction from affecting the integrity of the loaded 
co-crystals, a second acid was selected based on the observations in sections 
6.3 and 6.4 in order to reduce the saturation concentration for ibuprofen and 
consequently reduce the affinity of HPMCAS to interacting with ibuprofen. 
Malonic acid was selected as it has a SP value that is closer to HPMCAS SP 
value than that of ibuprofen and HPMCAS. Since malonic acid SP value is 
closer to that of the polymer rather than nicotinamide SP value, there should 
theoretically be no or little interaction between malonic acid and nicotinamide. 
 
8.4 The use of a blocking agent for ibuprofen-HPMCAS interaction 
Malonic acid was noticed to reduce the saturation point of ibuprofen by 
competing with it on the interaction with the polymer as in section 6.3.1. 
Therefore, malonic acid is used in this experiment to reduce the affinity of 
ibuprofen to interact with the polymer. This might preserve more co-crystals 
during the loading process. As it was mentioned earlier, there is some affinity 
between nicotinamide and malonic acid to interact and form co-crystals. 
However, based on the affinity rule derived from the SP values, malonic acid 
should preferably interact with HPMCAS more than nicotinamide. Hence, if no 
excess amount of malonic acid were used, the right environment for loading the 
co-crystals should be achieved.  
Films were prepared using the method described in section 2.3.4. Various 
concentrations of malonic acid were tested to find an optimum amount of 800 
mg/4000 mg HPMCAS to use with all films. 
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8.4.1 General analysis 
Visual inspection of these films revealed an increase in opacity of the polymeric 
matrix compared to films containing the same concentration of co-crystals only. 
In addition, small white crystals were noticed dispersing in the polymeric films.  
 
8.4.2 Thermal analysis 
TGA & DSC 
Thermal profiles for films containing ibuprofen-nicotinamide co-crystals with a 
blocking agent (malonic acid) prepared using acetone/chloroform and 
acetonitrile revealed about 2% weight loss between 30-100°C. A similar weight 
loss was observed in the thermal profile for unprocessed HPMCAS and was 
correlated to the evaporation of the residual moisture in the film. In addition to 
that, these profiles main difference from the thermal profile of films containing 
no blocking agent is the degradation step that around 140°C. This step can be 
correlated to the degradation of malonic acid (Appendix AI 11). On the other 
hand, the Tg values of these films were difficult to measure. However, two 
interesting peaks were detected in the thermal profile of films prepared using 
acetonitrile. Those peaks were found at 92°C and 104°C (figure 8.7). These 
peaks can be correlated to the melting peaks of ibuprofen-nicotinamide co-
crystals (93°C) and malonic acid-nicotinamide co-crystals (110°C). The 
endothermic peak at 92°C was noticed in the first heating run in the DSC 
thermal profile. This peak disappeared from the second heating run. It can be 
noticed that heat melted the co-crystals and the polymeric matrix prevented 
their reformation on cooling. This can be observed in the disappearance of the 
co-crystals peak from the second heating run. However, the second peak is not 
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close to the melting point of the individual components of the melted co-crystals. 
It is rather close to the melting point of malonic acid-nicotinamide melting point. 
Hence, this may indicate the presence of malonic acid-nicotinamide co-crystals 
in the film. Since the last co-crystal system was not added to the film, this 
means that malonic acid has substituted ibuprofen in the co-crystal and took its 
place (similar to substitution reaction in salts). This substitution was predicted 
according to the solubility parameter values of the three compounds. However, 
malonic acid was expected to interact preferentially with the polymer.  
Figure 8.7. Representative DSC thermal profiles for ibuprofen-nicotinamide co-crystals (green), 
malonic acid-nicotinamide co-crystals (blue), the first heating run of a film containing co-crystals 
and malonic acid prepared with acetonitrile (brown), and the second heating step for the same 
film (pink). 
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8.4.3 Powder X-ray diffraction 
The X-ray diffraction pattern reveals the existence of 3 peaks diffraction at 6°, 
19° and 28° (figure 8.8) These peaks can be observed in the diffraction pattern 
of unprocessed ibuprofen (6°) and nicotinamide-malonic acid co-crystals (19° 
and 28°). Therefore, according to the thermal and the X-ray analysis, it can be 
said that the film contains ibuprofen-nicotinamide co-crystals, malonic acid-
nicotinamide co-crystals, ibuprofen, and malonic acid crystals.  
Figure 8.8. Representative powder x-ray diffraction pattern for unprocessed nicotinamide 
(yellow), unprocessed ibuprofen (green), unprocessed malonic acid (purple), nicotinamide-
malonic acid co-crystals (teal), ibuprofen-nicotinamide co-crystals (red), and film containing 
ibuprofen-nicotinamide co-crystals with malonic acid (black). 
 
8.4.4 FT-IR transmission 
The FT-IR spectrum was used in order to probe the interactions that exist in the 
polymeric film. The FT-IR spectrum revealed a peak shift at 3354 to 3371 cm-1. 
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This peak was correlated to the C=N, NH vibrational energy in nicotinamide. 
There was no observed shift in the 1698 cm-1 in ibuprofen that assign for C=O, 
OH bond. In addition to that, there was a peak observed at in scan shows that 
the nicotinamide peak at 1686cm-1 (figure 8.9). This peak can be observed in 
malonic acid-nicotinamide co-crystals. This peak was found to assign for C=O, 
C-O vibrational energy in malonic acid. Hence, the FT-IR analysis reveals the 
existence of nicotinamide-malonic acid co-crystals in films loaded with 
ibuprofen-nicotinamide co-crystals in addition to malonic acid as well. 
Figure 8.9. Representative FT-IR spectra for unprocessed HPMCAS (blue), unprocessed 
malonic acid (teal), unprocessed ibuprofen RS (purple), unprocessed nicotinamide (silver), 1:2 
ibuprofen/HPMCAS (green), 1:5 nicotinamide/HPMCAS (black), ibuprofen-nicotinamide co-
crystals (red), film containing ibuprofen-nicotinamide co-crystals (light green), malonic acid-
nicotinamide co-crystals (yellow), and film containing ibuprofen-nicotinamide co-crystals with 
malonic acid (white). Films were prepared using acetonitrile. 
 
The analysis of films containing ibuprofen-nicotinamide co-crystals and malonic 
acid revealed the existence of a free ibuprofen and malonic acid in addition to a 
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mixture of two co-crystalline systems: ibuprofen-nicotinamide and malonic acid-
nicotinamide. Therefore, the use of malonic acid to improve the outcome of the 
loading process of co-crystals into a polymeric film can be described as in-
effective in terms that it was not 100 percent efficient in preserving the desired 
co-crystals. On the other hand, it was not feasible to quantify the percentage of 
both co-crystalline systems in the film. Therefore, any improvement in the total 
loading ratio is difficult to measure. 
 
8.5 Dissolution test 
Generally co-crystals have a faster dissolution rate than their parent drug 
(Blagden et al., 2007 , Vishweshwar et al., 2006 , Mirza et al., 2008). However, 
there is a dearth of information about the release and the dissolution behaviour 
of co-crystals dispersed in a polymeric carrier. Caffeine and malonic acid can be 
easily measured with UV spectroscopy as there is no major overlap for their 
absorption profiles. On the other hand, the UV absorption spectra for ibuprofen, 
nicotinamide and malonic acid overlap which render the use of UV to measure 
the release profile very complex. Therefore, the dissolution test was performed 
only on films containing caffeine-malonic acid co-crystals. The release pattern 
was obtained following the method described in section 2.2.5. The collected 
data was then compared to the dissolution rate of a film containing a similar 
caffeine concentration to that used in films containing co-crystals (1:10 w/w 
caffeine/HPMCAS). The experiment was repeated twice in order to reduce the 
effect of experimental error. Even though that the average dissolution rate of 
films containing caffeine alone is greater than that of films containing co-
crystalline caffeine (figure 8.10), the standard error for the experiment was high 
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and thus prevented any significance from being assigned or real comparison 
from taking place (Appendix AVI 1-3).  
 
Figure 8.10. Comparison of the dissolution rate of caffeine from a film containing 1:10 
caffeine/HPMCAS w/w, and a film containing equivalent amount of caffeine as co-crystals. Error 
bars removed for clarity and can be found at Appendix AVI 1-3. 
 
Given the above constraints, the graph (Fig. 8.10) shows that the dissolution of 
caffeine from the polymer is higher than the dissolution of it when formulated as 
a co-crystal and loaded into the polymeric film. 
 
8.4.6 Stability study 
The stability of caffeine-malonic acid co-crystals against high humidity and 
temperature was measured in order to monitor the effect of the film coating 
(dispersion of co-crystals in the polymeric film) on caffeine resistance to 
hydration. 
The stability test was performed on films containing caffeine-malonic acid co-
crystals only due to the abundance of caffeine-malonic acid co-crystals in 
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comparison to ibuprofen-nicotinamide co-crystals in films containing either. In 
addition, it is easier to detect the presence of caffeine-malonic acid co-crystals 
in comparison to ibuprofen-nicotinamide co-crystals using FT-IR microscopy. 
Although the ICH guidelines suggest the use of 40°C and 75% relative humidity 
for 6 months (Guideline, 2003), the parameters were chosen as 45°C and 95% 
relative humidity as the available time was 3 months. However, the sample 
didn’t reveal any difference after the end of the third month. Therefore, the 
samples were kept for additional 4 months. 
Caffeine-malonic acid co-crystals was reported in the literature to have a good 
stability for hydration more than caffeine alone (Trask et al., 2005). HPMCAS is 
known to be a hygroscopic material. Therefore, dispersing caffeine-malonic acid 
co-crystals in HPMCAS film will bring the co-crystals in contact with the 
moisture.  
HPMCAS films containing 500 mg of caffeine-malonic acid co-crystals were 
divided into small pieces and analyzed with FT-IR to ensure the presence of the 
co-crystals and to obtain a reference for future comparison. Samples were 
stored in a closed oven with a relative humidity (RH) of 95% and temperature of 
45°C. 
Caffeine-malonic acid co-crystals revealed a good stability against relative 
humidity of 75% for 7 weeks. However, when the RH was increased to 98%, the 
co-crystals was stable for the first week and the FT-IR analysis showed the 
disappearance of their transmission profile after 7 weeks (Schultheiss and 
Newman, 2009). On the other hand, another study in the literature revealed that 
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the co-crystals disappeared after one day of storing them at 98% RH at room 
temperature (Trask et al., 2005). 
The available stability study oven was limited to 95% RH, Therefore the study 
was performed on 95% and a temperature of 45°C to provide an extra 
challenge for the co-crystals dispersed in the HPMCAS film. 
The samples were removed periodically and analyzed using the FT-IR 
microscopy to monitor the presence of caffeine-malonic acid co-crystals. The 
analysis revealed that samples stored for 8 weeks containing intact co-crystals 
(Appendix AVII 1-23). Afterward the analysis revealed the disappearance of the 
co-crystals transmission profile and the appearance of caffeine or caffeine-
HPMCAS transmission profile. Therefore, it can be concluded that dispersing 
caffeine-malonic acid co-crystals in a film of HPMCAS increased the stability of 
those co-crystals against 95% RH and 45°C temperature. 
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8.5 Summary and conclusions 
Loading caffeine-malonic acid co-crystals was successful using acetonitrile and 
acetone/chloroform. However, the percentage of intact co-crystals was 
observed to be higher with the first solvent. 
On the other hand, loading ibuprofen-nicotinamide co-crystals into HPMCAS 
films revealed the presence of a very small number of intact co-crystals that 
couldn’t be detected by the DSC and were only detectable by x-ray. 
When malonic acid was used as a blocking agent to reduce the ibuprofen 
saturation concentration, it was noticed that some ibuprofen-nicotinamide co-
crystals were detected by the DSC in addition to the detection of malonic acid-
nicotinamide co-crystals as well. 
A- Caffeine-malonic acid co-crystals in HPMCAS film: 
Caffeine-malonic acid co-crystals were loaded into a polymeric vehicle using 
two solvent systems: acetonitrile and acetone/chloroform. Although acetonitrile 
was found to aid formation of caffeine monohydrate (chapter 3 and 4), the FT-IR 
results in this chapter showed no sign of caffeine monohydrate. The quantitative 
comparison between films containing caffeine-malonic acid co-crystals prepared 
using acetonitrile or acetone/chloroform was difficult through thermal analysis 
(DSC) as the Tg values for films prepared using acetone/chloroform were 
difficult to be measured. However, the calculated Tg values for films prepared 
using acetone/chloroform is lower than that prepared using acetonitrile (91.52° 
and 35.73°C for films prepared using acetone/chloroform compared to 110.37° 
and 72.73°C observed for films prepared using acetonitrile). Since malonic acid 
and caffeine in their free state can interact better with the polymer and 
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consequently reduce the Tg more. The amount of free drugs is inversely related 
to the amount of the intact co-crystals. Therefore, it can be concluded that the 
amount of free drug in the film prepared using acetone/chloroform containing 
less amount of co-crystals than the one prepared using acetonitrile. 
B- Ibuprofen-nicotinamide co-crystals in HPMCAS film: 
The second part of this chapter focused on the loading of ibuprofen-
nicotinamide co-crystals into a polymeric film in the presence of malonic acid. 
The DSC thermal profile shows the presence of two endothermic peaks at 92°C 
and 104°C. These peaks are expected to be the melting peaks of ibuprofen-
nicotinamide co-crystals (92°C) and malonic acid-nicotinamide (110°C) 
respectively. The X-ray diffraction pattern of films containing ibuprofen-
nicotinamide co-crystals revealed the presence of nicotinamide-malonic acid co-
crystals in the film. Therefore, it can be stated that films loaded with ibuprofen-
nicotinamide co-crystals and malonic acid as a blocking agent revealed the 
presence of: ibuprofen-nicotinamide co-crystals, malonic acid-nicotinamide co-
crystals, ibuprofen, nicotinamide, and a possible malonic acid-HPMCAS and 
ibuprofen-HPMCAS. 
C- Ibuprofen-nicotinamide co-crystals in HPMCAS film using malonic 
acid as a blocker: 
Malonic acid was used in order to protect the co-crystals of ibuprofen-
nicotinamide from interacting with the polymer. Malonic acid was chosen based 
on its SP value which is closer to that of the polymer than either ibuprofen or 
nicotinamide to the polymer SP value. 
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Malonic acid was not used in excess in order not to affect the co-crystals as 
well. Nevertheless, the analysis of these films showed the presence of malonic 
acid-nicotinamide co-crystals. 
The quantification of co-crystals was not feasible, thus it was difficult to quantify 
the effect of using the malonic acid on the loading of the co-crystals. 
 
D- Dissolution test of caffeine-malonic acid co-crystals in HPMCAS 
film 
The dissolution test of films containing caffeine-malonic acid co-crystals 
revealed a lower dissolution rate than films containing the same amount of 
caffeine alone. However, the standard error of the release profile was high. 
Thus the actual superiority for films containing caffeine alone is not fully 
confirmed. 
 
E- Stability test of caffeine-malonic acid co-crystals in HPMCAS film 
The ability of HPMC-AS as a protective film to enhancing the stability of 
caffeine-malonic acid co-crystal against high RH and temperature was 
measured through a stability test for films containing co-crystals over 7 months. 
The test revealed that co-crystals disappeared after 8 weeks of storage. This is 
considered to be higher than the documented stability test for caffeine-malonic 
acid co-crystals alone in the literature were the co-crystals stayed stable for 1 
day or less (Trask et al., 2005 , Schultheiss and Newman, 2009). Therefore, it 
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can be concluded that the polymer enhanced the stability of caffeine-malonic 
acid co-crystals against high RH and temperature. 
 
  
 
 
 
 
 
 
 
 
 
Chapter 9 
Summary, conclusions, and future work 
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Summary and conclusion 
This thesis has investigated whether co-crystals can be formed within a polymer 
film (HPMC-AS) and has used a range of techniques to characterise their solid-
state form. The dissolution and stability properties of the co-crystal in the film 
systems have also been investigated. The aim of the thesis was novel and the 
literature contains only one limited study of the behaviour of co-crystals formed 
and dispersed in a polymeric carrier, namely nicotinamide-carbamazepine 
dispersed in polyvinyl pyrrolidone (Good et al., 2011). The study in this thesis is 
much more extensive and highlights the difficulty of producing co-crystals within 
films. 
To outline the structure of this thesis: 
The first step was analyzing the raw materials to identify their properties. This 
step revealed that the anhydrous caffeine used in this study was obtained as 
polymorph I. On the other hand, malonic acid was shown to contain a mixture of 
two polymorphs in the received batch: α and β. 
Ibuprofen was characterised in its received state and was found to be its 
racemic mixture. Nicotinamide was found to be in its polymorph I form. 
The effect of the recrystallization solvent systems to be used in casting films on 
the initial starting materials was evaluated in chapter 3. The aim was to observe 
the effect of the preparation media (solvent systems) on the physicochemical 
properties of each of the raw materials. Three solvent systems were used: 
acetone/chloroform 3:2 v/v, ethanol/water 4:1 w/w, and acetonitrile. 
Ethanol/water was included in particular to dissolve the polymer as was advised 
by the manufacturer. . Acetonitrile was used because of its known capability to 
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form ibuprofen-nicotinamide co-crystals (Berry et al., 2008). A third solvent 
system was identified after preliminary experimental work. This system 
consisted of acetone/chloroform 3:2 v/v. Re-crystallization of the raw materials 
with the aforementioned solvent systems revealed no change in the solid state 
form of any of the raw materials properties except in the case of caffeine. Re-
crystallizing caffeine revealed the formation of caffeine monohydrate as 
evidenced by thermal and X-ray methods.   
The third step in this study was studying the formation and properties of the 
selected co-crystals using a solvent evaporation method (the co-crystals 
evaluated would be later incorporated into the polymeric film) and the effect of 
various solvent systems on their properties. It was noticed that caffeine-malonic 
acid co-crystals were successfully produced using all the solvent systems. 
However, use of acetonitrile revealed the formation of a mixture of a co-crystal 
and residual caffeine monohydrate in the final product of the co-crystallization 
experiment. A new co-crystal system was discovered during the study. It is a 
co-crystalline system of nicotinamide and malonic acid 1:1 mol/mol. This system 
was found to be easily formed with acetonitrile and acetone/chloroform using 
the solvent evaporation method for preparation. Very recently in comparison, 
solution mediated and drop grinding was used in the literature to prepare 1:1 
nicotinamide/malonic acid co-crystals using ethanol or methanol as a solvent 
system(Voguri, 2010). 
The next area for investigation was to study the interaction of each of the raw 
materials with the polymeric film. The interaction was found to be related to the 
solvent system used in the loading process. High polarity solvents were noticed 
to interfere with the interaction more significantly than low polarity solvents. For 
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example, malonic acid was found to have a higher affinity to the polymer and 
lowered its Tg value by a greater extent than basic additives with the same 
molar ratio in the film. 
Loading two acidic additives simultaneously to the polymer was found to affect 
the interaction of those materials with the polymer. It was found that compound 
A (e.g. flurbiprofen) interacts more favourably with the polymer than compound 
B (e.g. malonic acid and naproxen), saturating it and competitively inhibiting 
interaction.  The evidence for this was provided by the X-ray, FT-IR, and DSC 
analysis of the polymeric films that shows the existence of B crystals in the 
presence of A in the film at a lower concentration than films containing B alone. 
Additionally the disappearance of A crystals from the analysis data confirms 
their conversion into the amorphous form. This in turn reflects the interaction 
between the polymer and compound A that lead to saturating the polymer and 
reducing the saturation concentration for compound B. 
In a novel way the thesis explored the use of solubility parameters as a 
predictive tool for the incorporation of co-crystals into films. The behaviour could 
be predicted from use of calculated solubility parameter values of acidic 
additives. The solubility parameters theory was developed mainly to predict the 
miscibility of liquids. However, the theory was expanded to include the 
miscibility of solid compounds. However, it is worth mentioning that this theory 
cannot be applied for negative deviations from Raoult’s law solutions or 
compounds, in other words, it doesn’t take the polarity of the molecules into 
account. This was noticed when a mixture of acidic and basic compounds was 
dispersed in the polymeric film. It was also noticed with the formation theory 
prediction of the co-crystals alone (Mohammad et al., 2011). The theory 
 196 
 
developed and refined in this project suggested that an acidic drug with a closer 
SP value to the polymer will dominate the interaction process and prevent the 
majority of the other material from interacting with the polymer. This was 
investigated using flurbiprofen as a drug with a closer SP value to the polymer 
one than other acidic drugs (malonic acid, naproxen, and ibuprofen). The 
experiment revealed that naproxen and malonic acid mixtures with flurbiprofen 
in the polymeric film behaved according to the postulated theory. However, 
when ibuprofen was added to a film containing flurbiprofen both drugs dissolved 
in the film. The concentration was increased in order to reach the saturation 
point of ibuprofen. Nevertheless, the films remained clear. It is not clear if the 
presence of flurbiprofen enhanced the solubility of ibuprofen in the film. .  The 
way SP is calculated may have contributed to the theory not being generally 
applicable for the acidic systems.  
The SP theory was found to be not applicable for basic additives when mixed 
with acidic drugs in the polymeric film. This might be considered as one of 
limitations to the previous theory. However, it was noticed that adding malonic 
acid to films containing nicotinamide resulted in the formation of nicotinamide-
malonic acid co-crystals. These co-crystals were identified by analysis with 
powder X-ray diffractometry and FT-IR spectroscopy. It is difficult to 
compensate for the interaction between the co-crystal formers. 
On the other hand, adding malonic acid to films containing caffeine resulted in 
the formation of caffeine-malonic acid co-crystals. However, it was noticed that 
the amount needed of malonic acid to form caffeine-malonic acid co-crystals in 
the film was higher than that needed to form nicotinamide-malonic acid co-
crystals in the film.  Thus the use of another additive to block polymer binding 
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sites and allow the easier formation of co-crystals in films has been 
demonstrated.  Each system needs its own preliminary experiments to titrate 
the level of additive needed for the blockage.  
Adding an excess amount of malonic acid was noted to saturate the polymeric 
film and allow the rest of malonic acid molecules to interact with the basic 
molecule to form co-crystals. This method might be not practical when the 
acidic moiety is the API since using an excess amount might lead to 
overdosing. Therefore another approach was used to load the co-crystals into 
the polymeric film. Co-crystals were prepared and loaded to the polymer 
solution.  
Briefly we should consider whether the SP theory developed in this thesis is 
applicable to other published systems.  Carbamazepine-nicotinamide co-
crystals have previously been noted to form within the polymeric carrier PVP 
(Good et al., 2011). From the data presented in the study it is notable that both 
drugs possess a good affinity to form co-crystals in a polymeric carrier in an 
easy manner compared to the behaviour noted by the systems in this thesis, 
with both caffeine-malonic acid and ibuprofen-nicotinamide co-crystal systems 
in a polymeric film of HPMCAS not readily forming.  Applying the theory 
advanced in this thesis to nicotinamide-carbamazepine co-crystals in PVP 
revealed the closeness of carbamazepine SP value (27 MPa1/2) to that of 
nicotinamide (30 MPa1/2) over that of PVP (21 MPa1/2). These values propose 
the affinity of carbamazepine to interact with nicotinamide and form a co-crystal 
rather than interacting with PVP. This result provides the evidence for the 
possible application of the theory developed in this thesis to other polymers 
other than HPMC-AS. 
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Considering the effect of the choice of solvent for the materials in this thesis, 
loading the co-crystals into the polymeric vehicle was noted to be affected by 
the solvent used in this process. The depression of the Tg values of films 
prepared using acetonitrile was noticed to be greater than those prepared using 
acetone/chloroform for the same concentration of caffeine-malonic acid co-
crystals (91.52° and 35.73°C for films prepared using acetone/chloroform and 
110.37° and 72.73°C for films prepared using acetonitrile). In addition to the FT-
IR transmission profiles collected after analysing different points of films 
prepared with either solvent systems which revealed a higher percentage of co-
crystals existed in films prepared using acetonitrile than those prepared using 
acetone/chloroform. Nevertheless, the analysis method possessed limitations 
as it was hard to scan the whole film and in spite of repeating the whole 
analysis for the raw materials, co-crystals, films containing the raw materials 
separately, and films containing co-crystals in order to minimize possible error, 
there still exists the need to find a better quantification method to measure the 
percentage of the co-crystals in films prepared using each solvent. 
On the other hand, films containing ibuprofen-nicotinamide co-crystals in a 
concentration of around 500 mg per 4000 mg HPMCAS showed no sign of co-
crystals or any crystalline form in the film. Because acidic materials showed a 
higher affinity to polymer than basic compounds, an acidic drug (malonic acid) 
with a closer SP value to that of HPMC-AS was added in an attempt to reduce 
the interaction of ibuprofen with the polymer and thus promote its interaction to 
form co-crystals. The results showed that the final film contained four species; 
co-crystals, ibuprofen, nicotinamide and even a new co-crystal system 
(nicotinamide-malonic acid) figure 9.1. This behaviour was linked to the 
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solubility parameters of the three molecules.   The schematic below illustrates 
the range of the interactions between the three molecules and HPMC-AS.  
Figure 9.1. Chart representing the behaviour of acidic (A) and basic (B) moiety of co-crystals 
with and without the use of acidic blocker (BLK) in a polymeric film (P). 
 
Before work on this thesis commenced there was a dearth of information about 
the behaviour of co-crystals in polymeric carrier. Recently,  a report has come 
into the literature showing that nicotinamide and carbamazepine co-crystals 
tend to form co-crystals when dispersed in a polymeric carrier of PVP (Good et 
al., 2011). The formation rate and percentage co-crystal content varied in 
relation to the molecular weight of the PVP used in the experiment. However, 
the formation of the co-crystals in the polymer fits the previously mentioned 
theory. 
Whilst the formation of co-crystals may confer an advantage so that higher drug 
loads can be used, it is also important to understand how the polymer affects 
drug release.  This is studied using a dissolution test. The preliminary 
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dissolution study suggested that the films containing caffeine alone released 
caffeine more readily than those containing caffeine containing co-crystals. It is 
possible that the different micro-environmental pH’s controlled the dissolution 
behaviour. However, the high standard error values prevented too much 
significance being attached to the data. 
An accelerated stability study showed that co-crystals loaded into the polymer 
were intact for 8 weeks in 45°C and 98% RH in comparison to 8 weeks for co-
crystals in 25°C and 75% RH.  Therefore, the HPMCAS polymer acts to prolong 
co-crystal stability for this system. 
It can be concluded from the previous results of the project that dispersing 
caffeine-malonic acid co-crystals in a polymeric carrier was successful in 
improving their stability while it was not successful in improving their dissolution 
rate. 
 
Future work 
The relationship between two drugs dispersed in a polymeric carrier revealed a 
link between the acidic drugs solubility parameter values and their competitive 
interaction with the polymer. On the other hand, the same link was observed 
with the dispersion of an acidic drug (malonic acid) with basic drugs. However, 
the behaviour of the dispersed ibuprofen and flurbiprofen in HPMCAS was an 
exception from the discussed role. Therefore, it is worth to monitor the 
behaviour of other acidic and basic drugs in other polymers in order to evaluate 
the new approach for predicting the drugs behaviour. In addition, the proposed 
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theory can be tested on the behaviour of dispersed basic drugs in polymeric 
carriers. 
Since drug-polymer interaction is one of the techniques to produce small drug 
crystals, the observed effect of the preparation solvent on the degree of such 
interaction may resulted in affecting the properties of the produced crystals. 
Therefore, the effect of the solvent on the polymer properties and drugs-
polymers interaction should be studied. 
Using an acidic blocker to minimise the interaction between the acidic moiety of 
the co-crystals and the film is an interesting approach. However, more 
investigation is needed to refine the process of selecting this blocking agent. SP 
has been shown here to have an influence. However it is worth investigating 
other factors such as the expanded SP proposed by Hansen (Barton, 1991), the 
capability of forming hydrogen bonding and the polarity of the molecule. This 
theory needs to be investigated using other polymers and other co-crystal 
systems. Refining the blocking agent might improve the co-crystal yield inside 
the polymer and avoid its interaction with the co-crystal formers. Finally, a 
productive area would be to investigate the effect of a blocking agent that has 
no affinity to form an interaction with any of the co-crystal components on the 
loading process of those co-crystals in a polymeric film. 
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Appendix I (TGA) 
Figure AI.1. TGA scan of HPMCAS films containing TEC prepared with acetone/chloroform. 
Figure AI.2. TGA scan of HPMCAS films containing 1:100, 10:100, 20:100, 25:100, 30:100, 
50:100, and 60:100 w/w malonic acid/HPMCAS. 
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Figure AI.3. A representative TGA thermal profile for a film containing caffeine 
and malonic acid prepared using acetone/chloroform. 
 
Figure AI.4. Representative TGA thermal profile for co-crystals prepared with 
chloroform/methanol (pink), HPMCAS film prepared using acetonitrile (red), film containing co-
crystals prepared with acetone/chloroform (green), and film containing co-crystals prepared with 
acetonitrile (blue). 
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Figure AI.5. Representative TGA thermal profile for plain film (pink), co-crystals of ibuprofen and 
nicotinamide (red), films containing co-crystals prepared with acetonitrile (green), and a film 
containing co-crystals prepared with acetone/chloroform (blue). 
 
Figure AI.6. Representative thermal analysis for films containing ibuprofen-nicotinamide co-
crystals and malonic acid prepared using acetone/chloroform (green) and acetonitrile (blue), 
films containing co-crystals alone prepared using acetone/chloroform (teal) and acetonitrile 
(dark blue), and co-crystals of ibuprofen and nicotinamide (pink). 
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Figure AI.7. Representative TGA thermal profiles for films containing: 5% (green), 10% (blue), 
15% (red), and 20% (pink) of TEC. 
 
Figure AI.8. Representative TGA thermal profiles for films containing: 5% (green), 10% (blue), 
and 15% (red) of TEC. 
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Figure AI.9. Representative TGA thermal profiles for films containing: 10% (green), 15% (blue), 
and 20% (red) of TEC. 
 
Figure AI. 10. Representative thermal TGA profiles for films containing caffeine-malonic acid co-
crystals prepared using acetone/chloroform or acetonitrile. 
 217 
 
 
Figure AI. 11. Repredentative thermal profiles for films containing ibuprofen-nicotinamide co-
crystals prepared with either acetonitrile (green) or acetone/chloroform (blue), plain film 
prepared with acetonitrile (red), and ibuprofen-nicotinamide co-crystals (pink). 
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Appendix II (DSC) 
 
Figure AII.1, DSC triplicate scan of pure malonic acid. 
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figure AII.2. DSC triplicate scan of pure ibuprofen. 
 
Figure AII.3. DSC duplicate scan of pure nicotinamide. 
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figure AII.4. DSC duplicate scan of pure flurbiprofen. 
 
Figure AII.5. DSC duplicate scan of pure HPMCAS. 
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Figure AII.6. DSC scan of caffeine recrystallised with chloroform/methanol, acetone/chloroform, 
and ethanol water. First heating cycle. 
 
Figure AII.7. DSC scan of malonic acid recrystallised with acetone/chloroform and acetonitrile. 
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Figure AII.8. DSC scan of malonic acid recrystallised with acetonitrile. 
 
Figure AII.9, DSC scan of pure HPMCAS showing the Tg of the pure material. 
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Figure  AII.10. DSC scan of cast HPMCAS film using acetonitrile for preparation. 
 
Figure AII.11. DSC scan of cast HPMCAS film using ethanol/water for preparation. 
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Figure AII.12. DSC scan of cast HPMCAS film using acetone/chloroform for preparation. 
 
Figure AII.13. DSC scan of three films of HPMCAS containing 5% TEC prepared with 
acetone/chloroform, ethanol/water, and acetonitrile. 
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Figure AII.14. DSC scan of HPMCAS films containing 10% TEC prepared with 
acetone/chloroform, ethanol/water, and acetonitrile. 
 
Figure AII.15. DSC scan of HPMCAS films containing 15% TEC prepared with 
acetone/chloroform, ethanol/water, and acetonitrile. 
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Figure AII.16. DSC scan of HPMCAS films containing 20% TEC prepared with 
acetone/chloroform, ethanol/water, and acetonitrile. 
 
Figure AII.17. DSC scan of HPMCAS containing an ascending concentrations of malonic acid, 
prepared with acetonitrile. 
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Figure AII.18. Representative DSC thermal profiles for a plain film prepared using acetonitrile 
(pink), a film prepared using acetone/chloroform (blue), a film containing co-crystals prepared 
using acetonitrile (red), and a film containing co-crystals prepared using acetone/chloroform 
(green). 
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Figure AII. 19. A representative of the thermal DSC profile for a film containing 3:4:10 
ibuprofen/malonic acid/HPMCAS prepared using ethanol/water. 
 
Figure AII. 20. A representative thermal DSC profile for a film containing 3:2:10 w/w/w 
ibuprofen/malonic acid/HPMCAS prepared using acetonitrile. 
 
Figure AII. 21. A representative thermal DSC profile for a film containing 3:2:10 w/w/w 
ibuprofen/malonic acid/HPMCAS prepared using acetone/chloroform. 
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Figure AII.22. Representative thermal DSC profiles for films containing caffeine-malonic acid co-
crystals prepared using acetone/chloroform (green) and acetonitrile (blue). 
 
Figure AII. 23. Representative thermal DSC profiles for films containing: 30:100 (green), 40:100 
(blue), and 50:100 (red) w/w malonic acid/HPMCAS. 
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Figure AII. 24. Representative thermal DSC profiles for films containing: 100% HPMCAS (pink), 
1:100 w/w (green), 10:100 (red), and 20:100 (blue) w/w malonic acid/HPMCAS. all prepared 
using ethanol/water. 
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Appendix III (Powder X-ray diffraction) 
 
Figure AIII.1. X-ray scan of malonic acid as received (top) and the diffraction pattern of malonic 
acid obtained from CSD (bottom). 
 
Figure AIII.2. X-ray scan of pure HPMCAS. 
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Figure AIII. 3. Representative powder x-ray diffraction patterns for unprocessed malonic acid 
(green), a film containing 15:100 malonic acid/HPMCAS (blue), and a film containing 3:10 
malonic acid/HPMCAS (red)
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Assignment 
Caffeine 
malonic 
acid 
ch5-2-
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mh30-2-
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2994 
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2934 wide 2951 2959 2941 multi+ wide 2934 
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2365 
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1730 
C=N 1692 
1698 
1708 1694 wide 1698 1692 
1702 
1704 
 
Appendix IV (FT-IR) 
transmission) 
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 C=C 1599 
 
1600 
 
1613 1601 
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1073 
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        Table AIV.1. FT-IR band assignment for film containing caffeine malonic acid co-crystals prepared with acetone/chloroform or acetonitrile.
       
1047 very 
wide 
1047 very 
wide 
1047 very 
wide 
 
1025 
 
not distin 
 
1029 1027       
 
973 
 
974 
 
979 974 947 wide shal 974 wide shal 
 
861 912 v wide 912 v wide 863 v shal       
 
758 770 759 770 761 758 759 763   
 
742 
 
744 
 
748 743 746 749 
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Figure AIV.1.  a represent of FT-IR scan of malonic acid as received. 
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Appendix V (SEM) 
figure AV.1. SEM scan of caffeine-malonic acid co-crystals using different magnification powers. 
(A) and (B) 40X, (C) and (D) 400X, (E) 250, (F) and (G) 1500X, (H) 3000X.  
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Appendix VI (Dissolution test) 
 
Figure AVI.1. standard curve for caffeine in distilled water.  
 
Figure AVI.2. the dissolution test of the film containing 10% w/w caffeine with error bars. 
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figure AVI.3. Drug release profile with error bars for films containing caffeine-malonic acid co-
crystals prepared with acetone/chloroform. 
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Appendix VII (Stability study) 
 
Figure AVII.1. FT-IR scan of co-crystals in a film after 1 month of storage. The film prepared 
with acetone/chloroform. 
 
Figure AVII.2. FT-IR scan of co-crystals in a film after 1 month of storage. The film prepared 
with acetone/chloroform. 
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Figure AVII.3. FT-IR scan of co-crystals in a film after 1 month of storage. The film prepared 
with acetonitrile. 
 
Figure AVII.4. FT-IR scan of co-crystals in a film after 2 month of storage. The film prepared 
with acetone/chloroform. 
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Figure AVII.5. FT-IR scan of co-crystals in a film after 2 month of storage. The film prepared 
with acetonitrile. 
 
Figure AVII.6. FT-IR scan of co-crystals in a film after 2 month of storage. The film prepared 
with acetonitrile. 
 244 
 
 
Figure AVII.7. FT-IR scan of co-crystals in a film after 4 month of storage. The film prepared 
with acetone/chloroform. 
 
Figure AVII.8. FT-IR scan of co-crystals in a film after 4 month of storage. The film prepared 
with acetone/chloroform. 
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Figure AVII.9. FT-IR scan of co-crystals in a film after 4 month of storage. The film prepared 
with acetonitrile. 
 
Figure AVII.10. FT-IR scan of co-crystals in a film after 4 month of storage. The film prepared 
with acetonitrile. 
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Figure AVII.11. FT-IR scan of co-crystals in a film after 5 month of storage. The film prepared 
with acetone/chloroform. 
 
Figure AVII.12. FT-IR scan of co-crystals in a film after 5 month of storage. The film prepared 
with acetone/chloroform. 
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Figure AVII.13. FT-IR scan of co-crystals in a film after 5 month of storage. The film prepared 
with acetonitrile. 
 
Figure AVII.14. FT-IR scan of co-crystals in a film after 5 month of storage. The film prepared 
with acetonitrile. 
 248 
 
 
Figure AVII.15. FT-IR scan of co-crystals in a film after 5 month of storage. The film prepared 
with acetonitrile. 
 
Figure AVII.16. FT-IR scan of co-crystals in a film after 6 month of storage. The film prepared 
with acetonitrile. 
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Figure AVII.17. FT-IR scan of co-crystals in a film after 6 month of storage. The film prepared 
with acetonitrile. 
 
Figure AVII.18. FT-IR scan of co-crystals in a film after 6 month of storage. The film prepared 
with acetonitrile. 
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Figure AVII.19. FT-IR scan of co-crystals in a film after 7 month of storage. The film prepared 
with acetone/chloroform. 
 
Figure AVII.20. FT-IR scan of co-crystals in a film after 7 month of storage. The film prepared 
with acetone/chloroform. 
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Figure AVII.21. FT-IR scan of co-crystals in a film after 7 month of storage. The film prepared 
with acetonitrile. 
 
Figure AVII.22. FT-IR scan of co-crystals in a film after 7 month of storage. The film prepared 
with acetonitrile. 
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Figure AVII.23. FT-IR scan of co-crystals in a film after 7 month of storage. The film prepared 
with acetonitrile. 
 
